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Today, drug discovery predominately focuses on the design of ligands with high selectivity 
towards a specific biological target. A significant limitation in the case of multi-factorial 
diseases (e.g. neurodegenerative disorders) is that effective therapy may require multi-target 
drugs addressing the complexity of multi-factorial pathologies. Here, single- and multi-target 
ligand design was investigated to discover novel compounds active at multiple 
proteins/multiple binding sites including allosteric ligands. 
Calpain-1, a challenging target, was selected to develop and evaluate computational approaches 
to the discovery of novel ligands. Current selective calpain-1 inhibitors are reported to bind to 
an allosteric site and their mode of action has remained elusive. To elucidate this, a structure-
based virtual screening protocol was implemented to find chemically novel compounds with 
improved selectivity and a reduced side-effects profile. 
To develop methods for the discovery of multi-target ligands, a multi-target design approach, 
which could be beneficial in the treatment of Lung Carcinoma and Neurodegenerative diseases, 
was investigated. A novel ensemble of proteins was targeted to elevate intracellular cAMP, 
deemed to be beneficial in these diseases resulting in the discovery of ligands with high binding 
affinity at three targets, PDE10A, A1 and A2A receptors. 
In tandem, functional activity at the A2A receptor and PDE10A was investigated, resulting in 
the discovery of novel compounds, which exhibited anti-proliferative effects in lung carcinoma 
cell-lines correlating with the co-expression of the two targets and increased cAMP levels. 
Critically, the dynamics of one amino acid residue, Val84, was identified as a novel 
conformational descriptor of A2A receptor activation.  
Overall, novel single- and multi-target ligand design approaches are presented in this work, 
which could be applicable to a wide range of ligand design problems, across (multi-factorial) 
disease areas and target families. The findings may facilitate improved design of allosteric 
calpain-1 inhibitors using the PEF(S) domain, and encourage investigating the therapeutic 
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1.1 Drug discovery 
1.1.1 Tuning ligand selectivity in drug discovery  
A contemporary approach in drug discovery has been the design of potent ligands with high 
selectivity towards a target associated with a particular disease of interest, followed by 
structural optimization for drug development.[1] Generally, undesirable side effects might arise 
when ligands interact with e.g. other targets, DNA, RNA, lipids, sugars, metabolites.[2] 
Therefore, huge effort has been made to measure the off-target interactions that might lead to 
adverse side effects such as those with ion channels[3], transporters and cytochrome P450s 
(CYPs) etc.[4, 5] In addition, research has been directed to achieve family or subtype selectivity 
for homologous targets binding to similar native substrates. For instance, this has been a 
challenge in the kinase family (phosphotransferases), where each kinase could bind to its co-
factor ATP while transferring a phosphate group to a substrate.[6] Hence, one of the aims was 
to find a ligand that could either inhibit selectively one or alternatively a group of kinases that 
share a particular biochemical pathway of interest, in order to avoid the undesirable side effects 
that might arise.[7] Thus, it has generally been achievable to tune the selectivity of ligands to 
a subset of kinases rather than a single kinase.[8] 
In practice, it is challenging to design a drug exhibiting narrow selectivity over undesirable 
targets. It would be essential then, to develop an understanding of the factors driving selectivity 
towards any particular target of interest, and in turn this would allow for more effective design 
of ligands with the desired selectivity.[9–11] This gives rise to the need for rational approaches 
to tune ligand selectivity. One of the currently existing computational approaches for designing 
selective ligands is proteochemometrics (PCM) used for simultaneously modeling bioactivity 
of a group of ligands against a set of related protein targets.[12] In addition, structure-based 
approaches are generally employed to enhance ligand selectivity by improving the shape and 
electrostatic complementarities between the ligand and the binding pocket of the protein, as 
well as addressing issues such as conformational selection and the flexibility of proteins.[2]  
Designing allosteric ligands which target a site specific to the protein of interest but does not 
include all of, or is distinct from, the site occupied by e.g. a substrate or ligand, usually termed 
the active or the orthosteric site, would be one way to approach this problem.[13] Allosteric 
binding, through transmission of conformational effects, can in some cases inhibit or activate 
a protein mediated mechanism.[14] For instance, Hemoglobin (Hb) is one classical example of 
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allostery where a protein, which is a subunit of a multi-subunit protein, contributes to regulating 
the physiological properties of Hb allosterically.[14]  
To illustrate this approach, one of the challenges of designing selective ligands has been 
addressed in this work by selecting calpain-1, one of the dimeric calpains, as a protein target. 
Calpain-1 constitutes a promising therapeutic target for many diseases e.g. in cardiovascular, 
neurodegenerative and ischaemic diseases.[15, 16] Most compounds that target the active site 
of calpain-1 inhibit a broad spectrum of cysteine proteases, thereby resulting in undesirable 
side effects.[17] Selective calpain-1 inhibitors, such as PD150606, which included a specific 
α-mercaptoacrylic acid sub-structure, were reported to bind to an allosteric site of calpain, the 
penta-EF hand calcium binding domain, PEF(S), but their mode of action has remained unclear. 
[18]. Here, the crystal structure of PEF(S) was used in virtual screening to discover allosteric 
PEF(S) binders that populate a novel chemical space to assist in elucidating their mode of 
action while having promising selectivity and a reduced side-effects profile (Figure 1). 
 
 
Figure 1. The use of the crystal structure of the penta-EF hand calcium binding domain, PEF(S) 
of calpain-1 in virtual screening to discover PEF(S) binders that populate a novel chemical 
space, and elucidation of a novel allosteric mode of action with promising selectivity and a 







1.1.2 The transition from single-target to multi-target drug approach for the 
treatment of multi-factorial diseases  
The design of selective ligands[1, 2] has been proven successful for diseases with well-defined 
mechanism and pathophysiology. In the case of these diseases, multi-target drugs were 
undesirable and have been long associated with adverse side effects.[1, 2] In contrast, for multi-
factorial diseases, such as neurodegenerative disorders, inflammatory diseases, and cancer that 
exhibit more-complex pathological mechanisms due to an ensemble of factors (e.g. genetic and 
environmental) contributing to the severity of the diseases,[19–28] a single target approach 
often fails to demonstrate reliable therapeutic effects.[29–32]This gives rise to the need for 
multi-target drugs, which could address the complexity of multi-factorial diseases with 
improved therapeutic efficacy. Additionally, they may exhibit additive or synergistic effects. 
This could result then in better safety profiles in comparison to single-target drugs due to the 
lower dosage requirements and improved efficacy.[33]  
On this basis, multi-target drug design has emerged as a new paradigm in drug discovery, with 
more research being directed towards finding novel and effective multi-target drugs 
particularly for the treatment of multi-factorial diseases. In confirmation of this approach, many 
marketed multi-target drugs are already available exemplifying the success of this 
methodology. These drugs exhibit complex pharmacological profiles.[34] For instance, in the 
case of cancer and infectious diseases, the choice of drugs active at multiple targets may be 
attributed to the emergence of resistance in e.g. cancer or bacterial infection, resulting from 
genetic mutations or in the case of anxiolytic drugs to the requirement to modulate multiple 
receptors in the central nervous system (CNS).[35] This suggests that specifically designing 
multi-target drugs is a promising approach to treat multi-factorial diseases. 
1.1.3 Current status of multi-target drugs in relation to other therapeutic strategies 
An analysis was conducted by Ramsay et al[35]  for the US Food and Drug Administration 
(FDA) of approved new molecular entities (NMEs) over the period of 2015 to 2017. This 
analysis aimed to showcase the success of multi-target drugs in the clinic at that time, and was 
similar to a previous analysis done by Lin et al.[36] Information about the currently approved 
drugs was extracted from the DrugBank database, which includes drug target(s) and 
mechanism(s) of action (MoA), and they were subdivided into single-target and multi-target 
drugs. The major highlight of the analysis is shown in Figure 2, illustrating that the number of 
single-target drugs (34%) is greater than that of multi-target drugs (21%); however, the latter 
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have constantly increased over a period of years (16%).[37] In addition, combining the 21% of 
multi-target drugs and newly approved therapeutic combinations (10%), the total percentage 
of the two approaches is 31%, which is approaching that of single-target drugs (34%). This 
clearly reveals the rising interest in polypharmacological approaches in certain therapeutic 
areas, in particular multifactorial diseases such as CNS  disorders, cancer, and infectious 
diseases.[35] 
 
Figure 2. Analysis was done by Ramsay et al[35] for FDA approved new molecular entities 
(NMEs) from 2015 to 2017. Information about currently approved drugs was extracted from 
the DrugBank database, which includes drug target(s) and mechanism(s) of action (MoA). 
They were subdivided into single-target and multi-target drugs. The major highlight of the 
analysis was that despite the fact that the number of single-target small molecules (34%) is 
more than that of multi-target drugs (21%), the latter has consistently increased (16%). 
 
An alternative polypharmacological approach to multi-target drugs is combination therapy, 
which uses drugs with different modes of action for the treatment of complex diseases.[34] The 
percentage distribution of multi-target drugs and therapeutic combinations approved in 2015–
2017, according to the Anatomical Therapeutic Chemical (ATC) Classification System, is 
depicted in Figure 3. Generally, multi-target drugs are much more widely used as compared to 
combination therapies across all disease areas, in particular as anti-neoplastic agents and for 
the treatment of nervous system disorders.[35] 
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Figure 3. Distribution of multi-target drugs and therapeutic combinations approved in 2015–
2017 according to the Anatomical Therapeutic Chemical (ATC) Classification System reveals 
that generally, multi-target drugs are much more widely used as compared to combination 
therapies across all disease areas, in particular as anti-neoplastic agents and for the treatment 
of nervous system disorder[35]. 
 
In fact, the use of multi-target drugs exhibiting multiple biological properties may have 
advantages over combination therapies, where different challenges are encountered. The first 
is coping with several drugs with different bioavailabilities, pharmacokinetic properties (PK), 
and metabolism, which may not be the case when administering a single multi-target drug with 
multiple modes of action on several targets into the body.[34] In addition, pre-clinical 
development of a multi-target drug, which includes PK and ADMET (absorption, distribution, 
metabolism, and excretion – toxicity) optimization, is similar to that of single-target drugs. 
Thus the multi-target drug approach may be less complicated than combination therapies. One 
major advantage is that undesirable drug–drug interactions would not be encountered in the 
case of multi-target drugs.[34] Hence, from these considerations, the multi-target drug 
approach may be a more efficient and cost-effective poly-pharmacological option as compared 
to drug combinations. On the other hand, many challenges are encountered with multi-target 
drugs, which are mentioned in section 1.2.1. 
1.1.4 Examples of clinical success of multi-target drugs encourages movement towards 
multi-target ligand design 
The multi-target approach appears to be promising, in particular for the treatment of 
neurodegenerative disorders, given their complexity and multifactorial nature.[38] For 
example, rasagiline is a drug that was approved in 2006 for the treatment of neurodegenerative 
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diseases, and it exhibits a multi-target profile. In addition, safinamide is the first multi-target 
drug approved for neurodegeneration for more than a decade.[39] It was originally developed 
as an anticonvulsant agent and recently in March 2017 it was approved as an adjunctive 
treatment for Parkinson’s disease due it its multi-target nature. It is thought that this drug 
confers neuroprotective effects by combining monoamine oxidase-B inhibition with activity at 
sodium-gated ion channels with the release of glutamate, which in turn controls motor 
symptoms.[40] In addition, recently an increased number of multi-target drugs have been 
developed to treat schizophrenia and major depressive disorders.[38] 
For example, antagonizing three targets simultaneously, namely D2, serotonin 5-HT2A and α1-
adrenergic receptors has been a common approach used for the treatment of schizophrenia.[41] 
This generally aimed to improve antipsychotic efficacy and minimize adverse effects. For this 
purpose, the arylpiperazine substructure was used for analogue modification in order to tune a 
fine balance of receptor activities at D2, 5-HT1A and 5-HT2A. As a result, aripiprazole, was 
released into the market in 2015, as the first modulator of serotonin/dopamine activity. 
However, it exhibited undesirable side effects, reported to be related to its interaction with post-
synaptic D2 receptors. Subsequently, brexpiprazole was approved on October 2015, as a novel 
D2 and 5-HT1A partial agonist. In comparison to aripiprazole, it exhibited reduced inherent 
activity at D2 receptors and more balanced activities at 5-HT2A, 5-HT1A, and the α1B receptor 
subtypes.[41] Cariprazine is also another FDA approved drug that modulates 
serotonin/dopamine activity, also having an arylpiperazine substructure. It was marketed in 
September 2015 for the treatment of schizophrenia and bipolar disorders. Being a partial 
agonist of the D2 and D3 receptors, this mode of action is novel compared to other 
antipsychotics, which are D2 and 5-HT2A partial agonists.[42] 
Besides neurodegenerative disorders, another key multi-factorial disease where 
polypharmacological approaches are the most relevant is cancer. Several proteins and pathways 
contribute to the complexity of this disease, often leading to the progression of tumor 
growth.[43–45] Inhibiting multiple kinases and pan-inhibitors of histone deacetylases 
(HDACs) have recently been the most investigated polypharmacological approaches for cancer 
treatment. For example, lenvatinib is a reversible inhibitor of multi-tyrosine kinase receptors 
that simultaneously modulates their activities (vascular endothelial growth factor receptors 
(VEGFR), fibroblast growth factor receptors (FGFR), RET, mast/stem cell growth factor 
receptor kit (SCFR), and platelet-derived growth factor receptor (PDGFR) beta). These 
receptors are associated with pathogenic angiogenesis, tumor growth, and cancer 
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progression.[46] In addition, due it to its multi-target activity profile, lenvatinib was approved 
for the treatment of radioiodine-refractory thyroid cancers. Neratinib is another multi-tyrosine 
kinase inhibitor, which is irreversible, and it targets epidermal growth factor receptor (EGFR), 
and human epidermal growth factor receptor 2 (HER2), receptors that are highly expressed in 
several carcinomas, and are thought responsible for its anti-tumor activity.[47]  
Another common approach to multi-kinase inhibition includes dual inhibitors of cyclin-
dependent kinase (CDK) 4 and 6, which have been approved by the FDA for breast cancer 
therapy e.g  palbociclib, abemaciclib and ribociclib.[48] In addition, midostaurin, is a multi-
kinase inhibitor derived from the pan kinase inhibitor staurosporine. It was approved on April 
2017 for the treatment of acute myeloid leukemia via the inhibition of the activities of protein 
kinase C alpha (PKC alpha), VEGFR2, KIT, PDGFR and WT and/or mutant FLT3 tyrosine 
kinases.[49] 
In summary, there are several examples of clinically successful multi-target drugs and this 
suggests that more effort towards the development of multi-target ligand design would be 
beneficial. Examples such as these have inspired the implementation of multi-target ligand 
design approaches documented in this work, with the objective of further exploring the 
potential therapeutic benefits in multi-factorial diseases. 
1.2 Rational design of multi-target drugs 
1.2.1 Existing challenges in selecting multi-target combinations in drug discovery 
Based on an analysis of FDA-approved new molecular entities (NMEs) from 2015 to 2017,[35]  
highlighting the increasing number of marketed multi-target drugs, it appears that  extending 
the applicability of multi-target drugs across different therapeutic areas would allow the 
discovery of  more effective treatments.  It remains a challenging task however, to rationally 
design multi-target drugs.[50–52] 
The first challenge lies in selecting the right combination of targets for a particular disease. 
Despite the availability of many online resources[53–55] which can be used to identify possible 
targets, target selection is often ambiguous. For this reason, it is essential to develop an in-
depth understanding of the relationships between target(s) and disease(s), the associations 
between key metabolic pathways, which targets, are key, which drugs have the correct 
therapeutic profile, and which diseases are druggable by this approach in the absence of 
potential adverse events.[56] Moreover, it is highly beneficial to achieve additive or synergistic 
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effects.[57]. Hence, to achieve all these simultaneously requires the design of multi-target 
compounds with a particular functional activity profile.[58] 
In most cases multi-target drug design has historically been based on a fairly simple approach, 
that of merging two distinct pharmacophores derived from sets of active compounds, where 
each compound is initially selective towards its corresponding target, into the design of a single 
compound[59–61]. Based on the degree of similarity of the starting structural frameworks of 
each compound, pharmacophores could either be fused or merged. In contrast, if they are 
sufficiently different, then pharmacophores could be conjugated with cleavable or non-
cleavable linkers This strategy however could result in compounds with poor properties as 
drugs e.g. poor pharmacokinetics, which may not be suitable for acute or chronic diseases.[62] 
The nature of the targets involved and the availability of starting frameworks are both important 
parameters to be considered when generating multi-target compounds. It is also important that 
each framework retain interactions with specific target (i.e. those compounds from which the 
fragment was derived).[52] This is quite challenging to achieve and requires structure–activity 
relationships of the starting compounds with their corresponding targets, especially if these 
targets are either slightly related or completely unrelated e.g. belonging to different protein 
classes.[52] 
Other critical factors that need to be addressed include modulating each target to the required 
degree and avoiding any off-target effects. In particular, the latter aspect is of high importance 
in designing multi-target compounds against same protein family. Examples are multi-kinase 
inhibitors, or those of shared functional domains and/or binding sites across target families.[52] 
It is evident then that the rational design of multi-target compounds is challenging - the right 
choice of target combination is key while achieving balanced activity towards each target 
without any off-target activity whilst keeping drug-like properties. 
1.2.2 Reported Strategies for addressing the challenge in selecting the ‘right’ target 
combination for multi-target ligand design  
From the literature, network graphs are one approach that can help to obtain insight into the 
association of protein targets with multi-factorial diseases, and reveal a mechanism that can 
explain how perturbations in cellular networks might result in certain phenotypes, including 
disease. Hence, this is one approach to guide the selection of the ‘right’ combination of targets 
to find therapies for complex diseases The approach is to model metabolic and signaling 
pathways by mining high-throughput experimental datasets and integrating the data into 
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network models. This can assist in modeling outcomes of drug intervention and also in 
understanding the complex interactions between multi-target drugs and their cellular targets 
with the objective of explaining their efficacy and potential side effects.[63–70] A better 
understanding of the mode of action of multi-target drugs can then be achieved by focusing on 
the more promising targets in the disease networks where inhibition can influence the 
development of disease phenotypes such as cancer progression.[63, 70–73] In addition, this 
may allow better understanding of drug resistance and side effects, for example by highlighting 
particular targets or how their pathways are interconnected.[74–79] The robustness of disease 
networks can be used to explain the efficacy of multi-target drugs, for example by perturbing 
a specific subset of nodes in the network that are key to phenotypic development. Network-
based drug discovery is therefore one approach to search for target combinations that represent 
nodes in disease networks that could potentially be perturbed by multi-target drugs, enabling 
the development of more effective and safer therapies. 
1.2.3 Promising target combinations for multi-target drug design (focusing on GPCRs 
and Enzymes) 
G protein-coupled receptors (GPCRs) have been widely studied as drug targets due to their 
pharmacological tractability and strong association with human pathophysiology. Around 34% 
of all FDA approved drugs are GPCR targeted.[80, 81] Since GPCRs are in general druggable 
receptors, GPCR targeted ligands are appealing as part of multi-target compounds. For 
instance, histamine receptor antagonism was combined to cholinesterase and monoamine 
oxidase inhibition in a drug for Alzheimer’s disease.[82]  
However, defining the precise mode of action and mechanism can be challenging. The mode 
of action of GPCRs can be modulated by multiple signaling pathways[83], including functional 
selectivity (biased agonism). 
Over the past twenty years, a significant number of receptors have been characterized by X-
ray crystallography, including membrane-bound receptors such as GPCRs. This has been made 
possible by significant progress in cloning and purification of membrane-bound proteins and 
advances in structure solution and refinement. In fact, the currently available data on the 
structure and function of GPCRs evolved from homology modeling of related GPCRs such as 
rhodopsin (class A GPCRs) and has since been expanded to include X-ray structures of GPCR 
receptor subtypes belonging to other classes (B, C, D, E and F that don’t share any sequence 
homology among each other).[84–86] It is challenging to design GPCR ligands and understand 
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the mechanism by which they elicit agonism or antagonism. This requires an analysis of the 
complex dynamics of the system including allosteric effects. For this reason, MD simulation 
and analysis of the ligand-protein complexes is a promising approach.[87] A challenging aspect 
that needs to be considered in the design of GPCR ligands is the relatively large degree of 
flexibility exhibited by GPCR proteins. To take this into account, this can be partially addressed 
by docking methods that consider receptor flexibility (discussed in section 1.2.5.3 Docking 
methodologies). To develop a better understanding of signaling in cells and in vivo, efforts 
have been made to explore transient dimerization[88], heterodimers,[89] and internalized 
megamers[90] with a view to assist in the design of selective ligands that would lead to various 
aggregation states. 
Enzymes play a key role in life processes and in pathophysiologies, and they are also key drug 
targets. Approximately half of existing drugs are active against enzymes and recent studies of 
the human genome suggest that enzymes constitute the majority of druggable targets. Enzymes 
are therefore key targets for a number of diseases and the design of modulators of enzyme 
activity e.g. inhibitors continues to be an important avenue of research in drug discovery and 
development.[91] 
In fact, the active site of an enzyme and if present, allosteric pockets, may be suited for 
interactions with drug-like inhibitors. In comparison to GPCRs, it is often more straightforward 
to design inhibitors that compete with the native substrate (competitive inhibitors). Hence, 
targeting an enzyme active site is generally seen as an attractive approach in drug design. This 
is assisted by availability of many enzyme crystal structures. However, focusing on 
reversible/competitive active site inhibitors may not be the best approach in all cases. For 
example, effective drugs could be non-competitive or could be irreversible inhibitors of 
enzyme activity[91, 92]. 
An important measure of enzyme activity in the presence of an inhibitor is to study its kinetics. 
Two frequently used tools for the evaluation of binding to purified enzymes are surface 
plasmon resonance and isothermal titration calorimetry (ITC). In contrast, in GPCRs, it is 
important to measure functional effects, rather than binding.[93] 
Many successful examples of multi-target ligands targeting both enzymes and GPCRs have 
been reported in the literature. Examples include dual ligands of Cannabinoid CB1R inverse 
agonists and acetylcholine (AChE) inhibitors, μ-opioid receptor (MOP) agonists and nitric 
oxide synthase (NOS) inhibitors for the treatment of pain, and norepinephrine (NER) 
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antagonists and NOS inhibitors for the treatment of neuropathic pain.[94] Another example is 
that of compounds acting as A2A adenosine receptor antagonists and monoamine oxidase B 
(MAO B) inhibitors;[95] a promising target combination for the treatment of Parkinson’s 
disease. Additional examples include dual-active ligands of histamine H3R antagonists and 
AChE inhibitors, which have been suggested to be beneficial in treating cognitive 
disorders.[94] Given all of these examples, it would be beneficial to design multi-target ligands 
that simultaneously target specific enzymes and receptors as this may produce improved 
therapeutic benefit in multi-factorial diseases.[94] 
 
1.2.4 A novel multi-target combination- modulation of A1 and A2A receptors and 
inhibition of the enzyme PDE10A 
Cyclic-AMP (cAMP) is involved in many biological processes such as cell growth and 
adhesion, neuronal signaling, immune function, and metabolism etc. As a second messenger 
involved in multiple signaling pathways, in specific instances and in particular disease states, 
elevation of intra-cellular cAMP concentrations has demonstrated therapeutic benefit in multi-
factorial diseases such as CNS traumas, autoimmune disease, inflammatory diseases, and 
cancer.[96–98] For example, intracellular cAMP levels have been shown to have both pro-[99–
101] and anti-proliferative effects,[101–106] depending on the cancer cell type. cAMP levels 
are spatially and temporally coordinated (e.g. by specifically positioned PDE4 enzymes), 
creating concentration gradients within the cell to elicit specific actions and outcomes[107].  
The intracellular elevation of cAMP can be achieved by various ligands that preferentially 
target single receptors, such as Bay K8644 (a calcium channel agonist), TTX (a sodium channel 
antagonist) and H89 (a protein kinase A inhibitor). Other examples of compounds that elevate 
cAMP include KT5720 (a protein kinase A (PKA) inhibitor), LY29400 (an inhibitor of 
phosphoinositide 3-kinases (PI3Ks)), PD98059 (a MAPK kinase inhibitor), tyrphostin AG490 
(a tyrosine kinase inhibitor), myelin-associated inhibitors, and Forskolin.[33, 108–112] 
Inhibition of phosphodiesterases also results in maintenance of elevated intracellular cAMP 
concentrations; examples of known inhibitors include IBMX, a non-competitive selective 
phosphodiesterase inhibitor, and rolipram, a selective phosphodiesterase-4 inhibitor.[113, 114]  
Additionally, the modulation of adenosine A1 and A2A receptors contribute to the elevation of 
cAMP levels.[115, 116] 
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One particular enzyme of interest in this work is the phosphodiesterase 10A (PDE10A), which 
plays a role in neurodegenerative,[117–119] inflammatory[120] and cancer-related 
diseases.[98] Inhibition of PDE10A resulting in maintenance of elevated intracellular cAMP 
concentrations was suggested to be effective in the treatment of these diseases (Figure 4A. 
adapted and modified from Lee et al). Similarly, the modulation of two GPCRs the adenosine 
A1 and A2A receptors (A1R and A2AR), plays an equivalent role in elevating cAMP, 
demonstrating therapeutic benefits in these diseases (Figure 4B. adapted and modified from 
Ham et al).[121–129] Hence, it would be informative to design ligands that would elevate 
cAMP at A1R, A2AR, and PDE10A and investigate the potential therapeutic benefits of a multi-
target approach. 
 
Figure 4. A. The inhibition of PDE10A results in the elevation of the concentraton of cAMP 
which is suggested as an effective treatment in multi-factorial diseases such as CNS traumas, 
autoimmune disease, inflammatory diseases, and cancer [121–125] B. The antagonism of the 
A1R and the agonism of the A2AR, receptors plays an equivalent role in elevating cAMP, 
demonstrating therapeutic benefits in these diseases[127, 128]. Hence, designing ligands that 
elevate cAMP levels at the A1R, A2AR, and PDE10A targets would be interesting to be explored 
further for their therapeutic benefits in the aforementioned diseases.[96–98] 
 
Dual PDE inhibition and A2AR activation, via compound combinations, was synergistic in 
elevating cAMP, and was observed to inhibit proliferation of multiple myeloma and diffuse 
large B-cell lymphoma as well as induce apoptosis.[98] As such there is the possibility of 
targeting both the A2AR and PDE10A, in particular, as an anti-proliferative strategy for the 
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treatment of diseases with up regulated proliferation, such as cancer. The A2AR is expressed in 
e.g. both lung adenocarcinoma and squamous cell carcinomas.[130, 131] Similarly, PDE10A 
is overexpressed in lung adenocarcinoma, and its inhibition was found to suppress 
growth.[132]  
To explore this approach, a computational method that combines ligand- and structure-based 
techniques is presented, which employs in silico target prediction[133] and docking[134] for 
the design of synthetically feasible multi-target ligands that bind to the A1 and A2A receptors 
and that also inhibit PDE10A. The method has been extended to consider functional effects 
and aims to identify chemical series that show agreement in both ligand- and structure-based 
predictions at A2AR and PDE10A, as a sufficient dual-target combination to elevate cAMP.  
In this work, known PDE10A inhibitors belonging to the chemical series were identified and 
shortlisted as A2AR agonists via a structure-based approach, which consisted of docking and 
MD simulation. The MD simulation analysis also enabled the identification of a novel 
conformational descriptor characterizing A2AR activation. This addresses one of the 
outstanding challenges in designing GPCR ligands that is predicting their functional effects.  
The compounds were then validated experimentally as A2AR agonists in relevant biochemical 
assays, and subsequently tested for their anti-proliferative effects in lung carcinoma cell-lines.  
1.2.5 Current computational approaches for the design of multi-target drugs 
Rational drug design is widely practiced to find lead compounds, typically to generate leads or 
optimize candidate structures for a specific target. However, there is growing interest in finding 
multi-target ligands that exhibit a specific multi-target activity profile.  Ligand- and structure- 
based computational approaches are employed in e.g. virtual screening (Figure 5) to generate 
starting structures for optimization.[57, 135, 144–148, 136–143] The use of structure- and 
ligand-based techniques in drug design, is however dependent on whether there is sufficient 
structural information of the drug targets/ligands of interest.  
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Figure 5. The use of structure- and ligand-based techniques in drug design is dependent on the 
available data.  Where no structural information is available, this would lead to the sole use of 
ligand-based techniques, where known active compounds are used for the discovery of drug 
candidates based on similarity search, pharmacophore mapping or target prediction. Where 
structural information is available, e.g. a protein X-ray structure, then structure-based 
techniques may be employed. Structure-based techniques include docking, molecular 
dynamics, QM/MM, fragment-based design, and homology modelling etc. Both approaches 











In the case where no structural information is available this would lead to the use of ligand-
based techniques, where known active compounds are used for the discovery of similar and 
more suitable drug candidates (e.g. better pharmacokinetics or higher potency). The most 
commonly used ligand-based techniques are similarity search, pharmacophore mapping and 
target prediction. Similarity-based or fingerprint-based approaches select novel compounds on 
the basis of their chemical and physical similarity to known compounds with activity at the 
target of interest, implementing the theory that structurally similar molecules tend to have 
similar binding properties.[147] Quantitative structure–activity relationship (QSAR) models 
can be used to find a relationship between structures of molecules and their target 
response.[144] Pharmacophore mapping relies on a geometric molecular framework defining 
the fundamental features accounting for the bioactivity of a compound. Pharmacophore models 
generally employ key functional groups at defined locations for active ligands binding to the 
target of interest.[149] One of the pioneering pharmacophore modeling techniques was the 
active analog approach described by Marshall et al.[150] 
Structure-based techniques 
In cases where structural information is available for the targets of interest, then structure-based 
techniques may be employed either alone or combined with ligand-based techniques. The 
Protein Data Bank (PDB)[151] constitutes the biggest depository of protein structures 
determined by X-ray crystallography and NMR techniques and generally serves as the basis 
for most structure-based drug discovery projects. Structure-based techniques include docking, 
which predicts the preferred orientation of a compound to form a stable complex with a 
particular target of interest and a scoring scheme that can be used to rank structures, and binding 
solutions. In addition, molecular dynamics simulations describe the dynamics of proteins by 
simulating motion according to Newtonian mechanics.[144, 152] Furthermore, quantum and 
molecular mechanical (QM/MM) based methods may be employed to determine energetics of 
binding, reaction coordinates or to optimize the active site placement of ligands.[153] These 
methods are however very time consuming. Other structure-based methods include fragment-
based design, which attempts to identify fragments (low molecular weight compounds) as weak 
binders to the target of interest that are subject to fragment growing, which adds additional 
fragments or functional groups to optimize interactions with the binding site. Fragment linking 
is an alternative approach to link fragments to adjacent sites of a protein target to increase 
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binding affinity. The objective is e.g. to generate leads with high affinity and selectivity.[154] 
In the case where the structure of the protein target of interest is not yet solved, homology 
modeling might be required. Homology modeling is used to build a model for the protein 
structure by the use of a structural template protein (homologous) of similar sequence.[144]  
1.2.5.1 Virtual Screening in multi-target ligand design 
Virtual screening (VS) is an inexpensive computational approach with an essential role in drug 
discovery assisting expensive experimental high throughput screening to optimize compound 
screening and improve hit discovery.[148] Both ligand-based (LB-) and structure-based (SB-) 
techniques can be implemented in VS. In fact, the application of SB-VS has been successful 
across various protein targets in drug discovery.[148] For example, potent inhibitors of Hsp90 
(heat shock protein 90), a key therapeutic target in cancer, were discovered by applying SB-
VS of several hundred thousands of compounds from the 1.62M compound rCat database [155] 
against Hsp90. Another example involves the discovery of novel series, 1-(N-substituted 
piperidin-4-yl) benzimidazolones, by using the homology model of the M1 acetylcholine 
receptor (mAChR) derived from the crystal structure of bovine rhodopsin.[148] In addition, 
the SB-VS protocol devised by Jaiteh et al led to the discovery of dual-target ligands at the A2A 
adenosine receptor (A2AR) and monoamine oxidase B (MAO-B), a polypharmacological 
profile relevant for Parkinson's disease. Similarly, compounds discovered by LB-VS and 3D-
QSAR analysis, were successful in inhibiting MAO-A, MAO-B, AChE, and BuChE.[156] 
Hence, in many instances, the use of SB-VS and LB-VS have been successful in providing new 
avenues for drug discovery against multi-factorial diseases.[95]  
Besides the separate application of LB-VS and SB-VS in drug discovery, the combination of 
both could also be implemented. For instance, Lepailleur et al discovered benzo[h]-[1,6] 
naphthyridine ligands as dual H3R (Transcriptional elongation factor) antagonists/5-HT4R 
(Serotonin 4 receptor) agonists by applying a combination of pharmacophore-based virtual 
screening, similarity based clustering methods, and molecular docking.[157] Binding 
experiments confirmed the affinities of the selected ligands towards H3 and 5-HT4 receptors. 
In addition, fragments that exhibited dual activity against β-secretase1 (BACE-1) and glycogen 
synthase kinase 3β (GSK-3β) protein targets, two structurally unrelated enzymes associated 
with the onset of Alzheimer’s disease, were identified by a combined SB-VS and LB-VS 
protocol developed by Bottegoni et al.[136] Also Butini et al reported their combined SB-VS 
 17 
and LB-VS of multi-target ligands at the dopamine, serotonin 5-HT1A and 5-HT2A receptors, 
which are key proteins in neurological disorders.[158] 
Hence, VS is a cheaper and faster method than HTS, which could be used for screening large 
in silico libraries, and could be combined with HTS as a prior step. In addition, VS allows the 
investigation of totally novel compounds that have neither been synthesized nor purchased. 
However, it cannot completely replace HTS that experimentally tests the activities of hundreds 
to thousands of compounds against a particular protein target of interest, which is a 
fundamental step in drug discovery. 
In this work, SB-VS is employed both separately and in combination with LB-VS. An 
important consideration in VS is to shortlist a list of candidates that are synthetically feasible, 
for this reason RECAP (Retrosynthetic Combinatorial Analysis Procedure) has been 
employed.[159, 160] Ligand-based approaches are used in combination with structure-based 
approaches, and in particular target prediction is employed to find compound series that show 
agreement with the predictions of multi-target ligands at the A1R, A2AR, and PDE10A via target 
prediction and docking. A comprehensive description of the ligand-based techniques employed 
is included in section 1.2.5.2. In addition, structure-based approaches, in particular molecular 
docking and molecular dynamics simulations, which are used in designing allosteric calpain-1 
inhibitors and multi-targeted ligands that elevate intracellular cAMP are discussed extensively 
in sections 1.2.5.3 and 1.2.5.4 respectively. 
1.2.5.2 LB-VS – target prediction  
In general, ligand-based approaches are based on the principle of chemical similarity, where 
similar compounds are predicted to exhibit similar biological properties. Similarity searching 
for ligand-based in silico target prediction has been widely practiced. It is a popular approach 
that can predict whether candidate compounds are active against a particular target of 
interest[161] based on their molecular similarity to known bioactives reported in 
chemogenomic databases.[162, 163] Target prediction tools may be employed for this purpose. 
For instance, SwissTargetPrediction is a web server that implements 2D and 3D compound 
descriptors to predict whether test compounds are active (against a particular target) based on 
the similarity of the descriptors to those of known active compounds against the same protein 
target.[164] In addition, PIDGIN 1.0 (Prediction including Inactivity) is a tool that uses ECFP 
4 circular Morgan fingerprints trained on ChEMBL actives and PubChem inactives to predict 
the activity of the query compounds, and it has been later updated to its newer version (PIDGIN 
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2.0).[133, 165] Another tool for target prediction, which accounts for the polypharmacological 
profile of the query compounds, is PolyPharmacology Browser (PPB). PPB is a web-based 
platform that searches for nearest neighbors to predict the multi-activity profile of small 
molecules using ten different fingerprints accounting for composition, substructures, molecular 
shape and pharmacophores.[166]  
In this work, A1R, A2AR, and PDE10A were the protein targets of interest for the investigation 
of novel multi-target ligand design approaches.  Target prediction using PIDGIN 1.0 was 
employed to find compound series that show agreement between target predictions and docking 
focusing on multi-target ligands at these targets.  The series found by this method were 
synthesized and then experimentally validated as multi-target ligands in relevant biochemical 
assays.  
PIDGIN 1.0 uses Naïve Bayes (NB) classifiers, which are probabilistic models implementing 
Bayes' theorem and assuming independence between the features used. This family of 
algorithms has been extensively used for bioactivity prediction, due to their rapid training and 
prediction times, as well as their insensitivity to noise.[167] Other example of a multi-class 
Naïve Bayes classification algorithm includes one that has been trained by Nidhi et al[168] on 
data composed of over 960 target proteins extracted from the ‘World Of Molecular 
BioAcTivity’ (WOMBAT).[169] Another example was developed by Koutsoukas et al,[170] 
for predicting structure activity relationships (SARs) of orphan compounds. This employed 
either a Laplacian-modified Naïve Bayes classifier or a Parzen-Rosenblatt Window (PRW) 
learning algorithm. The algorithm was trained on data from the ChEMBL14 database,[171] 
consisting of more than 155,000 ligand-protein pairs of 894 different human protein targets.  
Given that these methods only consider the structure of the compound without taking into 
account that of the protein target, this may limit their predictivity. Hence, it would be best if 
ligand-based approaches are combined with structure-based techniques, which has been done 
here. This combination of techniques might provide a more complete picture of drug-target 
interactions, and it is expected to considerably increase confidence in the predictions being 
made, which would potentially yield a higher rate of success for rational drug design.[172] 
1.2.5.3 SB-VS-Molecular Docking  
Molecular docking is often used to predict the interactions between small molecules and protein 
targets, along with their optimum poses and conformations when fitting the protein-binding 
site as well as providing an estimate of the stability of the ligand–protein complexes formed. 
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Commonly used docking software include Glide[134], GOLD[173], DIVALI[174], 
DARWIN[175], CDOCKER[176], and AutoDock.[177] Docking is more efficient when the 
binding site of the protein target is experimentally determined by X-ray crystallography and 
available in the protein data bank (PDB). However, in the case where it is not known, 
information about the sites could be obtained by comparing them with a family of proteins of 
similar function, co-crystallized with other ligands. When nothing is known about the binding 
site, programs such as GRID[178, 179], POCKET[180], SurfNet[181, 182], PASS[183] and 
MMC[184] may be employed  to predict potential binding pockets within proteins. In the case 
where docking is performed without knowledge of the binding site, this would be referred to 
as blind docking.[185] 
Furthermore, it is important to find the most stable binding mode of a ligand by optimizing its 
geometry while docked to the protein target; hence, objective functions (e.g. molecular 
mechanics) are calculated and used to optimize docking. In addition, several sampling 
algorithms have been developed to estimate binding affinity using scoring functions, often used 
for ranking generated conformations or ranking series of binders. This help avoid generating 
all the possible conformations that would be too computationally expensive when taking into 
account all the translational, rotational, and conformational degrees of freedom of both the 
ligand and protein.[35] 
Various docking algorithms  
Matching algorithms (MA)[186–188] use molecular shape to map ligands into the active site 
of a protein taking into account chemical information and shape features. For this purpose, 
calculations are performed that generate a distance matrix, which aids in the search for ligand 
conformations that lead to the best match between pharmacophores representing the protein 
and the ligand atoms. In addition, chemical properties such as hydrogen-bond donors and 
acceptors are generally considered in these matching algorithms. These algorithms are used 
since they are fast, they enrich active compounds from large libraries,[189] and they are 
implemented in programs such as DOCK[190], FLOG[191], LibDock[192] and 
SANDOCK.[193] 
Incremental construction (IC) methods[194–196] place the ligand into the binding site in a 
fragmental and incremental manner, where the ligand is fragmented into many parts often by 
breaking rotatable bonds. Subsequently one of these fragments is chosen to be docked first into 
the active site, usually the largest fragment or one with a major functional role in contributing 
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in the interactions with the protein (e.g. a warhead structure). Then the remaining fragments 
are added incrementally, generating various orientations and conformations. This requires 
some flexibility of the docked ligands, until their optimum fit is obtained in the active site. 
These methods may be used in programs such as Glide,[134] DOCK 4.0,[197] FlexX,[194] 
Hammerhead,[198] SLIDE[199] and eHiTS[200]. 
Multiple Copy Simultaneous Search (MCSS)[201, 202] and LUDI[203] are also fragment-
based methods that are used for the de novo design of ligands. They rely on modifying known 
ligands to improve their binding to the protein target. Around 1,000 to 5,000 copies of 
functional groups are generated by the MCSS method and randomly positioned into the binding 
site, while concurrently exposed to energy minimization and/or quenched molecular dynamics 
within the force field of the protein. The copies are only allowed to interact with the proteins 
but not among themselves. Then, based on the interaction energies, a group of energetically 
favorable binding sites and orientations for the functional groups is identified, enabling 
mapping the whole binding site using different functional groups. By linking those different 
functional groups, new candidate compounds may be designed that optimally fit the mapped 
binding site (at least, optimum in terms of the fitness function employed). 
LUDI is a computer program which is focused on the interaction sites between the ligand and 
protein that are treated as distinct locations in space suitable for hydrogen bonding or 
hydrophobic interactions.[203] These interaction sites may be generated either by using rules 
or searching the database. Fragments are then placed into the interaction site and assessed by 
their distance to this site; by joining all the fitted fragments this would form a single compound. 
Monte Carlo (MC) algorithms belong to stochastic methods, whereby it is be possible to 
generate many ligand poses[204, 205] via bond rotation, rigid-body translation or rotation. 
Based on their interactions (and internal) energies, the ligand conformations are assessed, and 
if they pass, are modified to produce subsequent conformations. This is performed iteratively 
until a pre-defined quantity of conformations is assembled, allowing ligands to overcome 
energy barriers on the potential energy surface. Monte Carlo methods may be used in programs 
such as Glide, AutoDock (earlier version)[206], ICM[207], QXP[208] and Affinity 
(Accelrys)[209]. 
Genetic algorithms (GAs) are another class of well-known stochastic methods.[177, 210, 211] 
The idea for GAs originates from Darwin’s theory of evolution. In computer-based 
implementations, binary strings, which can be termed genes, are used to encode the degrees of 
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freedom of the ligands. The three main genetic operators in GAs are mutation, crossover, and 
selection. Random changes to the genes are made during mutations. Genes are exchanged 
between chromosomes during crossover (this is in fact the most effective optimization process). 
The fittest combinations are generally selected for further optimization by using a scoring 
function. New ligand structures result when genetic operators modify the genes. Scoring 
functions are used to assess the new structures, and those that are above a selection threshold 
may be used for the next generation. GAs are used in programs such as AutoDock[177], 
GOLD[173], DIVALI[174] and DARWIN[175]. There are differences in the selection 
algorithms employed e.g. using Darwinian (Gold) or Lamarkian (AutoDock) evolution. 
In this work, Glide is employed for protein-ligand docking in structure-based approaches for 
the design of allosteric calpian-1 inhibitors and multi-target ligands at A1R, A2AR, and 
PDE10A. Glide’s docking algorithm is represented as a docking “funnel” in Figure 6. It utilizes 
a hierarchical search protocol and estimates a full systematic search over ligand positions, 
orientations, and conformations in the receptor site. Then minimization of the poses selected 
by the initial screening is performed using the OPLS-AA force field in combination with a 
distance-dependent dielectric model. Subsequently, the lowest-energy poses are subject to a 
Monte Carlo procedure to examine nearby torsional minima. Finally, the total Coulomb-van 
der Waals energy (Ecvdw), with the Coulomb energy screened by a distance-dependent 
dielectric constant determines the final ligand pose that is selected. The scoring function, 
GlideScore, which is used to calculate binding affinity, is an extension of an empirically based 
scoring function, Chem-Score function of Eldridge et al.[134] 
 
Figure 6. Glide docking “funnel” shows the Glide docking hierarchy. [134] 
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Scoring functions  
Given that binding of ligands to their targets depends on their molecular interactions, 
physicochemical properties, as well as their conformations, scoring functions including these 
properties have been used in docking. Scoring functions are used to select the right poses of 
the ligands in a realistic time frame, where many assumptions and simplifications are 
made.[212] They are classified into three categories: force-field-based, empirical and 
knowledge-based scoring functions.[212]  
Force-field-based scoring functions,[213–215] are used to evaluate the binding energy by 
calculating the sum of steric, electrostatic and van der Waals interactions. For electrostatic 
interactions, a distance dependent dielectric term is used with a cutoff distance for inclusion of 
electrostatics. A Lennard-Jones potential is used to describe the van der Waals interactions. 
Implemented force-field-based scoring functions have limitations e.g. the cut-off distance 
employed to deal with the potentially large number of electrostatic and van der Waals 
interactions decreases the accuracy of computing interaction energies over longer distances.  
Furthermore, entropy contributions, polarizability and solvation effects could be accounted for 
in extensions of force-field-based scoring functions. These extensions are offered in software 
such as DOCK[216] GOLD and AutoDock, with differences in implementation in each 
program. Moreover, refinement of the docking results with these functions can be combined 
with other techniques, such as linear interaction energy[217] and free-energy perturbation 
methods (FEP),[218] which could potentially improve the accuracy of binding energy 
prediction. 
In the empirical scoring functions[219–223] the binding energy is divided into a number of  
components: hydrogen bonding, ionic interactions, hydrophobic effects and binding entropy. 
A final score is obtained by adding each energy component multiplied by a coefficient that is 
derived from regression analysis fitted to known ligand-protein complexes with reported 
binding affinities. 
Despite the simplicity of the energy terms that are evaluated in the empirical scoring functions, 
it is not clear whether their applicability domain is suited for ligand-protein complexes that are 
not included in the training set. The applicability domain is the region in the ligand-protein 
chemical activity space where the scoring functions would be reliable. Moreover, various 
software packages treat each term in the empirical scoring functions differently. Examples of 
programs using empirical scoring functions include LUDI, PLP,[224] and ChemScore.[225] 
 23 
In knowledge-based scoring functions,[226–231] crystal structures of ligand-protein 
complexes are used to perform statistical analysis of the ligand-protein distances and/or the 
frequencies of their interatomic contacts. It is assumed in these analysis that the higher the 
frequencies of the protein-ligand interactions the more they are favorable. The distributions of 
frequencies are transformed into pairwise atom-type potentials, where a score is computed 
according to a cut-off that considers favored interactions and penalizes repulsive ones. 
There are many advantages to knowledge-based functions, such as their simplicity and speed, 
which allows their use for screening large compound databases. Also these functions may be 
used in modelling uncommon interactions (if data were available and included in the scoring 
function generation) such as cation-π and halogen- π-aromatic interactions, which might not be 
accounted for in empirical approaches. Some interactions, in particular those involving metals 
or halogens, are still not well represented in training sets that might involve insufficient number 
of crystal structures, which limits their applicability domains. Examples of knowledge-based 
functions include PMF,[226] DrugScore,[232] SMoG[233] and Bleep[227] that vary in their 
distance cut-offs, size of training sets, the form of their energy functions, definition of atom 
types, and training data etc. 
Consensus scoring[234] has been used to evaluate docking and scoring by combining the 
results of several scoring functions. When the pose of a candidate ligand scores well across 
different scoring functions, it could be more confidently predicted to be a potential binder. This 
approach has been seen to improve enrichment and prediction of bound conformations and 
poses in VS.[235] However, accurate binding energy prediction is a severe challenge.  There 
are some (named) scoring functions that are already a combination of other scoring functions 
e.g. CScore[236] is an example that combines DOCK, ChemScore, PMF, GOLD, and FlexX 
scoring functions. 
Scoring functions in general share a common problem in affinity prediction can be attributed 
to limitations in considering solvation effects, entropy, kinetics, heat capacity and the generally 
inaccurate nature of empirical scoring. An approach to move towards addressing this could be 
the use of physics-based scoring functions such as MM-PB/SA and MM-GB/SA (MM stands 
for molecular mechanics, PB and GB for Poisson-Boltzmann and Generalized Born, 
respectively, SA for solvent-accessible surface area). Some studies suggested improved results 
obtained with MM-PB/SA[237, 238] or MM-GB/SA.[239] Nonetheless, it was reported that 
the GB/SA model poorly estimated protein desolvation in certain systems. In contrast, better 
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results were obtained when WaterMap was incorporated into the MM-GB/SA method instead 
of GB/SA protein desolvation.[240] Many comparative studies for various methods of affinity 
evaluation for protein-ligand complexes have been reported in the literature. One suggestion 
was that PDLD/S-LRA/β (protein dipoles Langevin dipoles linear response approximation) 
might be a good option for use in the final stages of VS. As for PB/SA, it might not provide an 
accurate estimate of binding energies because of its erroneous estimation of entropies and its 
mishandling of electrostatic energies.[241] Recent work on Deep Learning and artificial 
intelligence (A.I.) methodologies claim to improve scoring performance.[242, 243] 
In this work, GlideScore is the scoring function used in shortlisting ligands from the structure-
based design approaches. It is an extension and a modification of ChemScore, an empirical 
scoring function.[134] The equations of ChemScore and GlideScore functions are discussed 
further in Appendix A.  
Two forms of GlideScore may be employed, GlideScore 2.5 SP, Standard-Precision Glide and 
GlideScore 2.5 XP Extra-Precision Glide.[134] The GlideScore 2.5 SP is a “softer”, more 
lenient function, which predicts ligands to bind to the protein target of interest with reasonable 
affinities despite the imperfections in their poses. Thus, this GlideScore version would be more 
convenient for screening databases to minimize as much as possible false negatives. In contrast, 
GlideScore 2.5 XP is a stricter function that applies more stringent penalties for poses violating 
e.g. atom pair interactions. This version would then minimize false positives, which could be 
useful for lead optimization or for the selection of the final top candidates by VS.[134] In this 
work, the choice of SP or XP parameters in docking has been deduced from experiments 
performed on known actives and inactives for each of the protein targets considered, allowing 
for the maximum separation between their docking score distributions. 
Docking methodologies 
Rigid ligand and rigid receptor docking is one type of docking, where both the ligand and 
receptor are kept rigid, by limiting their space to three translational and three rotational degrees 
of freedom. This method can account for the ligand flexibility by a pre-computed set of ligand 
conformations, or by enabling some degree of atom–atom overlap between the protein and 
ligand. It has been used in programs such as DOCK, FLOG, Glide and some protein-protein 
docking programs, such as FTDOCK.[244] 
The first automated procedure for ligand-protein docking was DOCK, and it has been 
constantly improved. In this program, the ligand and receptor are treated as sets of spheres that 
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could be overlaid using a clique detection procedure.[245] And the scoring of the ligand-
protein complexes is done according to some criteria such as pharmacophore similarity, 
chemical complementarity, or steric fit, where geometrical and chemical matching algorithms 
are implemented. 
Flexible ligand and rigid receptor docking is another type of docking that could be used for 
ligand-receptor systems behaving within the induced fit paradigm. Usually it would be better 
to account for the flexibility of the ligand and the receptor, since both change conformation on 
association, and in particular in the cases where the receptor is highly flexible. However, 
sometimes a compromise between accuracy and computational time has to be made where it 
would be more feasible to keep the receptor rigid and the ligand more flexible during docking. 
This method is implemented in many docking programs such as AutoDock, FlexX, and Glide 
etc.[246, 247]  
Flexible ligand and flexible receptor docking is a third type of docking. As suggested by the 
literature, the flexibility of proteins is affected by ligand binding (induced fit);[248] however, 
it would be very challenging to account for receptor flexibility in docking alone. MD 
simulations could better account for protein flexibility by modeling most of the possible 
degrees of freedom of ligand-receptor complexes. Yet, sometimes due to the high 
computational expense of MD and inadequate sampling, this method might not be suitable for 
screening large chemical databases. 
Furthermore, various theoretical models - conformer selection, conformational induction, and 
historic induced fit, have been proposed to account for flexible ligand-protein binding. When 
a ligand binds selectively to a favorable protein conformation over a number of possible protein 
conformations, this is referred to as conformer selection. As in the case of conformational 
induction, the ligand transforms the protein’s conformation upon binding from what was in the 
unbound state.[174]  
“Soft-docking” is a method used to account for receptor flexibility[249] by allowing for some 
atom-atom overlap between the ligand and the receptor via modifying the van der Waals 
repulsion energy term in the scoring function used. Examples where this method is 
implemented include the LJ 8-4 potential in GOLD and the smooth potential in AutoDock 3.0. 
Given that the receptor coordinates are fixed in this method, and it simply relies on modifying 
the van der Waals parameters, this optimizes its computational efficiency, though it might 
result in inadequate flexibility.  
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Using rotamer libraries is another method for modeling receptor flexibility.[250, 251] These 
libraries consist of side-chain conformations derived from statistical analysis of structural 
experimental data. Employing this method offers relatively quick sampling, and it avoids 
minimization barriers. Coupled with biased probability methodology,[207] and Monte Carlo 
search of ligand conformations, rotamer libraries are used in the ICM (Internal Coordinates 
Mechanics) program.[207] 
Additionally, in order to account for side chain flexibility, AutoDock 4 adopts a simultaneous 
sampling method,[252] where users can select several side chains of the receptor to be sampled. 
As for the rest of the receptor it is dealt with as rigid during sampling with an energy grid map. 
Using a combination of protein conformations, utilizing the theory of conformer selection, 
would be another way to account for receptor flexibility.[152, 253] Ligands may be separately 
docked to each of the rigid protein conformations, in order to merge the results depending on 
the method chosen.[254] This method was first used in DOCK, where it produces an averaged 
potential energy grid for a combination of protein conformations.[152] Also in other programs 
such as FlexE several crystal structures of a particular protein are used, merging analogous 
parts and marking the dissimilar ones as different parts to be considered as alternatives. Protein 
conformations are sampled in a combinatorial manner during the incremental construction of 
a ligand, where the best scoring is selected based on the comparison between the ligand and its 
alternative. 
Hybrid docking is another approach used for modelling receptor flexibility. This method is 
implemented in Glide, and uses a set of hierarchical filters in the search for possible ligand 
poses and orientations within the receptor-binding site. As for ligand flexibility it may be 
accounted for by performing a thorough search of the ligand torsion energies, based on which 
ligand conformations are selected with a soft potential for docking into the receptor binding 
sites. Subsequently, to further model receptor flexibility rotamer exploration may be employed. 
For instance, IFREDA[254] accounts for receptor flexibility by employing a hybrid method 
that combines soft potentials and multiple receptor conformations. As for other programs like 
QXP and Affinity, a Monte Carlo search of ligand conformations may be done accompanied 
by a minimization step, where the user defines parts of the protein that are allowed to move to 
avoid clashes between the ligand and receptor. In addition, flexibility may be incorporated with 
SLIDE by removing clashes through directed single bond rotation of either the side chains of 
the protein or the ligand. In order to model induced-fit complementarities between the ligand 
and protein, an optimization approach based on the mean-field theory may be applied. 
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All of the methods mentioned either deal with the side chain or the full receptor flexibility. 
However, sometimes loops constituting the active sites of several enzyme families such as 
Bromodomains,[255, 256] contribute a major role in ligand binding, and undergo dramatic 
conformational changes while keeping the other parts of the receptor unchanged. In this case, 
methods that account for side chain and full receptor flexibility fail to deal with loop flexibility. 
Local Move Monte Carlo (LMMC) loop sampling method could be used in this case. This 
method relies on sampling ligand conformations within loop-containing active sites. It is the 
torsion angles resulting from side chain movements as well as the motion of the loop backbones 
that generates the allowed loop conformations. A grid-based force field that represents the 
protein environment and solvation effects was developed to minimize the computational costs 
for the evaluation of energy in these calculations.[257, 258]  
In this work, the flexible ligand and rigid receptor docking methodology in Glide is employed 
for the structure-based design of allosteric calpain-1 inhibitors and multi-target ligands at A1R, 
A2AR, and PDE10A. This docking methodology has been selected since all the protein targets 
of interest are fairly rigid as assessed by thermal stabilities (B factors)[259] in Glide. 
1.2.5.4 SB-VS-Molecular Dynamics Simulations 
Molecular dynamics (MD) is extensively used in molecular modelling. MD can account for the 
flexibility of the docked ligand-protein structures by moving each atom separately in the field 
of the other atoms in order to rationalize or even predict experimental behavior of the system. 
[260–262] MD is often used as a sampling technique to explore as many configurations as 
possible, which allows for the identification of low energy configurations or the calculation of 
the system’s equilibrium or dynamic properties.  It may be used to generate trajectories to study 
the system’s kinetics e.g. folding of a protein.[263] Programs such AMBER[264] and 
Desmond[265] are available to perform MD simulations.  
First, a structure of the ligand-protein complex is prepared, then mathematical equations 
(Equations 1-3)[263] are used to estimate the forces acting upon each atom of the system 
(molecular mechanics (MM)). The trajectories of the atoms are determined by numerically 
solving Newton's equations of motion. 
MD is an efficient method, which although relatively fast (compared to QM), enables 
consideration of the physics of biomolecular systems with an approximation that neglects the 
quantum effects. This is the Born-Oppenheimer approximation, where each particle in the 
system, whether a single atom or a rigid set of atoms, is treated as a point mass i.e. only the 
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nuclear displacements need to be considered, and not the quantum mechanical effects of the 
motions of the electrons.[266] 
The relationship between the velocity of an atom i, and its momentum, pi, with a mass mi, and 






   (Equation 1) 
Equation 2 shows the net force, Fi, exerted on the atom i by the remainder of the system as 




 (Equation 2) 
Equation 3 is the Newtonian equation of motion for atom i. 
𝑑𝑝𝑖
𝑑𝑡
=  𝐹𝑖   (Equation 3) 
In an MD system, the position and the velocity of each particle is recorded and Equations 1-3 
are iteratively and simultaneously solved over short time steps, whereby the system’s 
deterministic trajectory is computed. Given the discrete nature of the calculations, the Verlet 
algorithm[267] is employed as a correction. See Appendix B. 
The process is repeated iteratively as the simulation time progresses. An important 
consideration is that the time step has to be substantially shorter than the motions of the highest 
frequencies, which are the C-H stretches. Otherwise simulations might be inaccurate and 
deviations from the standard bond lengths might occur resulting in high forces and velocities 
that could lead to the “explosion” of the system. The standard time step is 1 fs, in order to 
increase the time, constraint algorithms are usually applied. The SHAKE algorithm[268] is 
often implemented and constrains the X-H bond lengths, eliminating the fastest motions, which 
allows increased time steps to 1.4 fs. The LINCS[269] and M-SHAKE[270] algorithms may 
further extend the time step to 2 fs by constraining all bond lengths. It has been reported that it 
would be possible to increase the time step further to 5 fs for instance, in the case where there 
are no explicit hydrogen atoms in a system using the LINCS algorithm.[271]  
An important consideration in any MD is the choice of the system ensemble[272] that has to 
be computed taking into account the nature of the simulation that is being performed. The 
factors constituting the simulation are the conservation of each of: matter (N), volume (V) or 
pressure (P), and temperature (T) or Energy (E). A canonical ensemble (NVT) is used in the 
simulations. In general, the ensemble used is the Isothermal-Isobaric (NPT), since biological 
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systems are normally maintained at constant pressure conditions with little change in 
temperature. In both types of ensembles a thermostat e.g. Berendsen[273] or Nose Hoover, is 
used to keep a constant temperature by adding or removing energy from an isothermal bath. In 
the case of the NPT ensemble, a barostat[274] is required e.g. Berendsen or Parrinello-Rahman 
to sustain a constant pressure.  
Periodic boundary conditions (PBC)[275] are employed in most biomolecular simulations in 
order to avoid artefacts at the edge of the simulation box. By applying PBC, leaving one face 
of the system (e.g. in a cubic system) would take the particle to the “opposite” side of the 
system, which can e.g. be implemented as a cube, octahedron etc. PBC better accounts for an 
‘infinite’ system, though it also exhibits artefacts arising from the interactions of the molecules 
with themselves in small systems, or interacting twice (in both sides of the box for example) 
with other molecules in somewhat larger systems. Hence, to ensure the best performance of 
PBC, the sizes of the system should be substantially larger than the interaction cut-off 
distances. 
Reproducing realistic motions of atoms requires all the necessary potential functions and 
parameters, optimized to be self-consistent, and this is termed a force field.[263] A force field 
generally employs a set of well-defined equations for bonding and non-bonding interactions, 
which contain harmonic potentials for bond lengths, bond angles, torsion angles and associated 
force constants, pair-wise calculated van der Waals and Coulombic functions with associated 
parameters and electrostatic terms.[276] Depending on the equations used and the parameters 
incorporated into them, which are determined for the systems of interest, this would determine 
which force field is selected for a particular problem. Commonly used force fields in Biological 
MD simulations are AMBER, CHARMM,[262] GROMOS,[277] and OPLS3,[278] which are 
parameterized differently.[279] In some force fields, the parameters are based on experimental 
data and quantum mechanics calculations, with assumptions and approximations implicit in the 
force field equations and MD simulations, which often result in inaccurate “macroscopic” 
results.  In other force fields each parameter could be virtually meaningless by its own, but 
rather all together they would result in simulations that are in agreement with experimental 
observations. In general, the latter types of force fields perform better in the systems that they 
are parameterized to work in, but poorly in systems that fall outside the scope of 
parameterization, which is often attributed to over-fitting. The majority of force fields lie 
between the two types by primarily using parameters derived from theory and experiments, 
which are then subject to some modifications in order to improve the simulations.[276]   
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There are many challenges in terms of computational costs that are encountered in large-scale 
simulations with non-bonding interactions, since every atom has to interact with every another 
atom. Also in the case where PBC is used, atoms might interact with themselves, which might 
result in infinite interactions. One of the easiest ways to solve these issues is to use a cut-off 
distance, beyond which no interactions would be calculated. For instance, a cut-off of 1.0-1.5 
nm is suitable for van der Waals interactions but not the long-range electrostatic interactions, 
where large errors might result, intensified by the abrupt change at the cut-off distance from 
full interaction to no interaction.[276] The commonly used techniques to account for this are: 
the Reaction Field (RF),[280] which merges the electrostatic interactions into a simple field 
beyond the cut-off; Ewald summation that uses Fourier transforms to sum up electrostatic 
interactions to infinity over PBC; Particle Mesh Ewald (PME),[281, 282] where the summation 
is done upon a mesh, which is a faster but somewhat less accurate form of the Ewald 
summation. 
Finally, the use of implicit atoms is one of the fundamental properties characterizing force 
fields. A dielectric constant and an adequately parameterized force field may be employed to 
approximate solvent molecules in order for them to be completely removed from simulations. 
Though this might substantially decrease the accuracy of the simulations, an advantage is that 
the computational cost is massively reduced. For instance, the implicit hydrogen atoms are 
used in united atom force fields such as GROMOS[277] to reduce the computational load. 
Given that the X-H bond length is short, since the van der Waals radius of the hydrogen gets 
shortened by the atom it is bonded to (in the case of X=C for example) it would be possible to 
approximate the –CH2 and the –CH3 to a sphere that is slightly bigger than carbon itself.  
In this work, Desmond[283] with the default force field OPLS3 was employed to perform MD 
simulations. The choice of this force field is that it has been reported in the literature to include 
much more reference data and associated parameter types in comparison to other force fields 
often used for small molecules (e.g. MMFF and OPLS_2005).[278] In addition, across 
different validation studies, OPLS3 appeared to exhibit higher accuracy when assessing 
different conformational and solvation properties of small molecules. A detailed description of 
the functional form of the OPLS3 force field is included in Appendix C.  
However, one of the limitations of MD is its high computational demand for simulation of large 
systems (although clearly not as high as QM). Implementations for the simulation of large 
biological systems generally require many processors and a significant time to be completed. 
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In addition, another disadvantage is the over-simplification of the force fields that are used to 
replicate the quantum-mechanical reality of the simulated systems, in particular where 
electronic effects (e.g. polarization (not generally present in most current force fields), 
aromaticity, dispersion) are important. These can be significant e.g. when transition metal 
atoms are involved in binding. Another limitation is the small-step progression, which makes 
it difficult to surpass conformational barriers of high-energy in a realistic time-scale that might 
result in inadequate sampling. Nonetheless, MD is an effective method in local optimization, 
and for this reason it is beneficial to carry out MD simulations after selecting the best 
conformation of the ligand/protein complex. Hence, an effective approach is to combine 
molecular docking with molecular dynamics simulations to predict key molecular interactions 
and dynamics upon ligand binding to protein targets.  This can then be associated with potential 
biological effects.[263] The described approach is implemented in this work, where docking is 
followed by MD simulation analysis to find a conformational descriptor characterizing receptor 
activation. 
Given that e.g the A2AR is a GPCR, which is a transmembrane protein, then it is essential to 
mimic its natural environment in order to correctly predict its dynamics in MD simulations. 
The thickness of the cell membrane is approximately 7 nm, and it consists mostly of 
phospholipids with other molecules such as glycolipids and steroids.  It is amphipathic by 
nature i.e. extremely apolar from the inside (mainly hydrocarbon) and polar from the outside. 
The homogenous bilayer made up of an ensemble of a single phospholipid is commonly used 
to simulate the membrane. It is capable of mimicking many of the physical properties of the 
bi-layer despite being less structurally diverse than the real cell membrane. The use of the 
homogenous bilayer of a single phospholipid avoids artefacts resulting from poor mixing or 
incorrect component ratios, and simplified molecular topologies. 1-palmitoyl-2-oleoyl-
phosphatidylcholine (POPC),[284] 1-palmitoyl-2-elaidoyl-phosphatidylcholine (PEPC),[285] 
1,2-dimyristoyl-phosphatidylcholine (DMPC),[286] and 1,2-dimyristoyl-sn-glycero-3-
phosphocholine and dipalmitoylphosphatidylcholine (DPPC)[271] are the commonly used 
phospholipid bilayers in the simulations of GPCRs. It has been reported in the literature that 
the use of POPC allows maximum mobility and flexibility of the receptor,[287, 288]. In this 
work (simulations of the A2AR) POPC has been selected to construct the membrane used in the 
simulations.  
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1.2.5.1 Examples of successful applications of molecular docking and MD simulations 
in drug discovery 
Molecular docking has been extensively used in SB-VS and has been successful in finding 
novel bioactives[289, 290] For instance, when docking was combined with other 
computational techniques and experiments, it has assisted in the analysis of drug metabolism 
by increasing understanding of the cytochrome P450 system.[291–293] Furthermore, the 
structure based design performed by Boehm et al using LUDI and CATALYST resulted in 
several novel and potent DNA gyrase inhibitors, where HTS proved ineffective.[294] In 
addition, Doman et al performed a comparative study for SB-VS and HTS,[295] where both 
were applied to screen protein tyrosine phosphatase-1B (PTP-1B) inhibitors.  The results of the 
study highlight the success of SB-VS, where the hit rate was enriched by 1700-fold via docking 
as compared to random screening. It has been noted however, that the hits are more diverse in 
the VS and HTS, which suggests that it might be beneficial to combine both for lead discovery. 
Furthermore, docking and MD simulations using the Autodock Vina program were performed 
for synthesized donepezil-indolyl hybrids[156] and donepezil-pyridyl hybrids[296] against the 
PDB crystal structures of four enzymes (AChE/BuChE/MAO-A/MAO-B). MD simulations 
identified the most promising donepezil hybrid[297] as a good starting point for analog 
modification for the design of novel multi-target ligands for the treatment of AD.  
Hence, docking and molecular dynamics simulations are key tools in drug discovery, and given 
all their successful implementations in pharmaceutical research, they have been employed here 
in structure-based ligand design approaches. Docking is used in the structure-based design of 
allosteric calpain-1 inhibitors, also it has been combined with molecular dynamics simulations 
to design and rationalize the functional effects of multi-target ligands that elevate intracellular 
cAMP. 
1.2.5.2 Computational approaches for lead optimization and prediction of 
physicochemical properties for compounds 
QSAR modelling 
In order to optimize the physico-chemical and biological properties of the identified lead 
compounds, and to efficiently minimize experimental work, quantitative structure–activity 
relationship (QSAR) modeling may be used. This approach is used to predict the effects of 
changes in molecular structure upon the physico-chemical properties of compounds. For this 
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purpose, representative molecular descriptors are selected as molecular features that are related 
to bioactivity, and which are, based on other studies, shown to be useful in QSAR modeling, 
and also have been used to assess structural similarity or diversity.[298, 299] 2D-QSAR 
methods tend to require less intensive calculations and therefore these are used as preliminary 
filters to screen compounds for later stages of drug development. In 3D-analyses, the usual 
approach is to construct pharmacophores from the geometric disposition of key functional and 
binding groups and are used to define the functional associations between the 3D-molecular 
determinants and bioactivity.[299]  
The results of QSAR analysis may be used to rationalize favorable molecular interactions 
between the protein and the compounds of interest. For instance, the design of tacrine- and 
donepezil-like multi-target ligands for the treatment of Alzheimer’s diseases constitutes an 
example of the use of 3D-QSAR approaches which are successful[300, 301] However, care is 
required in the use of QSAR modeling, as there are drawbacks associated with, in particular, 
over-fitting the data. False connections can be drawn when there are many experimental errors 
in the biological data (not uncommon in large databases)[62, 299], or there are few examples, 
or very similar bioactive compounds in the training set. Hence it is vital that a QSAR analysis 
is associated with an applicability domain assessment.[302]  
Prediction of CNS permeability  
For drugs that act centrally (CNS), it is important to understand drug partitioning across the 
blood–brain barrier (BBB). This is particularly relevant in this work, as all of the ligands 
designed (targeting PDE10A, A1 and A2A receptors, and calpain-1 proteins) are required to act 
centrally. Hence, it would be essential to understand CNS permeability of the studied ligands.  
CNS permeability is determined by several factors such as the ability to penetrate the BBB 
(between the blood capillaries and brain tissue, active and passive transport and diffusion 
across membranes), the extent of their distribution in the brain, and their activities at the targets. 
Taking all of these aspects into account, this increases the complexity of CNS drug 
discovery.[303] One important parameter to be considered is the drug unbound brain 
concentration (Cu,b), which is determined by the drug concentration at the site of the target, 
and how it affects the in vivo drug efficacy. Another important experimental parameter is the 
receptor occupancy, which is indicative of the level of target engagement by the drug. As for 
the total brain concentration (Cb), this indicates the level of nonspecific binding of the drug in 
the brain.[304, 305] It would be possible then to predict the efficacy of CNS drugs by drawing 
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quantitative structure-exposure relationships that relate the experimental parameters of brain 
exposure to the molecular parameters characterizing drugs.[305, 306] 
CNS drug efficacy and its penetration in the brain are favored by optimizing drug 
physicochemical properties, in particular lipophilicity, hydrogen bonding, aqueous solubility, 
pKa, and molecular weight. Transport of CNS drugs is facilitated through the BBB by moderate 
lipophilicity at a physiological pH of 7.4, where cLogP and cLogD are both in the range of 2–
5.[307] Higher lipophilicity may be associated with an increase in plasma protein binding 
leading to a decrease in drug solubility in the plasma, and increased metabolic and toxicity 
risks.[308]  
Unbound brain concentration (Cu,b) of CNS drugs is a major contributor to their in vivo drug 
efficacy, which is controlled by hydrogen bonding parameters such as hydrogen bond donor 
(HBD) and hydrogen bond acceptor (HBA) counts.[309] Accordingly, parameter ranges have 
been determined from analysis of available data that appear to optimize exposure in the CNS. 
These are to decrease the count of the HBD and HBA parameters to HBD < 3 and HBA < 
7.[310] In addition, the unbound brain concentrations of CNS drugs may increase with 
moderate lipophilicity (cLogP < 4) and a topological polar surface area (tPSA) range of 40–
80Å2. Also, it appears that CNS drugs may exhibit a lower safety risk when the aqueous 
solubility is more than 100 μM.[311] 
Programs such as QikProp in the Schrödinger[312] and FAF-Drugs3[313] software may be 
used to predict CNS permeability. It is still a challenging task to design CNS drugs with 
optimized physicochemical properties enabling efficient brain exposure.[307, 314, 315] In 
order to achieve more efficient penetration into the brain and gain enhanced efficacy, the 
computational predictions require further development including further exploration of the 
physicochemical properties space for available data on CNS drugs. In this work, FAF-Drug3 






1.3 Aims of this work  
In this work, single- and multi-target ligand design approaches for multi-factorial diseases were 
explored. 
In chapter 2, calpain-1, which constitutes a promising therapeutic target in a number of disease 
areas including cardiovascular, neurodegenerative and ischaemic disease was explored. The 
discovery of selective calpain-1 inhibitors has been extremely challenging due to the similarity 
of its active site to a wide range of cysteine proteases[316] In this chapter, a structure-based 
virtual screening protocol, which employs docking, was devised to design allosteric inhibitors 
in an attempt to address the issue of selectivity of inhibitors against this enzyme.[317] 
Previously, selective calpain-1 inhibitors, such as PD150606[18], which included a specific α-
mercaptoacrylic acid sub-structure (the chemical structure is depicted in Figure 7), were 
reported to bind to the penta-EF hand calcium binding domain, PEF(S) as well as the active 
site domain.[18] Although these are selective to calpain-1 over other cysteine proteases, their 
mode of action has remained elusive.[318] The structure-based virtual screening protocol 
reported here is a novel approach for the discovery of PEF(S) binders that populate a novel 
chemical space. This approach aims to elucidate an allosteric mechanism of action, which may 
offer improved selectivity and a reduced side-effects profile. 
In chapter 3, a multi-target approach was investigated in order to find compounds, that in a 
targeted fashion for a specific disease state, elevate intracellular cAMP. Specifically, the 
adenosine receptor (A1R and A2AR) targeted elevation of cAMP has already been shown to be 
beneficial for many multi-factorial diseases such as in CNS trauma, autoimmune diseases, 
inflammatory diseases, and cancer.[96–98, 115, 116]  Similarly, the elevation of intracellular 
cAMP concentrations upon PDE10A inhibition was suggested to be effective in the treatment 
of these diseases.[98, 117–121]  Designing compounds that target this novel combination of G 
protein-coupled receptors (GPCRs) and an enzyme has not been previously exploited. A 
computational method that combines in silico target prediction and docking for the design of 
synthetically feasible multi-target ligands, which bind to the A1 and A2A receptors and inhibit 
the phosphodiesterase 10A (PDE10A) enzyme is described. Ligands designed with this multi-
target combination in mind are intended as starting points for future development of multi-
target drugs. These could be beneficial in treating multi-factorial diseases (as discussed 
previously), particularly in this case neurodegenerative diseases.[116, 119] 
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In chapter 4, the method was extended to consider functional effects focusing on compounds, 
which are simultaneously agonists at A2AR and inhibitors of PDE10A, as a dual-target 
combination to elevate intracellular cAMP, and provide a proof of concept for the therapeutic 
benefits that might be exhibited in lung cancer. Triazoloquinazolines were computationally 
identified as a chemical series that showed agreement in both the ligand- and structure-based 
predictions of binding to A2AR and PDE10A (which is described in chapter 3). For the purpose 
of validating this chemical series as dual ligands at these targets, triazoloquinazolines, which 
are experimentally known PDE10A inhibitors, were docked into the orthosteric site of the A2AR 
crystal structure. This was performed as a virtual screening step in a structure-based approach 
that aimed to identify A2AR agonists as part of the dual-target ligand design objective. 
Subsequently, MD simulations were performed to study the dynamics of a specific amino acid 
residue in the orthosteric site,[319–321] in order to find a conformational descriptor 
characterizing A2AR activation. Finally, the anti-proliferative effects of the dual ligands at 
A2AR and PDE10A in lung carcinoma cell-lines were experimentally measured in order to 
provide proof of concept for the potential therapeutic benefits that these dual-target ligands 















2 Structure-based design of allosteric calpain-1 inhibitors 
populating a novel bioactivity space 
 
2.1 Introduction 
Calpains are proteins that belong to the family of calcium-dependent, non-lysosomal cysteine 
proteases expressed ubiquitously in mammals and other organisms.[317] Although the 
physiological roles of calpains are still poorly understood, they have been shown to be involved 
in many processes such as cell motility, long-term potentiation in neurons and cell fusion in 
myoblasts.[322] In particular, dimeric calpains have been reported to be involved in cell 
degeneration processes that characterize numerous disease conditions.[323] The discovery of 
selective calpain inhibitors however, has been extremely challenging.[316] In this chapter, a 
structure-based virtual screening protocol, which uses the PEF(S) crystal structure,[18] is 
reported in order to address this problem. It is shown for the first time that the inhibition of 
enzyme activity can be attributed to an allosteric mode of action, which may offer improved 
selectivity and a reduced side-effects profile. 
Calpain-1 (μ-calpain) and calpain-2 (m-calpain) are heterodimeric proteases composed of a 
large subunit with a molecular mass of ~80 kDa, associated with a small subunit of mass ~30 
kDa. The small subunit consists of two domains, namely the penta-EF hand calcium binding 
PEF(S) domain and a glycine rich (GR) domain which are essential for stabilizing calpain-1 
and calpain-2.[324] High sequence similarity of 62% is exhibited by the large subunits of 
calpain-1 and -2 in humans.[324] They consist of four different domains, an N-terminal anchor 
helix, the active site domain (CysPc), a domain that resembles the C2 membrane binding 
domains of phosphokinases (known as the C2L domain) and a second penta-EF hand calcium 
binding domain known as PEF(L). The PEF(L) domain is the determinant of the calcium 
concentration that is required for protease activation, which differentiates between the two 
isoforms: calpain-1 requires micromolar concentrations of Ca2+, whereas calpain-2 requires 
millimolar concentrations for activation.[18] 
Calpain-1 is a target dysregulated in many diseases such as neurodegenerative disorders, 
cardiovascular diseases, ischaemic disorders, arterial sclerosis, leishmaniasis and cancer.[15, 
16] In most cases of disease, calpain-1 activity is elevated (and hence its inhibition would be 
beneficial in treatment). However, it has been recently suggested that the up regulation of 
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calpain-1 appears to be beneficial in some cases, such as stage II Alzheimer’s disease, where 
its activation could be neuroprotective and beneficial in controlling cellular damage.[325] 
Until recently, it has been challenging to design selective calpain-1 inhibitors, and this is 
attributed to the fact that most compounds that target the active site inhibit a broad spectrum 
of cysteine proteases, thereby resulting in undesirable side effects.[326] For example, it has 
been previously reported that calpain-1 inhibitors,[326] which also inhibit the proteasome may 
induce apoptosis, whereas selective calpain-1 inhibitors do not. Hence, it may be beneficial to 
design selective calpain-1 inhibitors to avoid off-target related side effects. 
Classical allosteric inhibitors of calpain-1, which were originally reported to bind to PEF(S), 
exhibit a specific type of chemistry - that is α-mercaptoacrylic acid-based, such as compounds 
PD150606 and PD151746.[327] These inhibitors are potent, cell permeable and selective 
inhibitors of calpain-1 and calpain-2 exhibiting selectivity towards calpain over other cysteine 
proteases, with a slight selectivity for calpain-1 over calpain-2.  It has been reported however 
that PD150606 could equally inhibit the active site domain of calpain-1 without the presence 
of PEF(S).[318] This obviously suggests that its mode of action is rather unclear. The reported 
α-mercaptoacrylic acid based calpain inhibitors (Figure 7A. PD150606 and B. PD151746) and 
their disulfide analogues (Figure 7C. and D.) were synthesized by Adams et al, and shown to 
bind to PEF(S) from X-ray diffraction analysis (PDB IDs: 1NX3, 4WQ2 and 4WQ3).[18, 328–
330] Additional calpain-1 inhibitors that were reported to inhibit the calpain-1 complex, which 
consists of the PEF(S) and CysPc (active site of calpain-1), are also depicted in Figure 7, 
including their chemical structures. CHEMBL203568,[17] shown in Figure 7E. is a compound 
reported to inhibit the calpain-1 complex with an IC50 value of 4.9 nM.
 While 
CHEMBL204883[17], shown in Figure 7F. is a compound reported to inhibit the calpain-1 
complex with an IC50 value of 8 nM. However, CHEMBL203568 and CHEMBL204883 have 
not been confirmed as PEF(S) binders i.e. exhibiting an allosteric mode of inhibition. Their 
reported confidence score is 7 (in ChEMBL) indicating that these compounds might be binding 
to any of the subunits involved in the full-length calpain-1 complex. Hence, the use of PEF(S) 
(calpain-1 small subunit) in structure-based virtual screening may be an appealing approach 
for the design of allosteric calpain-1 binders with completely different structural architectures 
from the classical allosteric binders and inhibitors. In addition, this approach is expected to 
answer the question of whether PEF(S) binding would confer inhibition, given that the 
shortlisting of candidates is based on the prediction of their binding to PEF(S). 
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Figure 7. PD150606 A.  PD151746 B. bind to the PEF(S) of calpain, and show modest 
selectivity for calpain-1 over calpain-2. Adams et al, 2015, synthesized their disulphide 
analogues C. and D. respectively, which bind to PEF(S) and were reported with improved 
potencies in comparison to their monomer compounds. CHEMBL203568 E. is a compound 
reported to inhibit the calpain-1 complex (Uniprot IDs: P04632 and P07384) with an IC50 value 
of 4.9 nM and confidence score of 7. CHEMBL204883 F.  is a compound reported to inhibit 
the calpain-1 complex (Uniprot IDs: P04632 and P07384) with an IC50 value of 8 nM and 
confidence score of 7 
 
In this work, the PEF(S) (PDB ID: 4WQ2, calpain-1 small subunit) has been used in a structure-
based virtual screening protocol to ascertain whether novel chemical series bind to the allosteric 
pocket. To validate this approach, purchasable ligands of diverse and novel structural 
frameworks (very different from those that have been previously investigated) were evaluated 
in silico, using ligand/protein docking against PEF(S), and the compounds were subsequently 
tested in relevant assays. This pipeline for the structure-based virtual screening protocol is 
depicted in Figure 8. 
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Figure 8. The pipeline of the structure-based virtual screening protocol followed for 
shortlisting candidates of PEF(S) binders started with the collection of a pool of compounds 
with diverse chemical structures (very different from those that have been previously 
investigated), then candidates were shortlisted based on docking into the crystal structure of 
PEF(S) (PDB: 4WQ2, calpain-1 small subunit). The top ranked candidates were assessed for 
their chemical novelty in comparison to the classical allosteric binders and inhibitors using an 
MDS plot. The subset of compounds was then investigated using relevant experimental assays. 
 
As a general approach, it was hypothesized that the functional effect of PEF(S) binders on the 
active site of calpain-1 may be predicted by carrying out Molecular Dynamics (MD) 
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simulations[331, 332] on the full-length calpain-1 complex (PEF(S) and CysPc) in both the 
unbound and the ligand bound states at the PEF(S) domain. If the bound compound increases 
the average distance between the substrate and the interacting residues in the active site of 
calpain-1, then it was further postulated that it would inhibit the activity of the enzyme. In 
contrast, if the compound decreases this distance, it would favor interactions between the 
enzyme and the substrate, thus facilitating the enzyme reaction. A crystal structure of the full-
length calpain-1 complex (PEF(S) and CysPc) is currently unavailable, and hence the problem 
was approached by using the pipeline shown in Figure 8. Accordingly, the compounds that are 
predicted to bind to PEF(S) are either expected to inhibit or activate calpain-1. 
To explore the small molecule chemical architecture that would most likely alter the geometry 
of the calpain-1 active site, to inhibit its substrate cleavage allosterically, compounds with a 
diverse chemical structures were investigated computationally based on their predicted binding 
affinities towards PEF(S). The candidate PEF(S) binders, which were shortlisted by the 
structure-based virtual screening protocol depicted in Figure 8 were sulphonamides, N‐{3‐[3‐
(2‐alkoxyethoxy)‐5‐(4‐substituted-phenyl)‐1H‐1,2,4‐triazol‐1‐yl]phenyl}‐4‐methyl‐3‐
(trifluoromethyl)benzamides, and [1,2,4]triazolo[4,3‐b]pyridazin‐6‐yl]pyridines. 
Experimentally these compounds were also shown to bind to PEF(S) by displacing 2-p-
toluidinylnaphthalene-6-sulfonate (TNS, which binds to the allosteric site).[327] In addition, 
three compounds were able to inhibit the full-length calpain-1 complex (which includes PEF(S) 
and CysPc) allosterically, but not the active site domain of calpain-1 in the absence of PEF(S). 
The micro-molar inhibitory activity, via a proposed allosteric mechanism is a crucial finding 
given that these compounds show specificity in their mode of action, which is not the case for 
the classical allosteric inhibitors such as PD150606. The new inhibitors possess different 
scaffolds from the classical allosteric inhibitors. These compounds serve as a novel starting 
point for the expansion of the compound series (including SAR) to improve their potency. In 
addition, this finding suggests that compounds can inhibit the enzyme activity via the PEF(S) 
domain. An important aspect of this study is that by designing allosteric inhibitors, which do 
not inhibit the active site domain (that is common to a wide variety of cysteine proteases) these 
may be effective in treating calpain-1 related diseases without the side effects associated with 
inhibitors which inhibit the active site domain as well.[316] 
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2.2 Materials and Methods 
2.2.1 Extraction and preparation of purchasable compounds for structure-based 
virtual screening against PEF(S) 
Purchasable compounds (36,503) with diverse chemistry, including sulphonamide-, amide-, 
pyridine-, urea- and enamine-based compounds, were downloaded from the Aldrich market 
select database-2016.[333] 
The entire set of extracted ligands were prepared for docking with LigPrep 2.5[334] using the 
default settings and the Epik option, which introduces energy penalties associated with 
ionization and tautomerization.[335] 
2.2.2 Receptor Preparation of PEF(S)  
The preparation of the human PEF(S), calpain-1 small subunit (regulatory subunit) of the 
protein crystal structure (PDB[151] ID: 4WQ2)[18] bound to (Z)-3-(6-bromondol-3-yl)-2-
mercaptoacrylic acid was performed for protein-ligand docking with Glide[134]. The structure 
was prepared using the Protein Preparation Wizard of Maestro 9.3,[334] following the default 
protocol, which accounts for energy refinement, hydrogen addition, pKa assignment, and side-
chain rotational isomer refinement. Resolved water molecules were discarded and the structure 
was centered using the co-crystallized ligand as the center of the receptor grid generated for 
the protein structure. The co-crystal structure of the human calpain PEF(S) protein crystal 
structure (PDB ID: 4WQ2) bound to (Z)-3-(6-bromondol-3-yl)-2-mercaptoacrylic acid was 
selected as the target structure.   
2.2.3 Cut-off generation for compound selection from docking model 
In an attempt to validate the docking model, a set of known active and inactive compounds 
were docked against the PEF(S) protein crystal structure to ensure that it enriched actives. 32 
compounds manually extracted from ChEMBL[171] with IC50 values ≤ 1 μM (protein complex 
of the calpain-1, catalytic and small regulatory subunits: P07384, P04632 with confidence 
scores of 6 or 7) were docked against the PEF(S) model. In addition, 20 inactive compounds 
of the PEF(S) calpain-1 small regulatory subunit (Uniprot ID: P04632), extracted from 
PubChem (using the SQL query in Appendix D),[336] were docked.  
 A good separation was obtained for the medians of the docking score distributions for actives 
versus inactives for the docking model indicating that the actives are enriched. Figure 9 shows 
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the separation of the medians for the PEF(S) docking model, the medians are -7.48 (actives) vs 
-4.60 (inactives). In addition, the indole and the phenyl α-mercaptoacrylic acid-based inhibitors 
and their disulfide analogues (33 compounds), which were synthesized by Adams et al,[18] 
and shown by X-ray crystallography to bind to PEF(S), were docked against the PEF(S) 
docking model. The median of the docking score distribution obtained is -7.25 in comparison 
to the median of inactives, which is -4.60 (Figure 10). This further indicates that the model 
enriches these set of actives. A Mann-Whitney test, which included statistical analysis on the 
active and inactive docking score distributions, was performed with R[337] using the script 
provided by Kalash et al.[338] The differences in the medians was significant with p values 
less than 0.05. 
 
Figure 9. A good separation was obtained for the medians (dashed lines) of the docking score 
distribution for active versus inactive compounds for the calpain-1 docking model A. -7.48 
(active compounds) vs. B. -4.60 (inactive compounds). Statistical analysis was performed 
using a Mann-Whitney test on the docking score distributions of each target. The difference in 
medians was significant (p value < 0.05), indicating that the ChEMBL actives are enriched. 
 
 
Figure 10. The median (dashed line) of the docking score distribution obtained for the α-
mercaptoacrylic acid based inhibitors and their disulfide analogs, which were synthesized by 
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Adams et al,[18] was -7.25. The difference between this median and the median of PubChem 
inactives was significant (p value < 0.05), indicating that the actives of the Adams library are 
enriched. 
 
The Matthews correlation coefficient (MCC), which takes into account true and false positives 
and negatives, was computed using a Python script[338] for all the docking scores of the 
ChEMBL actives and PubChem inactives for the model. A search was performed for a docking 
score threshold that gave the highest MCC for the docking model. This has been done in order 
to shortlist purchasable candidates as PEF(S) binders, which displayed docking scores that are 
more negative than the docking score threshold with the highest MCC for the PEF(S) docking 
model (which was -6.35). 
2.2.4 Docking 
The purchasable compounds, prepared according to the protocol described in section 2.2.1, 
were docked into the PEF(S) protein crystal structure (PDB ID: 4WQ2). The Glide docking 
parameters included extra precision (XP) and the flexible ligand sampling option, which were 
deduced from docking experiments using known actives and inactives against the protein 
model.  The highest ranked compounds with respect to their predicted affinity towards PEF(S) 
were selected for binding assessment and calpain-1 activity evaluation i.e. those which 
displayed docking scores that are more negative than the score with the highest MCC for the 
PEF(S) docking model, which was -6.35. The compounds that did not exhibit potential 
PAINs[339] liabilities (with regard to the recent analysis of the use of this approach 
(Tropsha))[313, 340] upon virtual screening with the FAFDrug3 ADME-Tox filtering tool, 
were selected for experimental validation. The shortlisted compounds exhibited diverse 
structures (depicted in Table 1), with five sulphonamides 1-5, two substituted N‐{3‐[3‐(2‐
alkoxyethoxy)‐5‐(4‐substituted-phenyl)‐1H‐1,2,4‐triazol‐1‐yl]phenyl}‐4‐methyl‐3‐
(trifluoromethyl)benzamides 6-7, and three substituted [1,2,4]triazolo[4,3‐b]pyridazin‐6‐
yl]pyridines 8-10.   
2.2.5 Multi-Dimensional Scaling (MDS) analysis of the shortlisted compounds 1-10 
This step of the analysis aimed to plot the chemical space of ChEMBL compounds which are 
active against the full-length calpain-1 complex (with IC50 values ≤ 1 μM (protein complex of 
calpain-1, catalytic and small regulatory subunits: P07384, P04632 and confidence scores of 6 
or 7)), and the Adams library,[18] which were all validated against the PEF(S) docking model. 
In addition, the shortlisted candidates from the structure-based design protocol were included 
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in the same plot. This analysis enables an assessment of the novelty of the chemical space 
coverage of the shortlisted compounds 1-10. For this purpose, the SMILES of all compounds 
involved were standardized using the ChemAxon Command-Line Standardizer, where the 
following options were selected: “Remove Fragment” (keep largest), “Neutralize”, 
“RemoveExplicitH”, “Clean2D”, “Mesomerize” and “Tautomerize”.[341] 
Subsequently, Morgan fingerprints (radius 2, 1024 bits) were generated for all the compounds 
using KNIME 2.11.3.[342] The workflow generated Morgan fingerprints in the following 
sequence: It (a) read chemical data from an SDF file, (b) generated RDKit molecules from a 
molecule string representation (SDF), (c) generated hashed bit-based fingerprints for an input 
RDKit Mol column (d) converted RDKit molecules into string based molecule representations 
(SDF or SMILES) (e) excluded columns from the input table (f) renamed columns (g) and 
saved data table into a CSV file. 
A 2D-similarity matrix based on Euclidean distance of generated Morgan fingerprints was 
computed using the dist() function in R.[337] Then, a multidimensional scaling metric of the 
similarity matrix was computed by embedding it into two dimensions (k=2). Then, for each 
data set in the plot (corresponding to the Adams library, ChEMBL compounds, and the 
shortlisted compounds), 90% confidence ellipses were computed using the ellipse package. 
Finally, based on the generated Morgan fingerprints, a 2D MDS plot with 90% ellipse-like 
confidence regions was obtained using the R ggplot2 package,[343] with the x-axis and the y-
axis labeled Dimension 1 and Dimension 2 respectively. These are two relative and unit-less 
dimensions that recapitulate the pairwise similarity of the all points observed in the distribution 
of Euclidean distances in a lower dimensional space. 
2.2.6 Experimental validation of the virtual screening protocol 
The experimental validation of the structure-based design of PEF(S) binders was performed by 
Joel Cresser-Brown (JCB) and Connor Morgan (CM) (in the group of Professor Allemann) at 
Cardiff University, and their experimental protocols are described below. 
2.2.6.1 Expression and purification of PEF(S) 
The codon optimized gene encoding human PEF(S) was purchased from Epoch Biolabs (Texas, 
USA) in a pET21d vector. Human PEF(S) was produced in E. coli BL21-CodonPlus (DE3)-
RP (Agilent Technologies), and purified using the same procedure previously described for 
PEF(S) (work done by JCB).[18] 
 46 
2.2.6.2 Evaluating calpain-1 activity of the shortlisted candidates of PEF(S) binders 1-
10 
This assay uses a fluorogenic peptide from the calpain-1 substrate α-spectrin, containing a 
FAM-DABCYL FRET pair (H2N-K(FAM)-EVYGMMK(DABCYL)-OH). Cleavage by 
calpain-1 occurs between the Tyr-Gly residues and results in enhanced fluorescence as the 
quenching effect is relieved. The assays using purified porcine calpain-1 (CalBiochem, 25 nM) 
were performed in a buffer containing 1 μM calpain-1 substrate, 10 mM HEPES, 10 mM DTT, 
0.5 mM EDTA, bovine serum albumin (0.1%) pH 6.8. The assay was carried out using a 
fluorescent plate reader (BMG Optistar) with a final assay volume of 100 μl at a temperature 
of 37°C, using an excitation band pass filter centered at 490 nm and emission detected at 520 
nm. The compounds were added to the assay mixture before the reaction was initiated by the 
addition of CaCl2 (5 mM). None of the compounds had significant fluorescence at this 
wavelength. The compounds were dissolved in DMSO at 40 mM and diluted into assay buffer 
to give range of concentrations from 5 nM to 200 μM. In each assay run, the effect of DMSO 
alone over the concentration used was also measured. Although there was no effect of DMSO 
at lower concentrations, in some assay runs, DMSO at 0.005%-0.5% produced some inhibitory 
effect. This DMSO effect (which was only relevant for compounds with poor inhibitory ability) 
was subtracted before constructing the inhibition curves.[18] The IC50 values were obtained by 
fitting the data with non-linear regression using the SigmaPlot software,[344] and the reported 
results are the mean +/- standard deviation of three independent experiments (work done by 
JCB and CM). 
2.2.6.3 TNS displacement for compounds 1-5  
10 μM PEF(S) in 20 mM Tris base, 1.1 mM CaCl2, 1 mM EDTA and pH 7.4 was incubated 
with 46.7 μM 2-p-toluidinylnaphthalene-6-sulfonate (TNS, 1mM stock in 40% ethanol) in a 
Greiner CELLSTAR 96 well black flat bottom plate for 5 minutes at 25 °C. 
Compounds 1-10 were stored as 40 mM stock solutions in DMSO, then diluted from 500 μM 
to 500 nM by serial dilution over 10 wells with an Integra Viaflow 96 multichannel pipette in 
triplicate. 
The plates were then incubated in a FLUOstar Omega plate reader at 25 °C for 5 minutes then 
were analyzed using an excitation wavelength of 355 nm and an emission wavelength of 450 
nm with 10 flashes per well with orbital averaging. 
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The baseline (just TNS) was subtracted from the fluorescence (B). B was then subtracted from 
the Bmax (with no inhibitor) to invert the data. The data was plotted in excel as bar diagrams for 
the mean +/- standard deviation of three independent experiments (n=3) in triplicate. Whereas 
for compounds 6-10, their fluorescence interfered with TNS, (refer to Figure 11. for the blanks 
obtained for compounds 1-10) for this reason their results were omitted (work done by JCB). 
 
 
Figure 11. Blanks for compounds 1-10 measured at the TNS excitation and emission 
wavelengths, 355 and 450 nm respectively. It appeared that compounds 6-10 interfered with 
the fluorescence of TNS so they were not subject to the TNS displacement method to assess 
their binding to the PEF(S) domain. 
Compounds and reagents Compound 1 was purchased from Tocris, and compounds 2-10 were 
purchased from Ambinter, and used without further purification. PD150606 was purchased 
from Sigma Aldrich and used without further purification. 
2.2.6.4 Cloning of CysPC gene 
The pET28a-GB1-MAAKLVFF plasmid, a kind gift from Dr Cornelius Krasel of the Institut 
für Pharmakologie (Marburg, Germany), was used to create a Golden Gate acceptor plasmid 
by standard PCR, overlap extension PCR, endonuclease digestion and T4 DNA ligase 
reactions. When subjected to Golden Gate digestion/ligation with BsaI and T4 DNA ligase with 
an appropriate complimentary PCR product, the resulting plasmid has a section of DNA 
encoding RF under a constitutive promotor removed and the PCR product is incorporated in 
such a fashion that the translation product contains the protein of interest with an N-terminal 
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hexahistidine tag GB1 fusion tag that can be removed by the action of tobacco etch virus 
protease (TEV) (work done by JCB). 
Digestion/ligation proceeds as expected despite the presence of an additional BsaI site within 
the sequence encoding RFP. The CysPC domain of calpain-1 was inserted into this acceptor by 
PCR with the following primers (work done by JCB): 
Fwd:  CGACTAGTGGTCTCCAGTCCATGGGTCGCCATGAGAA 
Rev: CGACTAGTGGTCTCCATCAGTCCGGGGTCAGGTTACA for ligation using the 



































2.2.6.5 Expression and purification of CysPC 
BL21-CodonPlus (DE3) RP cells containing the human calpain-1 CysPC gene were grown at 
37 °C in kanamycin selective LB media until OD600 = 0.6 then induced with 1 mM IPTG. The 
protein was expressed overnight at 20 °C and cells harvested by centrifugation in a Sorvall 
RC6 Plus centrifuge (Thermo Fisher Scientific, Inc, MA, USA) using an SLA-3000 rotor at 
6080 RCF for 20 minutes at 4 °C. The cells were re-suspended in 20 mM HEPES, 100 mM 
NaCl, 0.5 mM TCEP pH 7.6 (buffer A) and lysed by sonication for 5 mins (pulsed 5 s on, 10 s 
off). The lysate was clarified by centrifugation at 4 °C for 40 minutes at 30310 RCF in a Sorvall 
RC6 Plus centrifuge. The supernatant was passed through a 0.2 μm syringe filter and applied 
to a Ni-NTA column. The bound protein was washed with 15 CV buffer A and eluted with 10 
CV buffer A containing 250 mM imidazole, which was further dialyzed in buffer A overnight 
in a 10 kDa membrane containing 1 mL aliquot of TEV protease. The cleavage product was 
then passed back through a Ni-NTA column to remove the 6xHis-GB1 solubility tag and TEV 
protease, with the flow through containing active CysPC as confirmed by SDS-PAGE, mass 
spectrometry and calpain-1 activity assay (work done by JCB).  
2.2.6.6 Expression and purification of TEV protease 
BL21 (DE3) cells containing the TEV gene codon optimised for E. coli expression were 
obtained from Prof. Nigel Richards (Cardiff University).  
The cells containing the TEV protease gene were grown at 37 °C in ampicillin selective LB 
media until OD600 = 0.6 then induced with 1 mM IPTG. The protein was expressed overnight 
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at 20 °C and cells harvested by centrifugation in a Sorvall RC6 Plus centrifuge (Thermo Fisher 
Scientific, Inc, MA, USA) using an SLA-3000 rotor at 6080 RCF for 20 minutes at 4 °C. The 
cells were re-suspended in 20 mM HEPES, 100 mM NaCl, 0.5 mM TCEP pH 7.6 (buffer A) 
and lysed by sonication for 5 mins (pulsed 5 s on, 10 s off). The lysate was clarified by 
centrifugation at 4 °C for 40 minutes at 30310 RCF in a Sorvall RC6 Plus centrifuge. The 
supernatant was passed through a 0.2 μm syringe filter and applied to a Ni-NTA column. The 
bound protein was washed with 15 CV buffer A and eluted with 10 CV buffer A containing 250 
mM imidazole. The eluent was mixed with 20% v/v glycerol (20 mL final volume), and stored 
at -80 °C in 1 mL aliquots (work done by JCB). 
2.3 Results and Discussion 
2.3.1 Structure-based virtual screening of purchasable ligands against PEF(S) 
36,503 commercial compounds consisting of diverse chemical structures including 
sulphonamide-, amide-, pyridine-, urea-, and enamine-based compounds, were docked using 
Glide into the pre-prepared (see methods for details) protein crystal structure of human PEF(S) 
(PDB[151] ID: 4WQ2).[18] From the docking scores, the distribution for actives versus 
inactives was obtained. The active molecules displayed a more favorable distribution of scores, 
which allowed differentiation of actives and inactives (see methods for details). 
Candidate PEF(S) binders from the purchasable database were shortlisted on the basis of a cut-
off with the highest Mathews Correlation coefficient. The cut-off obtained was -6.35, according 
to which compounds with more negative binding score were predicted to bind. The selected 
candidates were further screened against PAINs[339] using the FAFDrug3 ADME-Tox 
Filtering Tool.[313] Those compounds that didn’t exhibit any potential PAINs liability were 
considered for evaluation of calpain-1 activity. As a result, five sulphonamides 1-5, two 
substituted N‐{3‐[3‐(2‐alkoxyethoxy)‐5‐(4‐substituted-phenyl)‐1H‐1,2,4‐triazol‐1‐
yl]phenyl}‐4‐methyl‐3‐(trifluoromethyl)benzamides 6-7, and three substituted 
[1,2,4]triazolo[4,3‐b]pyridazin‐6‐yl]pyridines 8-10, which were the top ranked compounds 
according to the virtual screening criteria were shortlisted as candidates for PEF(S) binding.  
2.3.2 MDS plot shows that shortlisted PEF(S) binders occupy a novel region in 
chemical space 
An MDS plot of the chemical space was generated consisting of the ChEMBL compounds 
inhibiting the full-length calpain-1 complex (PEF(S) and CysPc) with IC50 values ≤ 1 μM, and 
 51 
the Adams library (a library of α-mercaptoacrylic acid-based calpain-1 inhibitors and their 
disulfide analogues),[18] which were all validated against the PEF(S) docking model (see 
methods for details) (Figure 12). In addition, the shortlisted candidates 1-10 from the structure-
based design protocol were also included in the plot, which enabled the assessment of the 
novelty of chemical space coverage of the shortlisted PEF(S) binders, in comparison to the 
classical calpain-1 inhibitors and PEF(S) binders. Figure 12, which is a two dimensional MDS 
plot based on Morgan fingerprints of radius 2 with 90% ellipse-like confidence regions, shows 
that the shortlisted compounds 1-10 exhibited new structures in comparison to the previously 
reported compounds by occupying a novel region in the chemical space of calpain-1 actives. 
 
Figure 12.  A two dimensional MDS plot based on Morgan fingerprints of radius 2, with 90% 
ellipse-like confidence regions for 32 ChEMBL compounds, 33 compounds synthesized by 
Adams et al,[18] and the 10 shortlisted candidates from the structure-based design protocol. 
These were shortlisted from a purchasable database based on their high predicted binding 
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affinity towards the PEF(S) domain of calpain via docking with Glide. The compounds 
identified belong to a new chemical space in comparison to the previously reported compounds 
that bind to the PEF(S) (Adams library) and the compounds which inhibit the full-length 
calpain-1 complex. Compounds 1, 9, and 10 were then experimentally tested as novel allosteric 
inhibitors of calpain-1. 
2.3.3 FRET based Inhibition Assay  
FRET based inhibition experiments were carried by JCB and CM. A fluorogenic assay of the 
full-length calpain-1 complex (which includes PEF(S) and CysPc) was used to determine the 
activity of compounds 1-10. Amongst the identified compounds, 1, 9, and 10 inhibited the full-
length calpain-1 complex with IC50 values of 7.5 (±1.1), 20.5 (±1.9), and 29.7 (±5.2) μM, 
respectively (Table 1). The same experimental protocol was performed to measure the activity 
of compounds against the active site domain of calpain-1, without the presence of PEF(S), to 
investigate a possible allosteric mode of action.  None of the compounds showed any inhibition 
in the absence of PEF(S), except for compound 1, which weakly inhibited the active site 
domain with an IC50 value >100 μM. In contrast, compound 3 exhibited higher inhibitory 
activity against the active site domain of calpain-1 with an IC50 value of 41.1 (±15.4) μM as 
compared to the full-length calpain-1 complex, which showed an activity of >100 μM, 
suggesting that in the presence of PEF (S) it preferentially binds to PEF(S). This could explain 
the reduction in the inhibitory activity of compound 3 since it is most likely unable to alter the 
geometry of the active site while it binds allosterically. The IC50 values were also measured for 
the classical α-mercaptoacrylic acid based calpain inhibitor PD150606, and these were 19.3 
(±1.6) μM for the full-length calpain-1 complex, and 17.8 (±2.4) μM with the active site domain 
without the presence of PEF(S). Hence, in contrast to compounds 1, 3, 9, and 10, PD150606 
exhibited an unspecific mode of action by equally inhibiting via both binding sites (active and 
allosteric sites). It is worth stating here that compound 1 is an asthma drug, Vidupiprant or 
AMG 853,[346] which exhibited higher potency than PD150606 in inhibiting the activity of 
calpain-1. The dose response curve of compound 1 (IC50 = 7.5±1.1 μM) is displayed in Figure 
13. Interestingly, identifying Vidupiprant as an allosteric inhibitor of calpain-1 is in agreement 
with previous reports showing a direct link between calpain inhibition and anti-inflammatory 
properties, where it was shown that non-steroidal anti-inflammatory drugs (NSAIDs) inhibit 
calpain, and that calpain inhibition reduces allergic inflammation.[347, 348] Potentially, this 
finding could highlight the importance of considering calpain inhibitors for the development 
of new anti-asthma therapies.   
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Table 1. IC50 values for compounds 1-10, and PD150606 determined by the FRET based 
inhibition assay, with the full-length calpain-1 complex and the active site domain of calpain-
1, reported as mean +/- standard deviations from three independent experiments (NR = no 
response) 
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19.3 ±1.6 17.8±2.4 
 
The allosteric inhibitory activity exhibited by compounds 1, 9, and 10 confirms the design 
approach, which shortlisted PEF(S) binders. The three active compounds include scaffolds that 
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are distinct from the classical allosteric inhibitors. The IC50 values obtained could be improved 
by efficient choice of substituents using standard medicinal chemistry approaches. In particular 
compound 1, which is a sulphonamide, exhibited specificity in its allosteric inhibition of 
calpain-1, and was more potent (7.5 μM) than PD150606 (19.3 μM) that additionally inhibits 
the active site domain, in the absence of PEF(S), with a similar IC50 value. 
 
 
Figure 13. Dose-response curve for the inhibition of full-length calpain-1 complex by 
compound 1, IC50 = 7.5 ± 1.1 μM. The IC50 value is reported as mean +/- standard deviation of 
three independent experiments (plot generated by JCB).  
2.3.4 TNS Displacement Assay 
TNS, which is a sensitive fluorophore that binds to PEF(S) was used to probe protein dynamics 
and conformational change. It fluoresces in the bound state i.e. in a hydrophobic environment, 
whereas when another compound displaces it, its fluorescence gets quenched. This fluorophore 
was used previously to assess the binding of PD150606 to PEF(S), a compound which has 
already been shown to bind to PEF(S) by X-ray crystallography (PDB ID: 1NX3).[327, 328] 
In this work, PD150606 (as a control), compound 1, the most potent allosteric inhibitor, 
compound 3, a weak allosteric inhibitor, and compounds 2, 4 and 5 which did not exhibit any 
inhibitory activity, have been tested (by JCB) for PEF(S) binding by the TNS displacement 
method. The results for compounds 6-10 were unreliable as it became apparent that they 
Compound 1 - Calpain-1 FAM inhibition assay
Inhibitor Concentration / M
















fluoresced under the assay conditions, therefore for this reason these results were omitted. As 
shown in Figure 14, all tested compounds, except for compound 5, quenched the fluorescence 
of TNS, exhibiting a similar trend in their quenching effect to that of the known PEF(S) binder, 
PD150606, hence confirming their binding to PEF(S). Therefore, it appears that compounds 2-
4 do indeed bind to PEF(S) in a similar fashion to compound 1, but they either weakly inhibited 
or failed to allosterically alter the geometry of the active site.  
 
Figure 14. PD150606, which was shown by X-ray crystallography to bind to PEF(S) (PDB 
ID: 1NX3), compound 1 (the most potent allosteric inhibitor), 3, which was the least potent 
among the identified allosteric inhibitors, 2 and 4, which did not exhibit any inhibitory activity, 
all quenched the fluorescence of TNS. All compounds showed a similar effect to that of 
PD150606 confirming their binding to PEF(S), except for compound 5, which neither exhibited 
any inhibitory activity nor displaced TNS.  
2.3.5 Analysis of molecular docking studies of representative calpain-1 inhibitors 1 
and 10, and compounds 2-5 
Docking studies predicted molecular interactions of the sulphonamide 1 and the 
[1,2,4]triazolo[4,3-b]pyridazin-6-yl]pyridine 10 with the PEF(S) protein crystal structure (PDB 
ID: 4WQ2). Figure 15A. shows the 2-chloro-4-cyclopropylsulfonamido phenyl ring of 
compound 1 is π-stacked with His131. The carbonyl of its carboxylic acid moiety H-bonds with 
same residue. The carbonyl of its amide moiety H-bonds with Trp168, and the phenyl ring 
attached to the tert-butylcarbamoyl moiety is π-stacked with the same residue. Figure 15B. 
shows a π-stacking interaction between the pyridine ring of compound 10 and Trp168, and H-
bonding of the nitrogen in that ring with the same residue. The hydrophobic interactions 
predicted for compounds 1 and 10 with Trp168 are also seen in the co-crystallized ligand/protein 
crystal structure (PDB ID: 4WQ3).[18] In addition, a more favorable binding affinity towards 
PEF(S) was predicted for compound 1 (IC50 = 7.5 ±1.1 μM) as compared to compound 10, 
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(IC50 = 29.7 ±5.2 μM), which could be the reason for the higher inhibitory activity exhibited 
by compound 1. In order to further explore the activities of compounds 1-10, MD simulations 
on the full-length calpain-1 complex, which includes the PEF(S) domain would be beneficial 
when (if) the crystal structure is available. As previously intimated, the inhibitory activity of 
each compound is predicted to correlate with the average distance between the substrate and 
the interacting residues in the active site of calpain-1. 
 
Figure 15. Docking studies predicted molecular interactions of compounds 1 and 10 with 
the human PEF(S) of calpain-1 small subunit (regulatory subunit) protein crystal structure 
(PDB ID: 4WQ2). A. The 2-chloro-4-cyclopropylsulfonamido phenyl ring of compound 1 
shows π-stacking with His131 and the carbonyl of its carboxylic acid moiety H-bonds with the 
same residue. The carbonyl of its amide moiety H-bonds with Trp168 and the phenyl ring 
attached to the tert-butylcarbamoyl moiety is π-stacked with the same residue B. The pyridine 
ring of compound 10 is π-stacked with Trp168 and the nitrogen of that ring H-bonds with same 
residue. The hydrophobic interactions of 1 and 10 with Trp168 are also seen in the co-crystallised 
ligand/protein crystal structure (PDB ID: 4WQ3).[18]  
 
Docking studies predicted molecular interactions of the sulphonamides 2-5 with the PEF(S) 
protein crystal structure (PDB ID: 4WQ2), which suggest that the hydrophobic interactions 
with Trp168 are essential for PEF(S) binding. Figure 16A. has the phenyl ring of compound 2, 
which is attached to the sulfonyl moiety, π-stacked with Trp168, and the same residue H-bonds 
with the carbonyl of the amide group. The hydroxyl of its cyclohexyl ring H-bonds with Gln100, 
and its sulfonyl group H-bonds with His131. Figure 16B. shows the predicted molecular 
interactions between compound 3 and the PEF(S) crystal structure. These are H-bonding 
between its carboxyl moiety and the Lys172 and Trp168 residues, H-bonding between its sulfonyl 
group and His131, and π-stacking with the Trp168 via its pyridine ring. Figure 16C. demonstrates 
the predicted molecular interactions for compound 4. The amino group of its amide moiety H-
bonds with the Glu97 and Trp168 residues, the phenyl ring of its benzamide group π-stacks with 
Trp168, and the carbonyl of its amide moiety H-bonds with Lys172. Figure 16D. shows the H-
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bonding interactions predicted for the carbonyl of the oxopyrrolidin-1-yl moiety in compound 
5 to the Lys172 and Trp168 residues, the H-bonding interactions of its sulfonyl moiety with 
His131, and π-stacking of the same residue with the aromatic ring of its trifluorophenyl moiety. 
Interestingly, the hydrophobic interactions predicted for compounds 1-4 with Trp168 are also 
seen in the co-crystallized ligand/protein crystal structure (PDB ID: 4WQ3).[18] However, 
compound 5 was predicted to exhibit hydrophilic interactions with Trp168, which could explain 
why it didn’t displace TNS, suggesting that the hydrophobic interactions with this residue are 
essential for PEF(S) binding. 
 
 
Figure 16.  Docking studies predicted molecular interactions of the sulphonamides 2-5 with 
the PEF(S) protein crystal structure (PDB ID: 4WQ2), which suggest that hydrophobic 
interactions with Trp168 are essential for PEF(S) binding A.  The phenyl ring of compound 2, 
which is attached to the sulfonyl moiety is π-stacked with Trp168, and the same residue H-bonds 
with the carbonyl of its amide group, the hydroxyl of its cyclohexyl ring H-bonds with Gln100, 
and its sulfonyl group H-bonds with His131 B. H-bonding interactions are predicted to occur 
between the carboxyl moiety of compound 3 and the Lys172 and Trp168 residues, H-bonding 
between its sulfonyl group and His131, and π-stacking with the Trp168 via its pyridine ring C. 
The amino group of the amide moiety for compound 4 H-bonds with Glu97 and Trp168, and the 
phenyl ring of its benzamide group π-stacks with Trp168, and the carbonyl of its amide moiety 
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H-bonds with Lys172 D. H-bonding interactions are predicted to occur between the carbonyl of 
the oxopyrrolidin-1-yl moiety for compound 5 and the Lys172 and Trp168 residues, H-bonding 
between its sulfonyl moiety and His131, and π-stacking of the same residue with the aromatic 
ring of its trifluorophenyl moiety.   
2.3.6 Computational assessment of CNS permeability for representative calpain-1 
inhibitors 1 and 10 
Given that calpain-1 may serve as a therapeutic target for neurodegenerative disorders, a 
computational assessment of the CNS permeability for compounds 1 and 10 was performed 
with FAFDrug3[313] to see whether these compounds could be considered as good starting 
points to target these diseases. Their physicochemical properties were calculated and CNS 
diagrams were obtained and are presented in Figure 17A. and B. Compound 1 did not pass the 
CNS filter, which takes into consideration the assessment of its ability to pass the blood brain 
barrier. Hence, it is predicted not to exhibit the desired permeability,[304] since the values of 
all the descriptors for compound 1 (logP, HBD, HBA, MW-molecular weight, tPSA (blue line)) 
fall outside the CNS filter area (light blue). As for compound 10, it is predicted to exhibit 
medium permeability since all the descriptors, except for the HBA, have passed the CNS filter. 
Hence, compound 10 might serve as a good starting point for analogue development. 
 
 
Figure 17. Compounds 1 and 10 are represented in diagrams A and B. 1 did not pass the CNS 
filter which takes into consideration the assessment of its ability to pass the blood brain barrier,  
values of descriptors for 1 (the descriptors logP, HBD, HBA, MW, tPSA (blue line)) fall 
outside the CNS filter area (light blue). For 10, it is predicted to exhibit medium permeability 
since only the HBA value lies outside the CNS filter area. 
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2.4 Conclusions 
In this work, the structure-based design method devised has been successfully validated, which 
has led to the discovery of chemically novel allosteric inhibitors of calpain-1, for the first time 
demonstrating an allosteric mode of action. Compounds 1, 9, and 10 inhibited the full length 
calpain-1 complex (which includes PEF(S) and CysPc) with IC50 values of 7.5 (±1.1), 20.5 
(±1.9), and 29.7 (±5.2) μM respectively. Compounds 9 and 10 did not inhibit the active site 
domain of calpain-1 in the absence of PEF(S), and compound 1 inhibited the active site domain 
weakly with an IC50 value >100 μM. In contrast, compound 3 exhibited higher inhibitory 
activity against the active site domain of calpain-1 with an IC50 value of 41.1 (±15.4) μM as 
compared to the full-length calpain-1 complex, which was >100 μM, suggesting that it 
preferentially binds to PEF(S). In addition, IC50 values were measured for PD150606, giving 
19.3 (±1.6) μM with the full-length calpain-1 complex and 17.8 (±2.4) μM with the active site 
domain (without the presence of PEF(S)). In comparison to the classical α-mercaptoacrylic 
acid based calpain inhibitor, PD150606, compounds 1, 9, and 10, exhibited specificity in their 
allosteric mode of action, since they didn’t inhibit the active site domain in the absence of 
PEF(S).  
Furthermore, PD150606, compound 1, the most potent allosteric inhibitor, compound 3, a weak 
allosteric inhibitor, and compounds 2, 4 and 5 (which did not exhibit any inhibitory activity) 
have been tested for PEF(S) binding by the TNS displacement method. Compounds (1-4) 
quenched the fluorescence of TNS, exhibiting a similar trend in their quenching effect to that 
of the known PEF(S) binder, PD150606.  
The micro-molar IC50 values obtained for compounds 1, 9, and 10 suggest that they may be 
good starting points for optimization, having novel scaffolds. Allosteric inhibitors discovered 
by this approach could exhibit more selectivity towards calpain-1 since they are unlikely to 
inhibit the active site domain, which is similar for a wide variety of cysteine proteases. This 







3 Structure- and ligand-based design of multi-target ligands at 




Compounds designed to display polypharmacology may have utility in treating complex 
diseases, where activity at multiple targets is required to produce a clinical effect. In particular, 
suitable compounds may be useful in treating neurodegenerative diseases by promoting 
neuronal survival in a synergistic manner via their multi-target activity at the adenosine A1 and 
A2A receptors (A1R and A2AR) and phosphodiesterase 10A (PDE10A), which modulate 
intracellular cAMP levels.[98, 349–351] In this chapter, a computational method for the design 
of synthetically feasible ligands that bind to A1 and A2A receptors and inhibit phosphodiesterase 
10A (PDE10A) is described. The method involves a retrosynthetic approach employing in 
silico target prediction and docking,[133, 134, 159, 352] which may be generally applicable to 
multi-target compound design at several target classes. 
Neurodegeneration involves the progressive loss of the structure and function of neurons, 
which is common in Parkinson’s, Huntington’s disease and schizophrenia.[353] Recently, 
there has been substantial interest in the search for alternative non-dopamine (non-DA) based 
approaches for the treatment of neurodegenerative diseases, as the classical DA-based 
approaches have long been associated with many undesirable side effects such as dyskinesia, 
hallucinations, and on/off effects.[354] Given that the adenosine neuromodulation system (via 
the adenosine A1 and A2A receptors) has been identified as a key target for the management of 
neurodegenerative diseases, via the targeted modulation of cAMP levels, this qualifies its 
targeting as a potential non-DA based treatment approach.[349, 355] Indeed, modulation of 
cAMP levels has proven to have benefits in neuronal survival in an adenosine receptor-
dependent manner.[356] In addition, recent findings suggest that phosphodiesterase 10A 
(PDE10A) also plays a role in neurodegenerative diseases with similar etiology such as 
Parkinson’s, Huntington’s disease, and schizophrenia.[117–119] Inhibition of PDE10A 
resulting in the maintenance of elevated intracellular cAMP concentrations has been suggested 
to be effective in the treatment of these diseases. Thus multi-target ligands that bind to different 
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adenosine receptors subtypes (A1 and A2A receptors) while simultaneously inhibiting PDE10A 
might be synergistic in modulating cAMP levels, and of therapeutic potential [98, 115, 116] 
In this work, a computational strategy is offered for the design of synthetically feasible ligands 
that bind to A1R and A2AR, and inhibit PDE10A - a novel multi-target combination of G 
protein-coupled receptors (GPCRs) and an enzyme, which has not been previously exploited. 
The designed ligands with this multi-target combination are intended as starting points for 
future development of multi-target drugs treating neurodegenerative diseases. It should be 
noted here that the current study considers only affinity of ligands to the above receptors, which 
are also experimentally validated as outlined below. However, for therapeutically relevant 
purposes, functional effects and optimization of selectivity towards A1R, A2AR and PDE10A 
also need to be considered, - which will be the area of future study. 
The workflow of the current study is shown in Figure 18. Starting with a focused chemical 
space consisting of known actives against A1R, A2AR and PDE10A, new synthetically feasible 
compounds were identified via RECAP (Retrosynthetic Combinatorial Analysis 
Procedure),[159, 352] which fragments molecules at pre-defined bonds and recombines them 
in a combinatorial manner. These were then evaluated in silico, using target prediction and 
ligand/protein docking. Compounds with favorable assessments in both steps were carried 
forward for substructural analysis. This analysis identified compound series with the highest 
frequency of prediction as multi-target ligands against the desired set of targets, which has the 
practical advantage of synthetic accessibility via a common synthetic route. 
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Figure 18. The computational strategy for rational design of A1R/A2AR-PDE10A multi-target 
ligands started with a focused chemical space consisting of known actives of A1R, A2AR and 
PDE10A. Then formed new synthetically feasible compounds, which were subjected to target 
prediction and docking for synthesis and pharmacological evaluation. 
A series of 2-aminopyridine-3-carbonitriles were selected for prospective validation of the 
pipeline, a series that was synthetically accessible via a one pot synthetic scheme i.e. providing 
products with the desired properties: cost-effective, synthetically efficient and available in a 
timely fashion.[357, 358] 
Subsequently the synthesized compounds were experimentally tested and confirmed as 
A1R/A2AR-PDE10A multi-target ligands. Selectivity against other subtypes of both protein 
families (A2BR, A3R, PDE7A, PDE7B, and PDE9A) was assessed due to the high degree of 
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conservation of residues between the adenosine receptor subtypes in their orthosteric sites and 
PDEs in their active sites.[351, 359–363] Additionally the pharmacological profile of the 
compound series was confirmed, and structure activity relationships (SAR) were also deduced. 
Hence, in this work a successful computational strategy is reported, which allowed the 
discovery of the first A1R/A2AR-PDE10A multi-target ligands. 
The novel A1R/A2AR-PDE10A ligands are thought to display a an additive effect in modulating 
the A1R, A2AR, and PDE10A targets simultaneously similar to that of combination compounds 
of Adenosine receptors and PDEs, reported by Rickles et al, which were synergistic in 
modulating cAMP levels.[98] 
3.2 Materials and Methods 
3.2.1 Method for the selection of reference molecules for the design of multi-target 
ligands   
Using an SQL script,[338] human A1R (2,860), A2AR (3,566) ligands and PDE10A inhibitors 
(843) were extracted from the ChEMBL 20 database with Ki and IC50 values less than or equal 
to 1 μM respectively, and confidence scores of 8 or 9.[171] Following extraction, the most 
frequent and common heterocycles between A1, A2A receptor ligands and PDE10A inhibitors 
were found by performing substructure analysis on each structure using the “Chemistry-
>Analyze scaffolds” function in DataWarrior 4.2.2.[364] Analysis of A1R, A2AR ligands and 
PDE10A inhibitors identified common and frequent heterocycles (pyridine, 1H-pyrazole, 
pyrimidine and 9H-purine for A1R and A2AR), and these were extracted from each set using 
RDKit, 9.1.[365] It should be noted that compounds containing 9H-purine were also extracted 
from the original set even though this substructure is characteristic of A1R and A2AR only. 
These are structurally similar to the common and frequent heterocycles identified (pyridine, 
1H-pyrazole, and pyrimidine). Figure 19 shows the most frequent heterocycles for the A1R, 
A2AR ligands, and PDE10A inhibitors and their relative frequencies in each set. It was found 
that they are furan, pyridine, xanthine, 1H-pyrazole, pyrimidine, piperazine, and 9H-purine. 
All of these heterocycles ranked among the top 30 for A1R, A2AR ligands and PDE10A 
inhibitors. This indicated their suitability for the design of multi-target ligands at these protein 
targets, given the overlap in chemical (heterocyclic) space. In the case where no percentage is 
displayed for a particular target, this means that the heterocycle does not appear among the top 
30 for the set of compounds involved.  
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Figure 19. Percentage occurrence of the most frequent substructures in the A1R, A2AR, and 
PDE10A ChEMBL compounds (Ki and IC50 ≤ 1 μM) reveals the following substructures for 
A1R, A2AR, and PDE10A inhibitors: benzene, furan, pyridine, xanthine, 1H-pyrazole, 
pyrimidine, piperazine, and 9H-purine. In cases where no percentage is displayed for a 
particular target, this means that the substructure does not appear among the top 30 for the set 
of compounds involved.  
3.2.2 Designing new multi-target ligands 
A1R (2,104), A2AR (2,489) and PDE10A inhibitors (679) consisting of the common and 
frequent heterocycles, were subjected to RECAP analysis/synthesis in MOE.[352] The RECAP 
function electronically fragments and recombines molecules based on chemical knowledge of 
11 chemical bond types derived from common chemical reactions.[159] As a result, 458,839 
novel RECAP-derived compounds were found. Finally, the designed RECAP library was 
filtered using RDKit library according to the common and frequent heterocycles identified, 
which narrowed the list down to 22,233 compounds.  
3.2.3 Target prediction 
The SMILES of the designed RECAP library were standardized using the ChemAxon 
Command-Line Standardizer where the following options were selected: “Remove Fragment” 
(keep largest), “Neutralize”, “RemoveExplicitH”, “Clean2D”, “Mesomerize” and 
“Tautomerize”.[341] The standardized canonical SMILES were exported to CSV files, and 
subjected to enriched target prediction using PIDGIN 1.0 implementing the method developed 
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by Liggi et al.[133, 366]  The target prediction for the designed RECAP library was performed 
using a recall probability threshold of 0.01 (which is a value consistent with greater confidence 
in the more positive predictions). 
Enrichment calculations for the predicted targets of the designed RECAP library were 
performed as a complementary approach in order to assess the likelihood of the active 
compounds against the targets of interest. In this procedure, the frequency of predicting A1R, 
A2AR and PDE10A targets for the designed RECAP library was compared with a background 
distribution of a diverse library covering a large chemical space and was assessed by two 
parameters: the estimation score and the average ratio. The cutoff selected for considering a 
target as sufficiently enriched required an estimation score less than or equal to 0.01.[366] The 
statistical relevance of the prediction was assessed via a Chi-squared test with Yates correction 
in Scipy,[367] using the contingency table of the RECAP library and a background of randomly 
sampled PubChem compounds (Figure 20). 
 
Figure 20. A. A1R, A2AR and PDE10A were predicted as enriched targets with an estimation 
score equal to 0 (enriched) and average ratios less than 0.1 (enriched) for the focused RECAP 
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library, where the percentage of RECAP compounds that were predicted as actives against the 
A1R, A2AR and PDE10A targets are: 51.1%, 52.8%, and 24.5%, with Chi-squared p values < 
0.005 and Chi-squared statistics of 11958.8, 12842.1, and 4015.7, respectively B. The results 
of the contingency table for the Chi-squared calculation are passed to a Scipy[367] i.e. the 
script for the calculation for A1R is scipy.stats.chi2_contingency ([[1029, 21204], [11371, 
10862]]). 
3.2.4 Receptor preparation 
The human A2AR protein crystal structure (PDB ID: 4EIY) bound to the antagonist ZM 241385 
and the PDE10A crystal structure (PDB ID: 4DDL) complexed with an inhibitor,[368, 369]  
were selected for docking with Glide[134]. Protein structures were prepared using the Protein 
Preparation Wizard of Maestro 9.3,[334] following the default protocol, which accounts for 
energy refinement, hydrogen addition, pKa assignment, and side-chain rotational isomer 
refinement. Resolved water molecules were discarded, and the structure was centered using the 
co-crystallized ligand as the center of the receptor grid generated for each protein structure. 
The co-crystal structures of A2AR with 4-{2-[(7-amino-2-furan-2-yl[1,2,4]triazolo[1,5-
a][1,3,5]triazin-5-yl)amino]ethyl}phenol (PDB ID: 4EIY), and PDE10A with 2-{1-[5-(6,7-
dimethoxycinnolin-4-yl)-3-methylpyridin- 2-yl]piperidin-4-yl}propan-2-ol (PDB ID: 4DDL), 
were selected as target structures.   
The A1R homology model was provided by Dr. Hugo Gutiérrez-de-Terán, and it was 
constructed according to the method reported by Yaziji et al,[283, 370, 371] where the protein 
sequence of the human A1R (accession number P30542) was aligned with the A2AR template 
of PDB ID: 4EIY. 
3.2.5 Ligand Preparation 
The entire set of 2,563 ligands was prepared for docking with LigPrep 2.5[372] using the 
default settings and the Epik option, which introduces energy penalties associated with 
ionization and tautomerization.[335] 
3.2.6 Cut-off generation for compound selection from docking models  
In an attempt to validate the A2AR, A1R, and PDE10A docking models, a set of known actives 
and inactives were docked against each target to ensure that they enriched actives. 81 A2A 
receptor ligands reported in the literature were docked against the A2AR model.[373, 374] For 
consistency 81 ChEMBL actives were also extracted manually (for each of the A1R and 
PDE10A proteins whose Ki and IC50 values are less than 10 μM), and these were docked against 
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their respective target class. In addition, PubChem inactives (200 compounds) of each target 
class were docked. 
A good separation was obtained for the medians of the docking score distributions for actives 
versus inactives confirming that the actives are enriched. Figure 21 shows the separation of the 
medians for the three docking models, -6.93 (actives) vs. -5.64 (inactives) for the PDE10A 
docking model, -7.66 (actives) vs. -6.01 (inactives) for the A2AR docking model, and -7.60 
(actives) vs. -5.66 (inactives) for the A1R docking model. Statistical analysis was performed 
with R using a Mann-Whitney test[337] on the active and inactive docking score distributions 
of each target. The differences in medians were significant with p values less than 0.05 (Script 
[338]). 
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Figure 21. The separation in the medians (dashed lines) obtained for the three docking models 
A.  -6.93 (ChEMBL actives) B. -5.64 (PubChem in-actives) for the PDE10A docking model, 
C. -7.66 (ChEMBL actives) D. -6.01 (PubChem inactives) for the A2AR docking model, E. -
7.60 (ChEMBL actives) F. -5.66 (PubChem inactives) for the A1R docking model, indicating 
that actives are enriched in the three docking models 
The F1 score which is the harmonic mean of precision and recall, was computed (using a Python 
script[338]) for all the docking scores of the ChEMBL actives and PubChem inactives for each 
model. A search was performed for a docking score threshold that gave the highest F1 score. 
Subsequently, substructure analysis was performed on compounds that were simultaneously 
predicted as A1R/A2AR-PDE10A multi-target ligands by target prediction, which also 
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displayed docking scores that are lower than or equal to those with the highest F1 score for each 
of the three docking models (A1R, A2AR, and PDE10A, using script provided by Kalash et al 
[338]). Furthermore, the thresholds found are intended to serve as reference scores for any 
structure-based design problem at these target classes.  
3.2.7 Docking 
The RECAP compounds that were predicted as A1R/A2AR-PDE10A multi-target ligands were 
docked against the A2AR protein crystal structure (PDB ID: 4EIY),[368] the A1R homology 
model and the PDE10A protein crystal structure (PDB IB: 4DDL)[369] to use their predicted 
binding energies as a filter, and investigate the molecular interactions. The Glide docking 
parameters used here are given in Table 2. The parameters were deduced from docking 
experiments using known actives and inactives against each protein model.  
Table 2. Glide docking parameters used for the A1R, A2AR, and PDE10A models were deduced 
from docking experiments using known actives and inactives against each protein model 











Flexibleb Flexibleb Flexibleb 
a SP option allows better coverage of conformational space whereas XP option gives higher 
accuracy on docked poses b Flexible ligand sampling is a default choice, which generates 
conformations internally during the docking process 
3.2.8 Substructural analysis 
Subsequently, substructure analysis was performed using DataWarrior 4.2.2, on the proposed 
A1R/A2AR-PDE10A multi-target ligands predicted by both ligand-based and structure-based 
techniques (considering docking scores less than or equal to the threshold of the best F measure 
for each docking model). The chemical series found were [1,2,4]triazolo[1,5-c]quinazolines 
(50.4%), imidazo[1,5-a]quinoxalines (14.4%), 6,7-alkoxyisoquinolines (10.6%), and 2-
aminopyridine-3-carbonitriles (9.2%), which are depicted in Figure 22, in addition to various 
compounds consisting of the common and frequent heterocycles identified originally in the 
substructural analysis of the extracted ChEMBL compounds.  
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Figure 22. 2,563 compounds of the focused RECAP library were predicted as A1R/A2AR-
PDE10A multi-target ligands, and docked against the A2AR protein crystal structure (PDB ID: 
4EIY), A1R homology model, and the PDE10A protein crystal structure (PDB IB: 4DDL). The 
RECAP series which showed an agreement between the ligand-based and structure-based 
predictions were mainly a. 6,7-alkoxyisoquinolines b. [1,2,4]triazolo[1,5-c]quinazolines c. 2-
aminopyridine-3-carbonitriles d. imidazo[1,5-a]quinoxalines  
 
3.2.9 Experimental validation of   2-aminopyridine-3-carbonitriles as multi-target 
ligands at A1R, A2AR, and PDE10A 
The experimental validation of 2-aminopyridine-3-carbonitriles as multi-target ligands at A1R, 
A2AR, and PDE10A, included the synthesis, characterization and pharmacological evaluation 
of the compounds 11-35. Cristina Val (CV) and Jhonny Azuaje (JA) at the Center for Research 
in Biological Chemistry and Molecular Materials (CIQUS) in the University of Santiago de 
Compostela performed the experiments. 
3.2.9.1 Synthesis of novel 4,6-substituted 2-amino-pyridin-3-carbonitriles 
Due to both synthetic accessibility of the reaction and yield, CV optimized a one-pot synthetic 
scheme for the purpose of synthesizing 2-aminopyridine-3-carbonitriles. For the other series, 
the synthetic routes were multi-step reactions, which due to synthetic complexity were not 
considered for synthesis. 
The synthetic routes reported in the literature for the formation of derivatives of 6,7-
alkoxyisoquinolines as selective PDE10A inhibitors involved multi-step reactions ranging 
from 3 to 13 steps.[375, 376] Whereas, the procedures for the synthesis of the imidazo[1,5-
a]quinoxalines, known PDE10A inhibitors, consisted of 3 to 7 step reactions.[377–379] The 
[1,2,4]triazolo[1,5-c]quinazolines have been reported as potent and selective A2AR antagonists 
and PDE10A inhibitors, and their synthesis involved 4 to 7 step reactions.[380–382] 
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Hence, given the fact that the 2-aminopyridine-3-carbonitriles were the only RECAP series 
that could be synthesized via a one-pot synthetic scheme,[383–385] they were selected for 
synthesis and subsequent validation as multi-target ligands by CV and JA. In particular, the 
compounds selected for synthesis did not exhibit any potential PAINs liability upon screening 
with the FAFDrug3 ADME-Tox Filtering Tool.[313] The one-pot synthetic route is shown in 
Scheme 1. 
 
Scheme 1.  The one-pot synthetic route followed for the synthesis of novel 4,6-substituted 2-
amino-pyridin-3-carbonitriles  
Chemistry. Unless otherwise indicated, all starting materials, reagents and solvents were 
purchased and used without further purification. After extraction from aqueous phases, the 
organic solvents were dried over anhydrous sodium sulfate. The reactions were monitored by 
thin-layer chromatography (TLC) on 2.5 mm Merck silica gel GF 254 strips, and each of the 
purified compounds showed a single spot; unless stated otherwise, UV light and/or iodine 
vapor were used to detect compounds. The synthesis of the target compounds was performed 
in coated Kimble vials on a PLS (6×4) Organic Synthesizer with orbital stirring. Filtration and 
washing protocols for supported reagents were performed in a 12-channel vacuum manifold. 
The purity and identity of all tested compounds were established by a combination of HPLC, 
elemental analysis, mass spectrometry and NMR spectroscopy as described below. Purification 
of isolated products was carried out by column chromatography (Kieselgel 0.040–0.063 mm, 
E. Merck) or medium pressure liquid chromatography (MPLC) on a CombiFlash Companion 
(Teledyne ISCO) with RediSep pre-packed normal-phase silica gel (35–60 μm) columns 
followed by recrystallization. Melting points were determined on a Gallenkamp melting point 
apparatus and are uncorrected. The NMR spectra were recorded on Bruker AM300 and XM500 
spectrometers. Chemical shifts are given as  values against tetramethylsilane as internal 
standard and J values are given in Hz. Mass spectra were obtained on a Varian MAT-711 
instrument. Analytical HPLC was performed on an Agilent 1100 system using an Agilent 
Zorbax SB-Phenyl, 2.1 mm × 150 mm, 5 μm column with gradient elution using the mobile 
phases (A) H2O containing 0.1% CF3COOH and (B) MeCN and a flow rate of 1 mL/min. The 
purity of all tested compounds was determined to be greater than or equal to 95% (work done 
by CV and JA). 
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The synthesis of the 4,6-substituted 2-amino-pyridin-3-carbonitriles 11-35 was done via the 
one-pot synthetic route shown in Scheme 1. Varying both substituents on the ylidene 
malononitrile and the ketone reagents resulted in a variation of the substituents on positions 4 
and 6 of the pyridine ring. 
Synthetic procedure 
Substituted ylidene malononitrile (1.0mmol), ketone (1.0mmol) and ammonium acetate 
(5.0mmol) in a 1:1 toluene/EtOH mixture (7mL) were stirred in a coated Kimble vial at 120ºC 
for 12-24 h. After reaction completion (TLC control), distilled water was added and the mixture 
was extracted with ethyl acetate (3 x 10 mL). The organic phase was dried (Na2SO4) and 
evaporated under reduced pressure to afford an oily residue that was purified by column 
chromatography using n-hexane – ethyl acetate in 2:1 mixture (work done by CV and JA). 
2-amino-6-(4-fluorophenyl)-4-phenylpyridine-3-carbonitrile (11)  
Purified by column chromatography (n-hexane-ethyl acetate 2:1) and then recrystallized from 
EtOH to give 0.246 g, 85% yield (97% purity by HPLC). MP 226–228 °C. 1H NMR (300 MHz, 
CDCl3), δ (ppm) 8.08–7.95 (m, 2H), 7.69–7.58 (m, 2H), 7.60–7.47 (m, 3H), 7.23–7.09 (m, 
3H), 5.34 (s, 2H). MS (EI) m/z (%): 289.07 (M+, 100), 262.07 (7). Analysis calculated for 
C18H12FN3: C, 74.73; H, 4.18; F, 6.57; N 14.52. Found: C, 74.70; H, 4.19; F, 6.55; N, 14.54. 
2-amino-6-(4-hydroxyphenyl)-4-phenylpyridine-3-carbonitrile (12)  
Purified by column chromatography (n-hexane-ethyl acetate 2:1) and then recrystallized from 
EtOH to give 0.227 g, 79% yield (96% purity by HPLC). MP 241–243 °C. 1H NMR (300 MHz, 
CDCl3), δ (ppm) 9.92 (s, 1H), 7.99 (d, J = 8.6 Hz, 2H), 7.78–7.59 (m, 2H), 7.58–7.47 (m, 3H), 
7.15 (s, 1H), 6.88 (s, 2H), 6.83 (d, J = 8.7 Hz, 2H). MS (EI) m/z (%): 287.04 (M+, 100), 259.89 
(10). Analysis calculated for C18H13N3O: C, 75.25; H, 4.56; N, 14.63; O, 5.57. Found: C, 75.27; 
H, 4.54; N, 14.62; O, 5.59. 
2-amino-4-phenyl-6-(1,3-thiazol-2-yl)pyridine-3-carbonitrile (13)  
Purified by column chromatography (n-hexane-ethyl acetate 2:1) and then recrystallized from 
EtOH to give 0.172 g, 62% yield (95% purity by HPLC). MP 154–156 °C. 1H NMR (300 MHz, 
CDCl3), δ (ppm) 7.95 (d, J = 3.0 Hz, 1H), 7.72 (s, 1H), 7.66–7.65 (m, 2H), 7.52–7.50 (m, 4H), 
5.30 (s, 2H). MS (EI) m/z (%): 278.03 (M+, 100), 276.97 (45). Analysis calculated for 




2-amino-6-(1-methyl-1H-pyrrol-2-yl)-4-phenylpyridine-3-carbonitrile (14)  
Purified by column chromatography (n-hexane-ethyl acetate 2:1) and then recrystallized from 
EtOH to give 0.189 g, 69% yield (98% purity by HPLC). MP 152–153 °C. 1H NMR (300 MHz, 
CDCl3), δ (ppm) 7.67–7.54 (m, 2H), 7.56–7.42 (m, 3H), 7.30 (s, 1H), 6.91 (s, 1H), 6.66–6.59 
(m, 2H), 5.23 (s, 2H), 3.70 (s, 3H). MS (EI) m/z (%): 274.14 (M+, 100). Analysis calculated for 
C17H14N4: C, 74.43; H, 5.14; N, 20.42. Found: C, 74.57; H, 5.12; N, 20.30. 
2-amino-4-(2-methoxyphenyl)-6-phenylpyridine-3-carbonitrile (15)  
Purified by column chromatography (n-hexane-ethyl acetate 2:1) and then recrystallized from 
EtOH to give 0.238 g, 79% yield (97% purity by HPLC). MP 199–200 °C. 1H NMR (300 MHz, 
CDCl3), δ (ppm) 8.03–7.93 (m, 2H), 7.52–7.41 (m, 4H), 7.31 (dd, J1 = 7.5 Hz, J2 = 1.8 Hz, 
1H), 7.17 (s, 1H), 7.11–7.02 (m, 2H), 5.27 (s, 2H), 3.88 (s, 3H). MS (EI) m/z (%): 301.16 (M+, 
100), 270.12 (7), 120.10 (16.3). Analysis calculated for C19H15N3O: C, 75.73; H, 5.02; N, 
13.94; O, 5.31. Found: C, 75.76; H, 5.04; N, 13.92; O, 5.33. 
2-amino-4-(2,4-dimethoxyphenyl)-6-phenylpyridine-3-carbonitrile (16)  
Purified by column chromatography (n-hexane–ethyl acetate 2:1) and then recrystallized from 
EtOH to give 0.238 g, 72% yield (99% purity by HPLC). MP 155–157 °C. 1H NMR (300 MHz, 
CDCl3), δ (ppm) 8.02-7.90 (m, 2H), 7.52–7.38 (m, 3H), 7.32–7.22 (m, 1H), 7.16 (s, 1H), 6.69–
6.55 (m, 2H), 5.25 (s, 2H), 3.88 (s, 3H), 3.86 (s, 3H). MS (EI) m/z (%): 331.14 (M+, 100), 
165.51 (9), 120.16 (11.3). Analysis calculated for C20H17N3O2: C, 72.49; H, 5.17; N, 12.68; O, 
9.66. Found: C, 72.50; H, 5.19; N, 12.71; O, 9.70. 
2-amino-4-(2H-1,3-benzodioxol-5-yl)-6-phenylpyridine-3-carbonitrile (17)  
Purified by column chromatography (n-hexane-ethyl acetate 2:1) and then recrystallized from 
EtOH to give 0.236 g, 75% yield (96% purity by HPLC). MP 220–221 °C. 1H NMR (300 MHz, 
CDCl3), δ (ppm) 8.12–7.86 (m, 2H), 7.56–7.38 (m, 3H), 7.20–7.08 (m, 3H), 6.95 (d, 
J = 8.0 Hz, 1H), 6.06 (s, 2H), 5.33 (s, 2H). MS (EI) m/z (%): 315.11 (M+, 100), 157.52 (5). 
Analysis calculated for C19H13N3O2: C, 72.37; H, 4.16; N, 13.33; O, 10.15. Found: C, 72.45; 
H, 4.06; N, 13.49; O, 10.00. 
2-amino-4-cyclohexyl-6-phenylpyridine-3-carbonitrile (18)  
Purified by column chromatography (n-hexane-ethyl acetate 2:1) and then recrystallized from 
EtOH to give 0.216 g, 78% yield (98% purity by HPLC). MP 125–126 °C. 1H NMR (300 MHz, 
CDCl3) δ (ppm): 7.95–7.92 (m, 1H), 7.53–7.43 (m, 3H), 7.05 (s, 1H), 6.73 (s, 1H), 5.22 (s, 
2H), 2.90–2.85 (m, 2H), 1.90–1.78 (m, 4H), 1.52–1.39 (m, 4H), 1.33–1.25 (m, 1H). MS (EI) 
m/z (%): 277.25 (M+, 74), 246.15 (56), 222.15 (100). Analysis calculated for C18H19N3: C, 
77.95; H, 6.90; N, 15.15. Found: C, 78.03; H, 6.96; N, 15.01. 
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2-amino-4-cyclohexyl-6-(2-fluorophenyl)pyridine-3-carbonitrile (19)  
Purified by column chromatography (n-hexane-ethyl acetate 2:1) and then recrystallized from 
EtOH to give 0.186 g, 63% yield (95% purity by HPLC). MP 126–127 °C. 1H NMR (300 MHz, 
CDCl3), δ (ppm) 7.89 (td, J = 7.8, 1.9 Hz, 1H), 7.47–7.31 (m, 1H), 7.25–7.03 (m, 3H), 5.18 (s, 
2H), 2.98–2.67 (m, 1H), 1.99–1.73 (m, 5H), 1.53–1.16 (m, 5H). MS (EI) m/z (%): 295.15 (M+, 
98.05), 263.05 (23.28), 251.00 (12), 240.00 (100). Analysis calculated for C18H18FN3: C, 73.20; 
H, 6.14; F, 6.43; N, 14.23. Found: C, 73.22; H, 6.17; F, 6.44; N, 14.25. 
2-amino-4-cyclohexyl-6-(2-methylphenyl)pyridine-3-carbonitrile (20)  
Purified by column chromatography (n-hexane-ethyl acetate 2:1) and then recrystallized from 
EtOH to give 0.236 g, 81% yield (97% purity by HPLC). MP 120–121 °C. 1H NMR (300 MHz, 
CDCl3), δ (ppm) 7.73–7.10 (m, 4H), 6.71 (s, 1H), 5.20 (s, 2H), 2.95–2.77 (m, 1H), 2.35 (s, 
3H), 2.01–1.69 (m, 5H), 1.56–1.34 (m, 4H), 1.34–1.18 (m, 1H). MS (EI) m/z (%): 291.14 (M+, 
100), 236.12 (48), 208.10 (91.7). Analysis calculated for C19H21N3: C, 78.32; H, 7.26; N, 14.42. 
Found: C, 78.48; H, 7.18; N, 14.34. 
2-amino-4-cyclohexyl-6-(thiophen-2-yl)pyridine-3-carbonitrile (21)  
Purified by column chromatography (n-hexane-ethyl acetate 2:1) and then recrystallized from 
EtOH to give 0.167 g, 59% yield (98% purity by HPLC). MP 160–162 °C. 1H NMR (300 MHz, 
CDCl3), δ(ppm) 7.63–7.62(m, 1H), 7.44 (d, J = 4.5 Hz, 1H), 7.12–7.09 (m, 1H), 6.96 (s, 1H), 
5.14 (s, 2H), 2.82–2.79 (m, 1H), 1.90–1.78 (m, 5H), 1.55–1.43 (m, 4H), 1.30–1.19 (m, 1H). 
MS (EI) m/z (%): 283.04 (M+, 100), 251.99 (19), 228.02 (92). Analysis calculated for 
C16H17N3S: C, 67.81; H, 6.05; N, 14.83; S, 11.31. Found: C, 67.89; H, 6.13; N, 14.77; S, 11.21. 
2-amino-4-cyclohexyl-6-(thiophen-3-yl)pyridine-3-carbonitrile (22)  
Purified by column chromatography (n-hexane-ethyl acetate 2:1) and then recrystallized from 
EtOH to give 0.147 g, 52% yield (96% purity by HPLC). MP 145–146 °C. 1H NMR (300 MHz, 
CDCl3), δ(ppm) 7.94 (dd, J = 3.0, 1.3 Hz, 1H), 7.59 (dd, J = 5.1, 1.3 Hz, 1H), 7.38 (dd, J = 5.1, 
3.0 Hz, 1H), 6.93 (s, 1H), 5.14 (s, 2H), 2.95–2.73 (m, 1H), 2.06–1.73 (m, 5H), 1.56–1.37 (m, 
4H), 1.38–1.19 (m, 1H). MS (EI) m/z (%):(%): 283.07 (M+, 100), 228.04 (93), 214.96 (52). 
Analysis calculated for C16H17N3S: C, 67.81; H, 6.05; N, 14.83; S, 11.31. Found: C, 67.91; H, 
6.09; N, 14.67; S, 11.33. 
2-amino-4-cyclohexyl-6-(furan-2-yl)pyridine-3-carbonitrile (23)  
Purified by column chromatography (n-hexane-ethyl acetate 2:1) and then recrystallized from 
EtOH to give 0.174 g, 65% yield (98% purity by HPLC). MP 177–178 °C. 1H NMR (300 MHz, 
CDCl3), δ(ppm) 7.55 (dd, J = 1.7, 0.8 Hz, 1H), 7.06 (dd, J = 3.4, 0.8 Hz, 1H), 7.03 (s, 1H), 
6.54 (dd, J = 3.5, 1.8 Hz, 1H), 5.15 (s, 2H), 3.01–2.68 (m, 1H), 2.04–1.74 (m, 5H), 1.55–1.39 
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(m, 4H), 1.34–1.20 (m, 1H). MS (EI) m/z (%): 267.11 (M+, 100), 212.02 (69). Analysis 
calculated for C16H17N3O: C, 71.89; H, 6.41; N, 15.72; O, 5.98. Found: C, 71.91; H, 6.43; N, 
15.71. 
2-amino-6-(2-fluorophenyl)-4-(4-methoxyphenyl)pyridine-3-carbonitrile (24)  
Purified by column chromatography (n-hexane-ethyl acetate 2:1) and then recrystallized from 
EtOH to give 0.188 g, 59% yield (97% purity by HPLC). MP 180–181 °C. 1H NMR (300 MHz, 
CDCl3), δ (ppm) 7.96 (td, J1 = 7.8, J2 = 1.9 Hz, 1H), 7.65–7.58 (m, 2H), 7.47–7.37 (m, 1H), 
7.31–7.23 (m, 2H), 7.23–7.09 (m, 1H), 7.09–6.98 (m, 2H), 5.32 (s, 2H), 3.88 (s, 3H). MS (EI) 
m/z (%): 319.12 (M+, 100), 304.18 (12), 249.13 (16). Analysis calculated for C19H14FN3O: C, 
71.46; H, 4.42; F, 5.95; N, 13.16; O, 5.01. Found: C, 71.48; H, 4.44; F, 5.97; O, 5.05. 
2-amino-4-(4-methoxyphenyl)-6-(2-methylphenyl)pyridine-3-carbonitrile (25)  
Purified by column chromatography (n-hexane-ethyl acetate 2:1) and then recrystallized from 
EtOH to give 0.205 g, 65% yield (95% purity by HPLC). MP 151–152 °C. 1H NMR (300 MHz, 
CDCl3), δ (ppm) 7.61 (d, J = 8.3 Hz, 2H), 7.40 (d, J = 7.3 Hz, 1H), 7.37–7.27 (m, 3H), 7.03 
(d, J = 8.2 Hz, 2H), 6.86 (s, 1H), 5.32 (s, 2H), 3.87 (s, 3H), 2.42 (s, 3H). MS (EI) m/z (%): 
314.10 (M+, 100), 271.06 (7), 208.11 (52). Analysis calculated for C20H17N3O: C, 76.17; H, 
5.43; N, 13.32; O, 5.07. Found: C, 76.31; H, 5.33; N, 13.52; O, 4.84. 
2-amino-6-(furan-2-yl)-4-(4-methoxyphenyl)pyridine-3-carbonitrile (26)  
Purified by column chromatography (n-hexane-ethyl acetate 2:1) and then recrystallized from 
EtOH to give 0.198 g, 68% yield (99% purity by HPLC). MP 205–207 °C. 1H NMR (300 MHz, 
CDCl3) δ (ppm): 7.65–7.54 (m, 3H), 7.16 (s, 1H), 7.11 (d, J = 3.5 Hz, 1H), 7.03 (d, J = 8.8 Hz, 
2H), 6.62–6.51 (m, 1H), 5.30 (s, 2H), 3.88 (s, 3H). MS (EI) m/z (%): 291.12 (M+, 100), 145.63 
(5). Analysis calculated for C17H13N3O2: C, 70.09; H, 4.50; N, 14.42; O, 10.98. Found: C, 
70.21; H, 4.38; N, 14.68, O, 10.73. 
2-amino-6-(4-hydroxyphenyl)-4-(4-methoxyphenyl)pyridine-3-carbonitrile (27)  
Purified by column chromatography (n-hexane- ethyl acetate 2:1) and then recrystallized from 
EtOH to give 0.222 g, 70% yield (99% purity by HPLC). MP 248–250 °C. 1H NMR (300 MHz, 
CDCl3), δ (ppm) 9.89 (s, 1H), 7.98 (d, J = 8.7 Hz, 2H), 7.61 (d, J = 8.7 Hz, 2H), 7.11–7.06 (m, 
3H), 6.84–6.81 (m, 4H), 3.82 (s, 3H). MS (EI) m/z (%): 317.17 (M+, 100), 302.04 (6), 158.50 
(14). Analysis calculated for C19H15N3O2: C, 71.91; H, 4.76; N, 13.24; O, 10.08. Found: C, 
71.94; H, 4.79; N, 13.25; O, 10.11. 
2-amino-4,6-bis(2-fluorophenyl)pyridine-3-carbonitrile (28)  
Purified by column chromatography (n-hexane-ethyl acetate 2:1) and then recrystallized from 
EtOH to give 0.219 g, 73% yield (98% purity by HPLC). MP 180–181 °C. 1H NMR (300 MHz, 
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CDCl3), δ (ppm) 8.05–7.90 (m, 1H), 7.56–7.41 (m, 2H), 7.33–7.06 (m, 6H), 5.34 (s, 2H). MS 
(EI) m/z (%): 307.06 (M+, 100), 279.99 (8). Analysis calculated for C18H11F2N3: C, 70.35; H, 
3.61; F, 12.36, N, 13.67. Found: C, 70.37; H, 3.63; F, 12.33; N, 13.66. 
2-amino-6-(2-fluorophenyl)-4-(2-methoxyphenyl)pyridine-3-carbonitrile (29)  
Purified by column chromatography (n-hexane-ethyl acetate 2:1) and then recrystallized from 
EtOH to give 0.245 g, 78% yield (97% purity by HPLC). MP 187–188 °C. 1H NMR (300 MHz, 
CDCl3), δ (ppm) 7.97 (td, J = 7.8, 1.9 Hz, 1H), 7.52–7.35 (m, 2H), 7.31 (td, J = 7.2, 1.5 Hz, 
1H), 7.26–7.19 (m, 2H), 7.17–6.95 (m, 3H), 5.27 (s, 2H), 3.88 (s, 3H). MS (EI) m/z (%): 319.12 
(M+, 100), 290.14 (7), 138.01 (14). Analysis calculated for C19H14N3FO: C, 71.46; H, 4.42; F, 
5.95; N, 13.16; O, 5.01. Found: C, 71.44; H, 4.43; F, 5.92; O, 5.04. 
2-amino-4-(2-methoxyphenyl)-6-(2-methylphenyl)pyridine-3-carbonitrile (30)  
Purified by column chromatography (n-hexane-ethyl acetate 2:1) and then recrystallized from 
EtOH to give 0.186 g, 64% yield (98% purity by HPLC). MP 181–183 °C. 1H NMR (300 MHz, 
CDCl3) δ (ppm): 7.47–7.40 (m, 2H), 7.32–7.28 (m, 4H), 7.09–7.02 (m, 2H), 6.86 (s, 1H), 5.29 
(s, 2H), 3.88 (s, 3H), 2.43 (s, 3H). MS (EI) m/z (%): 315.13 (M+, 100), 298.16 (12), 284.09 
(18), 208.10 (81.6). Analysis calculated for C20H17N3O: C, 76.17; H, 5.43; N, 13.32; O, 5.07. 
Found: C, 76.19; H, 5.41; N, 13.36; O, 5.03. 
2-amino-6-(furan-2-yl)-4-(2-methoxyphenyl)pyridine-3-carbonitrile (31)  
Purified by column chromatography (n-hexane-ethyl acetate 2:1) and then recrystallized from 
EtOH to give 0.244 g, 77% yield (96% purity by HPLC). MP 187–188 °C. 1H NMR (300 MHz, 
CDCl3), δ (ppm): 7.55 (s, 1H), 7.44 (t, J = 8.1 Hz, 1H), 7.30 (dd, J = 7.4, 1.7 Hz, 1H), 7.15–
6.98 (m, 4H), 6.54 (dd, J = 3.3, 1.7 Hz, 1H), 5.24 (s, 2H), 3.87 (s, 3H). MS (EI) m/z (%): 291.10 
(M+, 100), 262.14 (10). Analysis calculated for C17H13N3O2: C, 70.09; H, 4.50; N, 14.42; O, 
10.98. Found: C, 70.11; H, 4.51; N, 14.41; O, 11.01. 
2-amino-6-(4-hydroxyphenyl)-4-(2-methoxyphenyl)pyridine-3-carbonitrile (32)  
Purified by column chromatography (n-hexane-ethyl acetate 2:1) and then recrystallized from 
EtOH to give 0.193 g, 60% yield (96% purity by HPLC). MP 210–212 °C. 1H NMR (300 MHz, 
DMSO-d 6 ), δ (ppm): 9.91 (s, 1H), 7.93 (d, J = 9.0 Hz, 2H), 7.45 (t, J = 7.8 Hz, 1H), 7.29 (dd, 
J = 7.4, 1.7 Hz, 1H), 7.16 (d, J = 8.3 Hz, 1H), 7.07 (d, J = 7.5 Hz, 1H), 7.03 (s, 1H), 6.82 (d, 
J = 8.9 Hz, 2H), 6.77 (s, 2H), 3.77 (s, 3H). MS (EI) m/z (%): 317.13 (M+, 100), 300.09 (8), 
286.11 (6). Analysis calculated for C19H15N3O2: C, 71.91; H, 4.76; Cl, 13.24; O, 10.08. Found: 




2-amino-4-(2-chlorophenyl)-6-(4-hydroxyphenyl)pyridine-3-carbonitrile (33)  
Purified by column chromatography (n-hexane-ethyl acetate 2:1) and then recrystallized from 
EtOH to give 0.179 g, 59% yield (98% purity by HPLC). MP 215–217 °C. 1H NMR (300 MHz, 
DMSO-d 6 ), δ (ppm): 9.90 (s, 1H), 8.16–7.22 (m, 2H), 7.69–7.30 (m, 4H), 7.16–6.50 (m, 5H). 
MS (EI) m/z (%): 320.99 (M+, 100), 286.04 (5). Analysis calculated for C18H12ClN3O: C, 67.19; 
H, 3.76; Cl, 11.02; N, 13.06; O, 4.97. Found: C, 67.37; H, 3.94; Cl, 11.18; N, 12.88; O, 4.63. 
2-amino-4,6-bis(4-hydroxyphenyl)pyridine-3-carbo-nitrile (34)  
Purified by column chromatography (n-hexane–ethyl acetate 2:1) and then recrystallized from 
EtOH to give 0.151 g, 53% yield (97% purity by HPLC). MP 299–300 °C. 1H NMR (300 MHz, 
DMSO-d 6 ), δ (ppm) 9.92 (s, 2H), 8.19–7.79 (m, 2H), 7.68–7.37 (m, 2H), 7.42–6.99 (m, 1H), 
7.01–6.62 (m, 6H). MS (EI) m/z (%): 303.06 (M+, 100), 184.01 (6). Analysis calculated for 
C18H13N3O2: C, 71.28; H, 4.32; N, 13.85; O, 10.55. Found: C, 71.40; H, 4.54; N, 13.75; O, 
10.31. 
2-amino-4-(furan-2-yl)-6-(thiophen-3-yl)pyridine-3-carbonitrile (35)  
Purified by column chromatography (n-hexane-ethyl acetate 2:1) and then recrystallized from 
EtOH to give 0.123 g, 46% yield (95% purity by HPLC). MP 156–157 °C. 1H NMR (300 MHz, 
CDCl3) δ(ppm): 8.01 (dd, J = 3.0, 1.2 Hz, 1H), 7.66 (dd, J = 5.1, 1.2 Hz, 1H), 7.62 (dd, J = 1.8, 
0.6 Hz, 1H), 7.48 (dd, J = 3.6, 0.6 Hz, 1H), 7.45 (s, 1H), 7.40 (dd, J = 5.1, 3.0 Hz, 1H), 7.40 
(dd, J = 5.1, 3.0 Hz, 1H), 6.61 (dd, J = 3.6, 1.8 Hz, 1H), 5.26 (s, 2H). MS (EI) m/z (%): 267.06 
(M+, 100), 237.98 (6), 210.99 (7). Analysis calculated for C14H9N3OS: C, 62.91; H, 3.39; N, 
15.72; O, 5.99; S, 11.99. Found: C, 63.11; H, 3.47; N, 15.58; O, 5.97; S, 11.87. 
 
3.2.9.2 Pharmacological evaluation of novel 4,6-substituted 2-amino-pyridin-3-
carbonitriles 
Pharmacological evaluation was performed by CV. The assay used a radioligand binding 
competition assay, with A1, A2A, A2B, and A3 human receptors expressed in transfected CHO 
(A1), HeLa (A2A and A3), and HEK-293 (A2B) according to the procedure reported by Bosch et 
al.[385] 
The activity measurements against the phosphodiesterases PDE7A, PDE7B, PDE9A and 
PDE10A were performed using AD293 cells that were transiently and separately transfected 
with human PDE7A, PDE7B, PDE9A, and PDE10A following the procedure described by 
Shipe et al.[386] The IC50 values were obtained by fitting the data with non-linear regression 
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using Prism 2.1 software (GraphPad, San Diego, CA),[387] and the reported results are the 
mean of three experiments (n = 3) each performed in duplicate. 
3.3 Results and Discussion 
3.3.1 Design of synthetically feasible A1R/A2AR-PDE10A multi-target ligands 
Human enzyme and receptor data were extracted from ChEMBL 20.[171] Substructure 
analysis of A1R, A2AR ligands and PDE10A inhibitors with Ki and IC50 values less than or 
equal to 1 μM revealed that the most frequently occurring common heterocycles among the 
actives against the three target classes were pyridine, pyrimidine, piperazine, and 1H-pyrazole 
(Figure 19). Subsequently, A1R (2,104), A2AR (2,489) and PDE10A inhibitors (679) containing 
those frequent heterocycles were subjected to RECAP analysis/synthesis in MOE (see Methods 
for details). As a result, 458,839 (potentially) synthetically accessible ligands were found in 
silico. This list of candidates was filtered to those retaining the common heterocycles (listed 
above), in order to create a focused chemical space characteristic of A1R, A2AR and PDE10A 
(with the simultaneous trade-off of reduced novelty), giving rise to 22,233 compounds. 
3.3.2 Target prediction of the designed RECAP library 
To assess the likelihood of active compounds against A1R, A2AR and PDE10A via a 
complementary approach, PIDGIN 1.0 (Prediction including Inactivity), a tool which uses 
ECFP 4 circular Morgan fingerprints trained on ChEMBL actives and PubChem inactives was 
used to perform in silico target prediction for the focused RECAP library (22,233 
compounds).[133] Subsequent enrichment analysis of the predictions was done using an 
estimation score, the average ratio as developed by Liggi et al[366] and via a Chi-square test. 
For targets to be considered as enriched according to these methods, the estimation score and 
the Chi-square test p value should be less than or equal to 0.01 and 0.05, respectively. Hence, 
upon analyzing the enrichment parameters for the A1R, A2AR and PDE10A targets that were 
predicted for the focused RECAP library (Figure 20), the three targets were predicted with an 
estimation score equal to 0 (enriched) as well as average ratios less than 0.1 (enriched) with 
Chi-squared p values less than 0.005. The percentage of RECAP compounds of the focused 
library that were predicted as actives against the A1R, A2AR and PDE10A targets were 51.1%, 
52.8%, and 24.5% respectively. These numbers are relatively high, which however is 
understandable given that the input to the RECAP analysis consisted of experimentally 
established known ligands of the above protein targets. 
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3.3.3 Docking of the compounds predicted as A1R/A2AR-PDE10A multi-target ligands 
In the next step, docking and further substructure analysis were performed on compounds of 
the focused RECAP library, which were predicted as A1R/A2AR-PDE10A multi-target ligands 
from the ligand-based side in the previous step.  2,563 compounds were predicted as actives 
against the three desired targets and they were subsequently docked against a high resolution 
(1.8Å) A2AR protein crystal structure (PDB ID: 4EIY)[368],  its corresponding A1R homology 
model (see Methods for details) and PDE10A (PDB ID: 4DDL).[369] 
Compounds, which were carried forward to substructural analysis, were selected when their 
docking score gave a value less than a pre-determined cut-off value computed from the docking 
scores. This cut-off value was evaluated as the docking score with the best F measure statistic 
obtained by docking a set of known actives and inactives against the protein crystal structures 
and the homology model (see Methods for details). 
As a result, a distribution of RECAP compounds that were favorable as multi-target ligands by 
target prediction and docking was obtained, where 62.47% of the RECAP compounds that were 
predicted as A1R/A2AR-PDE10A multi-target ligands and docked against PDE10A exhibited 
docking scores lower than -6.49 (the threshold of the best F measure discriminating between 
actives and inactives for known ligands). Out of the RECAP compounds, which displayed 
docking scores, lower than -6.49 against PDE10A, 48.89% and 35.23% displayed docking 
scores lower than -7.26 and -8.49 against A1R and A2AR (the thresholds of the best F measures).   
3.3.4 Substructure analysis of the compounds predicted as A1R/A2AR-PDE10A multi-
target ligands 
Substructure analysis was performed on compounds having a favorable assessment by target 
prediction and docking (i.e. those compounds whose docking scores were below the threshold 
for all three targets). The analysis revealed frequently occurring series, which shared the same 
core structure, and are shown in Figure 22. 
The chemical series were identified as [1,2,4]triazolo[1,5-c]quinazolines (50.4% of all 
positively predicted multi-target ligands by in silico target prediction as well as docking), 
imidazo[1,5-a]quinoxalines (14.4%), 6,7-alkoxyisoquinolines (10.6%), and 2-aminopyridine-
3-carbonitriles (9.2%). These were in addition to various compounds containing the common 
and frequent heterocycles identified earlier (15.4%). Each series identified could be considered 
for synthesis, SAR studies and validation as A1R/A2AR-PDE10A multi-target ligands. 
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3.3.5 Synthesis of novel 2-aminopyridine-3-carbonitriles 
Due to both ease of the reaction and anticipated yield, a one-pot synthetic scheme was selected 
for synthesizing one promising series, 2-aminopyridine-3-carbonitriles. The design resulted in 
25 compounds for synthesis of which 21 were novel compounds and four (11, 12, 15, and 27) 
have previously been reported in the literature.[388–391] Compounds 11-35 were synthesized 
according to the synthetic route illustrated in Scheme 1, and all products were obtained with 
good yields, ranging from 46% to 85% (see Methods for details).  
3.3.6 Pharmacological evaluation of novel 2-aminopyridine-3-carbonitriles 
Bioactivity testing was performed using A1 and A2A human adenosine receptors expressed in 
transfected CHO (A1) and HeLa (A2A) cells, as well as AD293 cells that were transiently 
transfected with human PDE10A. Table 3 includes the list of synthesized 4,6-substituted 2-
amino-pyridin-3-carbonitriles, along with their Ki values against A1R, A2AR, and IC50 values 
against PDE10A. It can be seen that 15 compounds of the 25 synthesized 2-amino-pyridin-3-
carbonitriles exhibited inhibitory activity against PDE10A below 10 μM. In addition, 13 
compounds were adenosine receptor binders exhibiting selectivity towards A1R and A2AR, 
which is a new profile not seen in previous work reported by Mantri et al., where 2-amino-
pyridin-3-carbonitriles were promiscuous towards the four adenosine receptor subtypes.[390] 
Given that the objective of this work is to find compounds displaying specific multi-target 
activity, compounds 18, 26, 31, and 35 were identified as A1R/A2AR-PDE10A multi-target 
ligands, inhibiting PDE10A with IC50 values of 2.4, 3.2, 10.0, and 5.1 μM respectively, and 
binding to A1R with Ki values of 294 and 34 nM (compounds 18 and 26, respectively), and to 
A2AR with Ki values of 41, 95, and 55 nM (compounds 26, 31, and 35, respectively). Notably, 
compound 26 exhibited the desired multi-target profile as a PDE10A inhibitor and a dual binder 
to A2AR and A1R. 
It was previously reported that substituted pyridines exhibited PDE inhibitory activity,[392, 
393] and 2-amino-pyridin-3-carbonitriles are adenosine receptor ligands.[390] In this study 
suitable compounds matching both criteria as A1R/A2AR-PDE10A multi-target ligands, 




Table 3. Percent inhibition of the synthesized 4,6-substituted 2-amino-pyridin-3-carbonitriles 
at 10 μM (PDE10A) or IC50 (μM)




Compound R4 R6 
% Inhibition at 10 μM (PDE10A) 
or IC50 (μM) 
% displacement at 0.1 μM (A1R and A2AR) 
or Ki 




394 ± 12 nM 32% 22% 
12 
 
142 ± 7 nM 38% 52% 
13 
 
12% 8% 2.0 ± 0.2 μM 
14 
 






53% 543 ± 13 nM 28% 
16 
 
12% 1% 5.7 ± 0.3 μM 
17 
 





294 ± 10 nM 50% 2.4 ± 0.2 μM 
19 
 
84 ± 8 nM 34% 68% 
20 
 
17% 18% 3.7 ± 0.3 μM 
21 
 




44% 60% 0.9 ± 0.2 μM 
23 
 







108 ± 6 nM 30% 10% 
25 
 
6% 32% 1.5 ± 0.2 μM 
26 
 
34 nM ± 2 
nM 
41 ± 2 nM 3.2 ± 0.4 μM 
27 
 





78 ± 5nM 948  ± 13 nM 38% 
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(a) IC50 values of the 2-aminopyridines-3-carbonitriles were measured for the four 
phosphodiesterases PDE7A, PDE7B, PDE9A and PDE10A at 10 μM concentration. For those 




58% 338 ± 12 nM 73% 
30 
 
12% 50% 6.4 ± 0.4 μM 
31 
 
38% 95 ± 4 nM 








2% 10% 4.0 ± 0.3 μM 
34 
 




15% 55 ± 2 nM 5.1 ± 0.4 μM 
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measured isoenzymes, IC50 were determined (b) Calculation of the Ki values at A1R, A2AR, 
A2BR and A3R was approximated using the Cheng-Prusoff equation: Ki =IC50/[1 + (C/KD)], 
where IC50 is the concentration of compound that displaces the binding of the radioligand by 
50%, C is the concentration of radioligand, and KD is the dissociation constant of each 
radioligand. 
3.3.7  (SAR) Structure-activity relationship analysis 
The purpose of the SAR analysis was to rationalize the variation in activity of the newly 
discovered A1R/A2AR-PDE10A multi-target ligands against PDE10A, given that 2-amino-
pyridin-3-carbonitriles are a novel class of PDE10A inhibitors. Compounds of this 
substructural class were also previously documented as adenosine receptor ligands.[390] 
Computational SAR studies focused on the PDE10A data, where the variation in potency was 
rationalized in relation to the physicochemical properties of the compounds (which were 
computed by FAFDrug3, Table 4). 
A trend observed repeatedly in several cases was that when logP decreased, associated with an 
increase in tPSA, then this led to an improvement in the activity against PDE10A. Initial 
analysis concentrated on compounds 11-14, which have a phenyl substituent at position 4 of 
the pyridine ring. Compound 13 was the most potent PDE10A inhibitor with an IC50 of 2.0 
μM, and a computed logP of 3.1 and tPSA of 103.9Å2. Similarly, for compounds 15-17 having 
a phenyl substituent at position 6 of the pyridine ring, compound 16 was the most potent against 
PDE10A with an IC50 of 5.7 μM and a computed logP of 4.0 and tPSA of 81.2Å
2.  For 
compounds 18-23, which have a cyclohexyl ring at position 4 of the pyridine ring, compound 
22 displayed the most potent PDE10A inhibitory activity with an IC50 of 0.9 μM and a 
computed logP of 4.7 and tPSA of 90.9Å2. For compounds 24-27, with a p-methoxyphenyl 
substituent at position 4 of the pyridine ring, compound 26 with the smallest predicted 
lipophilicity of 3.1 and tPSA of 85.1Å2 displayed a good PDE10A inhibitory activity with an 
IC50 value equal to 3.2 μM. A more potent compound was 25 with an IC50 value of 1.5 μM and 
a computed logP of 4.4 and tPSA of 71.9Å2. For compounds 29-32, with an o-methoxyphenyl 
substituent at position 4 of the pyridine ring, compound 32 displayed PDE10A inhibitory 
activity with a higher potency (IC50 value of 5.6 μM), and a computed logP of 3.7 and tPSA of 
92.2Å2. Finally, a similar general trend is observed for the compounds 33 and 34 with a 4-
hydroxyphenyl substituent at position 6 of the pyridine ring, where compound 34 was a more 
potent PDE10A inhibitor with an IC50 of 3.1 μM and computed logP of 3.4 and tPSA of 
103.2Å2. Hence, it could be deduced that in the majority of the series considered, where the 
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substituents on a single position is varied, a decrease in computed lipophilicity associated with 
an increase in polarity generally improved the activity of compounds against PDE10A. This 
general trend can be attributed to the hydrophilic nature of the pocket, which favors the 
interactions between the ligand and the PDE10A protein by compounds exhibiting these 
properties. 
Table 4. Physicochemical properties (LogP and tPSA) computed for the synthesized 4,6-
substituted 2-amino-pyridin-3-carbonitriles using FAFDrug3 ADME-Tox tool 
 




































































































3.3.8 Compound selectivity assessment 
The selectivity of compounds 11-35 against the selected major off-targets A2BR, A3R, PDE7A, 
PDE7B, and PDE9A, was predicted using PIDGIN at a threshold for binding greater than or 
equal to 0.8, and subsequently tested experimentally. The IC50 values were determined for 
compounds with % inhibition at phosphodiesterases greater than 70%. As shown in Table 5, 
the synthesized compounds are mostly inactive against those off-targets except for compounds 
26, 27, 31, and 33 that exhibited IC50 values of 3.4, 3.5, 15.1 and 1.8 μM against PDE7A, and 
compounds 33 and 35, which exhibited IC50 values of 7.3 and 4.7 μM against PDE7B. 
Remarkably, compound 18 was found to exhibit selectivity over all tested off-targets using the 
above criterion, with the lowest selectivity measured for PDE7B (of 55% inhibition at 10 μM 
ligand concentration). This can be compared to the IC50 value of 18 at PDE10A, which is 2.4 
μM (indicating approximately 2-fold selectivity for 18). 
In general, the experimental results on off-targets for the synthesized 4,6-substituted 2-amino-
pyridin-3-carbonitriles 11-35 agree with the predictions generated using PIDGIN utilized to 
bias the compound design towards more selective compounds such as 18 (Table 5). This 
compound would serve as a good starting point for analog modification to improve selectivity 















Table 5. Percentage inhibition of the synthesized 4,6-substituted 2-amino-pyridin-3-
carbonitriles at 10μM (PDE7A, PDE7B, PDE9A), or IC50 (μM) and percentage displacement 





















2% 27% 9% 28% 1% 
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2% 2% 47% 39% 1% 
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3.3.9 Analysis of the predicted binding modes of the synthesized 2-aminopyridine-3-
carbonitriles 
The synthesized 2-aminopyridine-3-carbonitriles were docked against A2AR (PDB ID: 4EIY), 
the A1R homology model, and PDE10A (PDB ID: 4DDL). Figure 23 shows the common 
predicted ligand-target interactions for representative multi-target ligands of A1R-PDE10A, 
A1R-A2AR, and A2AR-PDE10A, namely for compounds 18, 28, and 35.  
It can be seen that compounds 18 and 35, with IC50 values of 2.4 and 5.1 μM respectively, share 
similarities in predicted binding modes, since their pyridine rings display π-stacking with 
Phe686 and Phe719 of PDE10A (Figure 23). These are the type of interactions predicted to be 
exhibited by the majority of the synthesized ligands from this work, as well as the only existing 
interactions between co-crystallized PDE10A inhibitors discovered by fragment screening 
(PDB IDs: 5C2E, 5C1W, 5C29, 5C2A having ligands with Ki values of 2, 8,700, 880, and 4.8 
nM, respectively).[386]  It is noted that the ligand bound to 5C2A exhibits a considerable 
selectivity towards PDE10A over all the other PDEs (in the range of 100-1000 fold and greater 
over the majority of PDEs, with the least selectivity observed being in the range of 25-100 
fold). This ligand exhibits only π-stacking interactions with Phe686 and Phe719, similar to the 
mode of interactions of compound 18 with PDE10A, which is relatively selective over all tested 
PDEs, with the lowest selectivity being measured for PDE7B (of 55% inhibition at 10 μM 
ligand concentration) and compound 35, which is selective against all tested PDEs except 
PDE7B (Tables 3 and 5). Additional interactions were seen in analogs discovered by fragment 
screening, namely hydrogen bonding with Gln716 and Tyr683 in the PDE10A selectivity pocket 
(PDB IDs: 5C28 and 5C2H with Ki values of 2200 and 0.0082 nM respectively).[386]
 The 
ligand bound to 5C2H exhibits π-stacking with Phe686 and Phe719 and hydrogen bonding with 
Tyr683 in the PDE10A selectivity pocket.  The 5C2H ligand showed a very high selectivity 
towards PDE10A, greater than 5000-fold, which emphasizes the consideration of compound 
18 for analog modification to target the selectivity pocket in order to improve the selectivity 
towards PDE10A. In addition, hydrogen bonding with Tyr683 in the PDE10A selectivity pocket 
is also seen in many other highly selective PDE10A inhibitors reported in the literature[394] 
(PDB IDs: 5DH5,[395] 5B4L,[396]  with Ki = 0.23 nM, and IC50 =0.76 nM respectively). This 





Figure 23. Docking studies predicted molecular interactions characteristic of the 4,6-
substituted 2-amino-pyridin-3-carbonitriles with the A2AR protein crystal structure (PDB ID: 
4EIY), A1R homology model, and PDE10A protein crystal structure (PDB ID: 4DDL), which 
are displayed for representative multi-target ligands with the following combinations: 
compound 18 (A1R-PDE10A), 28 (A1R-A2AR), and 35 (A2AR-PDE10A) a. interactions with 
A2AR-the overlaid compounds 28 and 35 exhibit H-bonds via amino and carbonitrile groups 
with Asn253, and the pyridine rings are π-stacked with Phe168 b. interactions with  A1R-the 
overlaid compounds 18 and 28  exhibit H-bonds via amino and carbonitrile groups with Asn254, 
and the pyridine rings are π-stacked with Phe171 c. interactions with PDE10A-the overlaid 
compounds 18 and 35 have the pyridine rings π-stacked with Phe686 and Phe719. The molecular 
interactions predicted for the active molecules are consistent with observed interactions 
between co-crystallized ligands and their corresponding protein crystal structures (PDB IDs: 
4EIY and 4DDL) and the interactions with the A1R homology model reported in the literature. 
 
Moreover, it is noted that compounds 26 and 31 with IC50 values of 3.2 and 10.0 μM 
respectively (which are selective against all tested PDEs except PDE7A, Tables 3 and 5) were 
predicted to exhibit an additional type of interaction, H-bonding with Gln716 via their overlaid 
furan rings at position 6 of the pyridine ring (Figure 24). In fact H-bonding with Gln716 was the 
only interaction, besides π-stacking with Phe686 and Phe719, which has been observed in many 
of the highly selective PDE10A ligands reported in the literature (PDB IDs: 4DDL,[369] 3SN7, 
3SNL, and 3SNI,[379] 5DH4 and 5DH5[395] with IC50 values of 4.9, 0.7, 0.7, 11 nM and Ki = 
0.23 nM respectively). As for other type of interactions generally exhibited by known PDE10A 
inhibitors such as hydrogen bonding with Gln726 and π-stacking with Phe729 (PDB ID: 5EDE),
 
[397]none were predicted for any of the compounds presented in this work. 
 99 
 
Figure 24. Docking studies predicted molecular interactions for the overlaid compounds 26 
and 31 with PDE10A: π-stacking of the pyridine rings with Phe686 and Phe719, and H-bonding 
with Gln716 via their overlaid furan rings at position 6 of the pyridine ring 
Common predicted binding modes could also be observed for the synthesized compounds 
against the adenosine receptors A2AR and A1R. Figure 23 displays the interactions of two 
representative compounds 28 and 35, which exhibit Ki values of 948 and 55 nM respectively. 
These are H-bonding of their pyridine rings with Asn253 and π-stacking of their amino and 
carbonitrile groups with Phe168 of A2AR. As for A1R, the overlaid compounds 18 and 28, with 
Ki values of 294 and 78 nM respectively, H-bond via their amino and carbonitrile groups with 
Asn254, and their pyridine rings are π-stacked against Phe171. It can be observed that the 
ligand/protein interactions predicted for the active compounds against the A2AR are also those 
seen in the co-crystallized ligand/protein crystal structures (PDB IDs: 4EIY,[368] 3EML,[398] 
5IU4,[399] with a Ki value of 0.8 nM for ZM 241385, which is the ligand common to the three 
PDB IDs). The interactions with the A1R are similar to those reported with the A1R homology 
model (for ligands with IC50 values of 2.9 and 6.2 nM (from the literature) and predicted to 
interact with the A1R homology model).[400, 401]
 
Generally, the compounds exhibited good selectivity towards A1R and A2AR (Tables 3 and 5) 
with a nanomolar range of binding affinities. As for the selectivity towards PDE10A, this could 
be improved by analog modification of compound 18 to favor the hydrogen bonding interaction 
with Tyr683 in the PDE10A selectivity pocket. In addition, the potency of compounds against 
PDE10A could also be optimized to achieve therapeutically relevant efficacy. 
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3.3.10 Computational assessment of CNS permeability 
Compounds 18 and 26 exhibited the desired multi-target profile by inhibiting PDE10A and 
binding to A2AR and/or A1R. The physicochemical properties of these compounds were 
calculated by FAFDrug3,[313] and both compounds passed Lipinski rule of 5 and the CNS 
filter, which takes into consideration the assessment of their ability to pass the blood brain 
barrier (Figure 25).[304] Hence, while further experimental work would be needed to establish 
the validity of those predictions, compounds 18 and 26 may serve as good starting points for 
further functional efficacy assessment and selectivity optimization towards PDE10A, A2AR 
and/or A1R for subsequent consideration of development for the treatment of 
neurodegenerative diseases.  
 
Figure 25. Compounds 18 and 26 (represented in A. and B. respectively), have passed the CNS 
filter which takes into consideration the assessment of their ability to pass the blood brain 
barrier, values of compounds 18 and 26 (blue line) fall within the CNS filter area (light blue) 
3.4 Conclusions 
Here, a successful computational strategy is reported for designing the first A1R/A2AR-
PDE10A multi-target ligands with potential therapeutic utility for neurodegenerative diseases. 
A retrosynthetic approach was employed using MOE/RECAP, followed by target prediction 
and docking of the resulting library against the desired targets. 2-aminopyridine-3-carbonitriles 
have been identified as a series that showed agreement between both the ligand- and structure-
based predictions of activity against A1R, A2AR and PDE10A. The synthesis of this series via 
a one-pot synthetic scheme was pursued experimentally. As a result, compounds 18, 26, 31, 
and 35 were validated as A1R/A2AR-PDE10A multi-target ligands with IC50 values of 2.4, 3.2, 
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10.0, and 5.1 μM against PDE10A, and binding to A1R with Ki values of 294 and 34 nM (18 
and 26 respectively), and to A2AR with Ki values of 41, 95, and 55 nM (26, 31, and 35 
respectively).  
Furthermore, selectivity profiling of the synthesized 4,6-substituted 2-amino-pyridin-3-
carbonitriles against other subtypes of both protein families showed that the multi-target ligand 
18 exhibited a minimum of 2-fold selectivity over all tested off-targets. In addition, compounds 
18 and 26 exhibited the desired multi-target profile against A1R, A2AR and PDE10A, which 
would serve as good starting points for further functional efficacy assessment and analog 
modification for the improvement of selectivity. In particular, investigating the signal 
transduction profiles of these compounds using techniques previously described,[400] as well 
as evaluating functional effects in cAMP signaling assays may help determine if these 
compounds do indeed provide synergistic elevations in intracellular cAMP. The functional 
profile investigated here is likely to elevate cAMP levels synergistically via the combination 
effect on multiple targets simultaneously (as an A1R antagonist/A2AR agonist, and PDE10A 
inhibitor). 
In summary, a computational approach for the design of multi-target ligands has been 
investigated. The method was validated experimentally via the synthesis and pharmacological 
evaluation of 2-aminopyridine-3-carbonitriles as A1R/A2AR-PDE10A ligands. This approach 
is generally applicable to a wide range of multi-target ligand design problems, across disease 













4 Structure-based identification of dual ligands at A2AR and 




Targeting compounds that elevate cAMP concentrations via the agonism of A2AR and the 
inhibition of PDE10A is a promising way to inhibit cancer cell proliferation.[98] This is 
achieved through the A2AR-Gαs-adenylate cyclase axis, while further promoting cAMP 
elevation by the inhibition of its breakdown via PDE10A. In fact, elevation of cAMP has been 
shown to exhibit anti-proliferative effects,[101–106] in various cell types. Given that A2AR and 
PDE10A are both expressed in non-small cell lung cancer (NSCLC) cell-lines, [130, 131] then 
their targeting could be a promising anti-proliferative strategy in NSCLC. Indeed, there is the 
opportunity for multi-target approaches to improve therapy in NSCLC given that the first 
generation therapies have failed due to the use of single target agents that allow the survival of 
cancer cells via other pathways.[28] 
In chapter 3, triazoloquinazolines were predicted as dual ligands at the A2AR and 
PDE10A.[338] It has been challenging however, to identify compounds, which elevate cAMP 
at these targets.[402–404] In this chapter, this problem is addressed by docking 
triazoloquinazolines, which are known PDE10A inhibitors, into the orthosteric site of an active 
form of A2AR.[319] Subsequently, MD simulation analysis was performed in order to identify 
a conformational descriptor that characterizes A2A receptor activation.[320, 321, 405] 
Following this, the compounds are validated as A2AR agonists in relevant biochemical assays 
and tested for their anti-proliferative effects in lung carcinoma cell-lines.  
Cyclic adenosine monophosphate (cAMP) is a second messenger that has a major role in 
transduction and cell signaling in several pathways and biological systems.[96] cAMP 
elevation may be achieved via the activation of the adenylate cyclases by Gs proteins, and the 
inhibition of cAMP-degrading phosphodiesterases.[406] Given that cAMP intracellular 
signaling has been shown to inhibit proliferation, this signaling pathway would impact the 
survival and growth of cancer cells.[406] Indeed, compounds that elevate cAMP demonstrate 
therapeutic benefits in several cancer-related diseases such as breast cancer, colon cancer, lung 
cancer, glioblastoma etc.[407] In some cases, however, they exhibited pro-proliferative effects, 
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[99–101] whereas in many other cases anti-proliferative effects[101–106] depending on the 
cell type. For instance, cAMP elevation leads to the blockade of growth factor-stimulated cell 
growth via the inhibition of the mitogen-activated protein (MAP) kinase cascade, resulting in 
anti-proliferative effects in mesangial cells, fibroblasts, and smooth muscle cells. In contrast, 
cAMP elevation exhibits pro-proliferative effects in other cell types such as hepatocytes, 
thyroid cells, and PC12 cells.[99–106]  
A2AR is expressed in both lung adenocarcinoma and squamous carcinoma cell-lines, which are 
two histologically distinct types of non-small cell lung cancer (NSCLC cell-lines).[130, 131] 
Likewise, PDE10A is overexpressed in lung adenocarcinoma, and its inhibition was found to 
suppress growth,[132] demonstrating a correlation between the levels of overexpression and 
survival.[408] Also, a recent study suggests that the cAMP signaling pathway contributes to 
the suppression of cell growth in NSCLC.[409] Therefore there is the possibility of targeting 
both A2AR and PDE10A as an anti-proliferative strategy for NSCLC, given that the agonism 
of the A2AR and inhibition of PDE10A lead to cAMP elevation. 
Indeed, dual PDE inhibition and A2AR activation via compound combinations has exhibited 
synergy in cAMP elevation and been observed to inhibit proliferation of multiple myeloma and 
diffuse large B-cell lymphoma, as well as induce apoptosis.[98] Based on these results, the 
anti-proliferative effects of dual ligands at A2AR and PDE10A in lung adenocarcinoma and 
squamous cell carcinomas cell-lines were explored as promising avenues for investigation. 
Many virtual screening protocols have been reported in the literature, implementing either 
ligand- or structure-based approaches for the design of PDE10A inhibitors or A2AR agonists.
 
Examples of ligand-based protocols include in silico target prediction, pharmacophore-based 
and fragment-based approaches and comparative molecular field analysis (CoMFA).[386, 402, 
403, 410–412] Docking, as a structure-based approach, has also been employed for the design 
of either PDE10A inhibitors or A2AR agonists.[413] In addition, many molecular dynamics 
approaches have been used to investigate the conformational dynamics at the A2A adenosine 
receptor or PDE10A.[350, 404, 413–418] None of the reported protocols, however rationalize 
or correctly predict the functional activity of ligands against the targets of interest, in particular 
A2AR, which is addressed in this work.  
Here, a novel structure-based approach for identifying ligands that activate the A2AR while 
simultaneously inhibiting the PDE10A is devised. Given that PDE10A is an enzyme, 
compounds that target its active site would most likely confer inhibition. The real challenge 
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lies in finding compounds that activate the A2AR given that binding to its orthosteric site may 
not guarantee the desired functional activity. For this reason, the design of A2AR agonists was 
focused on the objective of finding dual-target ligands. 
Triazoloquinazolines have been predicted as a chemical series of dual ligands with activity at 
A2AR and PDE10A by ligand- and structure- based techniques (as described in chapter 3.)[338] 
So known PDE10A inhibitors, belonging to this chemical series, were docked into the 
orthosteric site of the active form of the A2AR protein crystal structure (PDB ID: 2YDO). This 
crystal structure that enriches A2AR agonists over antagonists and inactives was selected for 
docking studies. Experiments were performed by the Ladds group members at the 
pharmacology department in the University of Cambridge using both yeast-based[419] and 
mammalian cell-based assays[400] to demonstrate that triazoloquinazolines are indeed A2AR 
agonists. A particular focus in the structure-based computational approach was on the key 
interacting residues, which are reported in the literature to discriminate between agonist and 
antagonist activity of A2AR ligands. It is reported that[320, 405]
 Val84, Leu85, Leu249, Ser277 and 
His278 show significant differences between the active and inactive conformations of the A2AR 
protein crystal structures. In particular, Val84
 in TM3 (Transmembrane Helix 3), an amino acid 
residue that is located in the orthosteric site, has to move upon agonist binding owing to a steric 
clash with the agonist, which may contribute to the 2Å shift observed in H3 (Helix 3).[319–
321] Hence, it is postulated that the motion of this residue upon A2AR ligand binding might 
discriminate between agonist and antagonist activity, which has not previously been 
investigated by MD approaches.[412–417, 420]  
Molecular dynamics (MD) analysis is used to determine the motion of Val84 in TM3 and to 
deduce whether it is an essential requirement of A2AR activation. In this work, the motion of 
Val84 was found to be a good conformational descriptor for the characterization of receptor 
activation by the A2AR ligands.  Hence the MD-assisted approach provides a template for 
generating A2AR agonists as part of the dual-target ligand design objective by identifying a 
shortlist of candidates that displace the Val84 amino-acid residue. 
Furthermore, the compounds showed concentration-dependent anti-proliferative effects in lung 
squamous cell carcinoma and lung adenocarcinoma cell-lines. These effects correlate with the 
co-expression of A2AR and PDE10A and the increased cellular levels of cAMP, with the H1563 
adenocarcinoma cell-line being the most sensitive given that it exhibits the highest combined 
expression of A2AR and PDE10A. In particular, compound 36 shows a strong correlation 
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between the increase in potency for cAMP elevation and inhibition of proliferation in lung 
carcinoma cell-lines as the combined expression of A2AR and PDE10A increases across the 
LK-2, H520, H1792 and H1563 cell-lines. The anti-proliferative effects that were exhibited by 
these dual-target compounds in a concentration-dependent manner suggest their potential 
clinical value.  
4.2 Materials and Methods 
4.2.1 Design approach of the dual ligands at the A2AR and PDE10A  
Triazoloquinazolines were shortlisted as candidates of dual ligands at the A2AR and PDE10A, 
given that this chemical series displayed the highest frequency of prediction against the desired 
set of targets by the ligand- and structure- based techniques (see chapter 3).[338] However to 
elevate cAMP, the focus was to find dual ligands that are simultaneously agonists at A2AR and 
inhibitors of PDE10A. 
From the ZINC12 database,[421] eleven purchasable triazoloquinazolines that were 
experimentally known PDE10A inhibitors, were found upon a search done for the 
triazoloquinazoline substructure with the following criteria: Uniprot ID: Q9Y233 and IC50 < 
10 μM. The triazoloquinazolines that were identified to meet these criteria had the following 
IDs: 3154141, 3141002, 6206233, 9937921, 9939949, 2968902, 14728559, 424907, 
13229753, 44924158, and 8747709. These were downloaded for subsequent docking into the 
orthosteric site of the A2AR protein crystal structure. 
4.2.2 Selection of the A2AR protein crystal structure for shortlisting triazoloquinazoline 
candidates as A2AR agonists 
All the active forms of the A2AR protein crystal structure with the following PDB IDs (4UG2, 
4UHR, 3QAK, 2YDO, and 2YDV)[319, 320, 405] and the inactive forms with the following 
PDB IDs (5IU4, 3UZA, 5K2A, 4EIY, 3EML, 5NM2, 5JTB, 5UVI, and 5UIG)[368, 398, 399, 
422–426] were downloaded into MOE.[352] It has been reported in the literature that Val84
 in 
TM3, which is located in the orthosteric site, has to shift its position upon agonist binding 
owing to a steric clash with the ligand, which may contribute to the 2Å shift observed in 
H3.[319–321]  To evaluate the change in the interaction upon agonist binding, the distance was 
calculated using MOE from a fixed amino acid residue to Val84. The fixed amino acid residue 
selected was Leu249 in TM6. This was achieved by aligning all the active and inactive forms of 
the A2AR protein crystal structures (using the sequence editor > alignment> align/superimpose 
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option). Then, the mean RMSD value of all the aligned structures was calculated for Leu249, 
which turned out to be low (0.40Å) confirming that it is reasonably static in its relative position.  
For each PDB ID of the active and inactive forms of the A2AR crystal structures, the distance 
between the α-carbons of Val84 in TM3 and Leu249 in TM6 was measured in MOE using the 
measure> distances option. Table 6 lists all the Val84-Leu249 inter-residue distance values for 
the active and inactive forms of the A2AR protein crystal structures. The inter-residue distances 
of the active forms ranged from 14.30 to 14.53Å, and for the inactive forms they ranged from 
12.96 to 13.36Å. The largest displacement of the Val84 residue was measured for the active 
form with PDB ID: 2YDO, and the distance was equal to 14.53Å, this is in comparison to the 
inactive form of the A2AR protein crystal structure (PDB ID: 5IU4), which had the minimum 
distance (12.96Å). Given that Val84 displayed the highest displacement from the Leu249 residue 
in this crystal structure, it was hypothesized that this would allow an optimum conformational 
space for A2AR agonists to explore when docked into its orthosteric site. Hence, the A2AR 
protein crystal structure with the PDB ID: 2YDO was selected as the best candidate for 
shortlisting A2AR agonists. 
Table 6.  The inter-residue distance values for Val84-Leu249 for all the active and inactive forms 
of the A2AR protein crystal structures 
 







4UG2 14.30 5IU4 12.96 
4UHR 14.38 3UZA 13.15 
3QAK 14.46 5K2A 13.01 
2YDO 14.53 4EIY 13.07 










4.2.3 Ligand Preparation  
39 potent agonists and 38 potent antagonists of the A2AR (Uniprot ID: P29274) with EC50 and 
IC50 values less than 1 μM and confidence scores equal to 9 were manually extracted from 
ChEMBL. 133 A2AR inactives were extracted from PubChem (using SQL query in Appendix 
D) and the eleven purchasable triazoloquinazolines were selected form the ZINC12 database. 
The entire set of ligands were prepared for docking into the orthosteric site of the A2AR protein 
crystal structure, with LigPrep 2.5[372] using the default settings and the Epik option, which 
introduces energy penalties associated with ionization and tautomerization.[335] 
4.2.4 Receptor Preparation  
Docking with Glide[134] was performed against the human A2AR protein crystal structure 
(PDB IDs: 2YDO and 5IU4). The protein structures were prepared using the Protein 
Preparation Wizard of Maestro 9.3,[334] following the default protocol, which accounts for 
energy refinement, hydrogen addition, pKa assignment, and side-chain rotational isomer 
refinement. Resolved water molecules were discarded, and the structure was centered using the 
co-crystallized ligand as the center of the receptor grid generated for each protein structure. 
The co-crystal structures of A2AR with Adenosine (PDB ID: 2YDO) and with ZM 241385 
(PDB ID: 5IU4) were selected as target structures.   
4.2.5 Enrichment of agonists by the A2AR docking model (PDB ID: 2YDO) 
In an attempt to validate the A2AR docking model, the set of prepared A2AR agonists, 
antagonists and inactives were docked using Glide against the prepared protein structure. 
The Glide docking parameters used were extra precision (XP) and flexible ligand sampling, 
which obtained the best separation for the medians of docking score distribution for agonists 
versus antagonists and agonists versus inactives. This implies that this docking model enriches 
the agonists. Figure 26 shows the separation of the medians for the A2AR docking model: A. -
11.24 (agonists) B. -7.88 (antagonists) and C. -6.74 (inactives). Statistical analysis was 
performed with R[337] using a Mann-Whitney test on the agonist and antagonist docking score 
distributions, as well as agonist and inactive docking score distributions. The differences in 
medians were significant at a p value of less than 0.05 (script provided in [338]). 
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Figure 26. A good separation was obtained for the medians (dashed lines) of the docking score 
distributions for A. agonists (-11.24) B. versus antagonists (-7.88) and C. versus inactives (-
6.74) confirming that the agonists are enriched.  Statistical analysis was performed with R using 
a Mann-Whitney test[337] on the agonist and antagonist docking score distributions, as well 
as agonist and inactive docking score distributions. The differences in medians were significant 
for a p value less than 0.05. 
4.2.6 Cut-off generation for compound selection as candidates of A2AR agonists from 
the docking model  
The Matthews correlation coefficient (MCC), which takes into account true and false positives 
(agonists) and negatives (antagonists), was computed (using a Python script[338]) for the 
docking scores of the agonists and antagonists against the A2AR docking model. A search was 
performed for a docking score threshold that gave the highest MCC in order to shortlist 
promising candidates of A2AR agonists, which displayed docking scores that are lower than the 
score with the highest MCC, and this gave a threshold of -7.33 for the A2AR docking model.  
4.2.7 Docking 
The eleven purchasable triazoloquinazolines, which were prepared with LigPrep, were docked 
against the A2AR protein crystal structure (PDB ID: 2YDO). The Glide docking parameters 
used were extra precision (XP) and flexible ligand sampling. The parameters were deduced 
from docking experiments using known actives and inactives against the protein-docking 
model. Six triazoloquinazolines (36-41) displayed docking scores that are lower than -7.33, 
which was the docking score with the highest MCC for the known agonists and antagonists.  
Their chemical structures are depicted in Figure 27. As a further step, compounds 36, 39 and 
40, with the highest predicted affinities and the most potent agonists identified, compound 41, 
which did not exhibit any agonist activity, CHEMBL3799351 (antagonist with an IC50 = 4.35 
nM and confidence score equal to 9), and CGS 21680 (the selective and potent A2AR agonist), 
Adenosine (non-selective Adenosine receptor agonist), were docked into the inactive form of 
the A2AR protein crystal structure (PDB ID: 5IU4) for MD simulation and analysis. The six 
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triazoloquinazolines (36-41) were then shortlisted for validation as A2AR agonists in relevant 
biochemical assays. 
 
Figure 27. The chemical structures of the six triazoloquinazolines (36-41) that displayed 
docking scores that are lower than -7.33, which was the docking score with the highest MCC 
for the known agonists and antagonists. They were then then shortlisted for validation as A2AR 
agonists in relevant biochemical assays. 
4.2.8 MD Simulations 
Based on a structural analysis of the available A2AR crystal structures, the distance between the 
α-carbons of Val84 in TM3 and Leu249 in TM6 was selected to be investigated as a 
conformational descriptor for receptor activation. The two A2AR co-crystallized structures of 
(PDB IDs: 5IU4 and 2YDO), which exhibited the largest difference in α-carbon distances 
between Val84 in TM3 and Leu249 in TM6 (12.96Å versus 14.53Å respectively), were selected 
for molecular dynamics simulation analysis. Subsequently, compounds 36, 39, 40, and 41 that 
were docked into the orthosteric site of the inactive form of the A2AR protein crystal structure 
(PDB ID: 5IU4) were subjected to a 100 ns MD simulation protocol. Likewise, 
CHEMBL3799351, CGS 21680, Adenosine, which were all docked into the orthosteric site of 
the inactive form of the A2AR protein crystal structure (PDB ID: 5IU4), and the apo structure 
(PDB ID: 5UI4), were chosen for the same analysis.   The starting structures were prepared 
using Maestro 9.3 following the default procedure for protein preparation. The protocol uses 
the "Cap termini" option, which adds the coordinates to the residue to have them in order. Next, 
“Analyze network” in the Interactive H-bond optimizer was used to check on the assignments 
of hydrogen orientations in the hydrogen-bonding network. They were subsequently optimized.  
All MD simulations described in this study were performed using Desmond 3.2 available in 
the Schrödinger software package.[265] An orthorhombic box was used to build the model 
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systems with periodic boundary conditions in an isothermal–isobaric ensemble with a constant 
number of particles (NPT ensemble). The system temperature was kept at 300 K, and the 
pressure was kept at atmospheric pressure. The definition of transmembrane regions was taken 
from the OPM database.[427] The receptor structures were embedded in a pre-equilibrated 
palmitoyloleoyl-phosphatidylcholine membrane (bilayer) and solvated with simple point 
charge water and 0.15 M NaCl. All other parameters were set on default values. The 100 ns 
simulations were carried out with Desmond 3.2 via command line on the computer cluster 
CALCULON (University of Cambridge) by using 20 central processing units. The trajectories 
obtained were analyzed with the software VMD,[428] and then plots were obtained for the 
RMSD values of His250 in TM6, and the α-carbons distances between Val84 in TM3 and Leu249 
in TM6 for the simulated systems over 100 ns using seaborn library[429].  
4.2.9 Experimental validation of the virtual screening protocol 
Ian Winfield (IW), Dewi Safitri (DS), and Sabrina Carvalho (SC) in the Ladds group, at the 
Pharmacology Department of the University of Cambridge, performed the experimental 
validation of triazoloquinazolines 36-41 as dual ligands at A2AR and PDE10A, and tested the 
anti-proliferative effects of the compounds in lung carcinoma cell lines. 
4.2.9.1 Materials 
Triazoloquinazolines 36-41 were supplied from Ambinter (Orléans, France), and CGS 21680, 
NECA and ZM 241385 from Tocris Biosciences (Abingdon, UK). All compounds were stored 
in 10 mM stock solutions in DMSO. Rolipram was purchased from Cayman chemicals 
(Michigan USA), and other laboratory reagents were from Sigma-Aldrich (Poole, UK), of 
analytical grade.  
4.2.9.2 Mammalian cell culture  
CHO-K1 (gifted by Dr. Ewan St. John Smith, University of Cambridge, UK) CHO-K1-A2AR 
and CHO-K1-A3R cells (gifted by Prof. Karl-Norbert Klotz, University of Wuerzburg, 
Germany), were routinely cultured in Hams F-12 nutrient mix, supplemented with 10% fetal 
bovine serum (FBS). H520, H1563, H1792 and LK-2 cells (gifted by Dr. Whalid Khaled, 
University of Cambridge, UK) were grown in RPMI media + 10% FBS. All media was further 
supplemented with 1X antibiotic, antimycotic solution (Sigma Aldrich, Poole, UK). Culturing 
of all cell types was done at 37°C in a humidified atmosphere containing 5% CO2. (work done 
by IW and DS) 
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4.2.9.3 Generation of CHO-K1 cell line stably expressing the A2AR 
CHO-K1 cells stably expressing the A2AR cells were generated via transfection with 500 ng 
pcDNA3.1-A2AR (cDNA.org), per well of a 24-well plate, which was performed with FuGENE 
HD (Promega, Wisconsin, USA), at a 1:3 (w/v) DNA:FuGENE ratio. Prior to adding 800 μg/ml 
G418 (Sigma Aldrich, Poole, UK), the cells were further cultured for 48 hours. Then every 48 
hours, G418 containing media were replaced until foci of cells were attained, which were left 
to grow to 100% confluency. Afterwards, each well was tested for the ability of CGS 21680 to 
elevate cAMP, performing further culturing with appropriately responding clones as described 
(work done by IW).  
4.2.9.4 Phosphodiesterase 10A inhibition assays 
A PDE10A assay kit (BPS Bioscience, San Diego, CA) was used by IW to test the PDE10A 
inhibition of compounds 36-41 as described in the manufactures protocol. 400 pg of purified 
PDE10A was used per reaction, and the plates were read using a TECAN infinite M200. 
4.2.9.5  Yeast methods 
Generation of yeast strains was done by IW and SC according to previously reported protocols, 
and they have been routinely grown as previously described by Knight et al.[400] Yeast cells 
expressing either the A1R, A2AR, or A2BR were treated with either NECA, CGS 21680 or 
compounds 36-41, in order to measure the activity of each, as previously described.[400]  
4.2.9.6 cAMP accumulation assays 
Prior to assay, harvesting of cells was performed with trypsin containing 0.05% EDTA, they 
were then washed with PBS, and subsequently resuspended in stimulation buffer (PBS 
Proliferation assays containing 0.1% BSA and 25 μM rolipram). Seeding of cells was done at 
2000 cells well-1 of a 384-well white optiplate, and then they were stimulated at room 
temperature with compounds 36-41 (ranging 10 mM – 100 pM) for 30 minutes. The cells were 
subsequently lysed, and the measurement of cAMP levels was done using a LANCE cAMP 
detection kit (PerkinElmer), and the plates were read with a Mithras LB940 microplate reader 
(work done by IW). 
4.2.9.7 Proliferation assays 
To test the effect of compounds 36-41 upon proliferation, various cell types were seeded onto 
clear 96-well plates at proper densities for each; CHO-K1 (2000 cells well-1), CHO-K1-A2AR 
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(2000 cells well-1), H520 (2500 cells well-1), H1563 (2500 cells well-1), H1792 (2500 cells well-
1), LK-2 (2500 cells well-1). This was done in suitable media, and they were cultured for 24 
hours. After the subsequent addition of compounds 36-41 (ranging 316 nM - 100 μM), cells 
were allowed to grow further for 72 hours. Quantification of changes in cell number was done 
by adding 5 μl CCK-8 reagent to each well, accompanied by incubation at 37°C for 1-3 hours. 
The determination of OD450 was done using a Mithras LB940 micro-plate reader at 450 nm 
(work done by IW and DS). 
4.2.9.8 RT-PCR 
Extraction of RNA from H520, H1792, H1563 and LK-2 cells was done using a RNAqueous®-
4PCR Total RNA Isolation Kit (Life Technologies, Paisley, UK) by DS as per the 
manufacturer’s instructions. Then, DNAse I treatment was performed to remove the 
contamination by genomic DNA. Subsequently, the quantification of the degree of purity of 
RNA samples was performed using a NanoDropTM Lite spectrophotometer (Thermo Scientific, 
UK). The samples that were used in cDNA synthesis are those of yields >100 ng/μL and A260/280 
ratios >1.9. The cDNA synthesis was done using a QuantiTect reverse transcription kit 
(Qiagen, Manchester, UK), for which a total of 1μg of freshly isolated RNA was consumed per 
reaction. RT-PCR was subsequently implemented according to what has been previously 
reported[430].  The RT-PCR that has been done used gene specific primers to human: GAPDH 
(Sense 5’–TGCACCACCAACTGCTTAGC– 3’; Antisense 5’-
GGCATGGACTGTGGTCATGAG–3’), A1R (Sense 5’-CCACAGACCTACTTCCACACC–
3’; Antisense 5’–TACCGGAGAGGGATCTTGACC–3’, Primerbank ID - 
115305570C1[431]), A2AR (Sense 5’-CGCTCCGGTACAATGGCTT–3’; Antisense 5’–
TTGTTCCAACCTAGCATGGGA–3’, Primerbank ID - 156142194C1[431]), A2BR (Sense 5’–
TGCACTGACTTCTACGGCTG–3’; Antisense 5’–GGTCCCCGTGACCAAACTT–3’, 
Primerbank ID - 22907046C1[431]), A3R (Sense 5’–GGCCAATGTTACCTACATCACC–3’; 
Antisense 5’–CCAGGGCTAGAGAGACAATGAA–3’, Primerbank ID - 4501953A1[431]) 
and PDE10A (Sense 5’-TGA TGACTTTTCTCTCGACGTTG–3’; Antisense 5’–
AAGCCACCTACACAGTGTCTC–3’, Primerbank ID - 359465520C1[431]). Then, gel 
electrophoresis (using 2% agaorse gels) was performed to resolve PCR products. The imaging 
of gels was subsequently done using a G Box iChemi gel documentation system employing 
GeneTools analysis software (Syngene, Cambridge, UK) and densitometry. 
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4.2.9.9 Data analysis 
Data analysis was performed by the Ladds group members using GraphPad Prism 6e (San 
Diegeo, CA). All data for -galactosidase assays were normalized to the responses resulting 
from NECA stimulation, whereas the data for cAMP inhibition/accumulation assays were 
normalised to those obtained upon stimulation with 100 μM Forskolin or CGS 21680. As for 
proliferation assays, the normalization of all data was done relative to the responses obtained 
upon treating cells with 1% (v/v) DMSO.  Subsequently, a three-parameter logistic equation 
was used for fitting each set of normalized data -galactosidase or cAMP data, in order to 
calculate pEC50/pIC50 and Emax values. Also the fitting of the proliferation data was done using 
a three-parameter logistic equation constraining the basal value to 100 and the system 
maximum to the IMax value obtained for compound 37, since it elicited the maximum inhibition 
of cellular proliferation in all cell types tested. A one-way ANOVA with Dunnett’s post-test, 
or Student’s t-test was used to assess the statistical significance for all assays, where p < 0.05 
was considered to be significant. 
4.3 Results and Discussion 
4.3.1 Method of selecting triazoloquinazolines as candidates of dual ligands at A2AR 
and PDE10A  
Triazoloquinazolines were identified as a compound series that showed the highest frequency 
of prediction at A2AR and PDE10A by the ligand- and structure- based techniques.[338] For 
the purpose of finding dual-target ligands that elevate cAMP, the focus was on ligands that 
simultaneously activate the A2AR and inhibit the PDE10A. In particular, additional attention 
was given to identifying A2AR agonists.  
From the ZINC12 database,[421] six purchasable triazoloquinazolines (see methods for details), 
which are known to inhibit the PDE10A with IC50 values ranging from 15 nM to 10 μM, were 
shortlisted. This was done by docking them into the orthosteric site of the A2AR protein crystal 
structure (PDB ID: 2YDO), which displayed the highest displacement of the Val84 residue, 
(Table 6) an amino acid residue whose motion is essential for A2AR activation.  The Val84-
Leu249 inter-residue distances were found for the active forms of the A2AR protein crystal 
structure reported in PDB, and compared to the inactive forms in PDB. Hence, the docking 
model (PDB ID: 2YDO) was selected based on this criterion, and it was able to enrich A2AR 
agonists over A2AR antagonists and inactives (refer to methods for the choice of this protein 
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structure and the validation of the docking model used). This is in line with a previous study 
done by Rodríguez et al,[404] where the A2AR crystal structure (PDB ID: 2YDO) displayed 
the highest enrichment factor value (EF1%) for docked agonists over the other active crystal 
structures of A2AR. The 2YDO crystal structure enriched agonists 63.5-fold better than random 
and 2.9-fold better than antagonists (63.5% versus 21.9%). However, this docking approach 
failed to find any A2AR agonists (which used three active structures PDB IDs: 2YDO, 2YDV, 
and 3QAK). The authors rationalized this as the result of bias of the chemical libraries towards 
A2AR antagonists over agonists. 
In this approach, the selection of the six triazoloquinazolines, as promising candidates of A2AR 
agonists was based on the docking scores that are lower than the score with the highest MCC 
for the A2AR docking model, which was -7.33 (see methods for details). Compound 39 
exhibited the most favorable docking score (highest predicted affinity) among the six 
shortlisted compounds. Compounds 36-41 were screened against PAINs (PAN Assay 
Interference Compounds)[339] using FAFDrug3,[313] and none of the compounds exhibited 
any potential PAINs liability. 
4.3.2 Analysis of the predicted binding modes of representative triazoloquinazolines 
36-39 shortlisted for experimental validation 
Docking studies predicted molecular interactions characteristic of triazoloquinazolines with the 
A2AR protein crystal structure (PDB ID: 2YDO). Compounds 36-38, were predicted to be 
selective A2AR ligands, which could be attributed to their interactions with His250 (Figure 
28).[432, 433] This residue is located in the core region of the receptor and part of a sub-pocket 
formed by Leu85, Met177, Trp246 and Leu249. Despite the fact that it is conserved among the A1R 
and the A2AR subtypes (as suggested by a recent study, due to the high conservation of amino 
acid residues in the adenosine receptor subtypes), the subtype selectivity might not be attributed 
to the receptor-specific amino acid residues, but rather conformational differences.[363] In 
addition, given that mutation experiments have failed so far to highlight any receptor-specific 
amino acid residues responsible for subtype selectivity, this would further support the 
hypothesis.[433, 434] Hence, the selectivity of A2AR agonists could be attributed to the 
conformational change of the His250 amino acid residue that contributes to shaping the 
orthosteric site to favor their selectivity.[363] Indeed, the interaction with this residue is only 
observed for the selective A2AR co-crystallized agonists, CGS 21680 (PDB ID: 4UHR) and 
UK432097 (PDB ID: 3QAK) but not the non-selective co-crystallized agonists NECA (PDB 
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ID: 2YDV) and adenosine (PDB ID: 2YDO). It has been reported, however, that the occurrence 
of this interaction cannot discriminate between agonist and antagonist activity.[433, 434]  
Hence, the predicted interactions with His250 might serve to quantify the binding in the 
lipophilic sub-pocket formed by these residues, suggested to be the driving force for A2AR sub-
type selectivity.  
As shown in Figure 28, compound 36 forms H-bonds via the nitrogen of the quinazoline ring 
with the Asn253, and via the imidazo ring with Glu169. Its triazole ring is π-stacked with Phe168, 
and its phenyl group in the quinazoline moiety is π-stacked with His250. The overlaid 
compounds 37 and 38, H-bond via their amino groups with Glu169 and Asn253, and their triazole 
rings are π-stacked with Phe168, whereas their overlaid 3,4-dimethoxy-phenyl and 2-
Bromophenyl (for 37 and 38 respectively), are π-stacked with His250. As for compound 39, it 
exhibits H-bonding via the nitrogen of the triazole ring with Asn253. The triazole ring is π-
stacked with Phe168, and the phenyl group of the 1,3-benzoxazole is π-stacked with Tyr271.  
The molecular interactions predicted for the selective A2AR agonists 36-38 are consistent with 
the observed interactions between the co-crystallized ligands and the active A2AR crystal 
structures (PDB IDs: 4UG2, 4UHR,[320] 3QAK,[405] 2YDO and 2YDV[319]). As for 
compound 39, its extra interaction with Tyr271 is similar to that exhibited by UK432097 but not 
to any of the reported co-crystallized antagonists.[120–125, 127, 128] The compounds were 
not predicted to display all the interactions exhibited by the agonist co-crystallized ligands[319, 
320, 405] and in particular the Thr88 and Ser277 interactions, which are also characteristic of the 
ZM 241385 antagonist.[418] Hence, these interaction types are not characteristic of agonist 
activity. However, it has been reported in the literature that mutating these residues has a 
stronger influence on agonist activity than upon the antagonist activity of the A2AR ligands, but 
not on the binding to the A2AR.[120]
 As for the co-crystallised A2AR antagonists (PDB ID: 
5IU4,[399] 3UZA,[422] 5K2A,[423] 4EIY,[368] 3EML,[398] 5NM2,[424] 5JTB,[425] 5UVI, 
and 5UIG)[426] they show only interactions with Phe168, Asn253, and Glu169 residues. 
Therefore, the type of predicted interaction is not indicative of receptor activation by the 
triazoloquinazolines. However, the docking model used enriched A2AR agonists over A2AR 
antagonists and inactives. This suggested an investigation (using MD) whether the His250 
movement would differ between selective versus non-selective A2AR agonist binding and also 
to investigate whether the motion of Val84 would vary upon agonist and antagonist binding. 
This would allow discrimination between these different classes of compounds. 
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Figure 28. Docking studies predicted molecular interactions characteristic of 
triazoloquinazolines with the A2AR protein crystal structure (PDB ID: 2YDO): A. compound 
36 H-bonds via the nitrogen of the quinazoline ring with Asn253, and via the imidazo ring with 
Glu169, and the triazole ring is π-stacked with Phe168, and the phenyl group in quinazoline is π-
stacked with His250 B. the overlaid compounds 37 and 38 H-bond via their amino groups with 
Glu169 and Asn253, and the triazole rings are π-stacked with Phe168, the 3,4-dimethoxy-phenyl 
and the 2-Bromophenyl substituents of compound 37 and 38 are π-stacked with His250 C. 
compound 39 H-bonds via the nitrogen of the triazole ring with Asn253 and the triazole ring is  
π-stacked with Phe168, and the phenyl group of the 1,3-benzoxazole is  π-stacked with Tyr271. 
The molecular interactions predicted for the selective A2AR agonists 36-38 are consistent with 
observed interactions between co-crystallized ligands with the active form of the A2AR protein 
crystal structures (PDB IDs: 4UG2, 4UHR, 3QAK, 2YDO and 2YDV). 
4.3.3 MD simulation suggests that the conformational change of the His250 residue 
contributes to shaping the orthosteric site pocket to favor selectivity for A2AR 
agonists  
In order to investigate further whether the conformational change of His250 contributes to 
shaping the orthosteric site to favor the selectivity for agonists at A2AR, an RMSD analysis was 
performed on this residue over a 100 ns MD simulation. This is a commonly used approach to 
determine conformational flexibility upon ligand binding.[435, 436] The analysis was 
performed for compounds 36 and CGS 21680 (the selective and potent A2AR agonists) and 
compound 39 and Adenosine (the non-selective adenosine receptor agonists) docked to the 
A2AR structure (PDB ID: 5IU4). The RMSD values of His250 over the 100 ns simulation time 
are represented as the moving average trend-lines (bin-size of 10 frames) in Figure 29. Similar 
trend is seen in the case of compounds 36 and CGS 21680, wherein both RMSD values of 
His250 increase over the simulation time converging towards similar RMSD values. This 
indicates that a conformational change is occurring in this residue upon selective A2AR agonist 
binding. The greater increase in RMSD values observed for compound 36 in comparison to 
CGS 21680 could be related to the higher degree of selectivity that this compound exhibits as 
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an A2AR agonist over the other adenosine receptor subtypes. This is in contrast to CGS 21680 
that exhibits agonist activity against the A3R receptor subtype (refer to section 4.3.6). This is 
not the case for compounds 39 and Adenosine (non-selective agonists) where the RMSD values 
are relatively constant over the 100 ns simulation. The RMSD distributions for the His250 
residue in the last 50 ns of the MD simulation performed for compounds 36, 39, CGS 21680, 
and Adenosine docked to the A2AR, are plotted in Figure 30. The separation in RMSD value 
distributions for the selective A2AR agonists (36 and CGS 21680) versus the non-selective 
A2AR agonists (39 and Adenosine) is clearly illustrated. A Kolmogorov-Smirnov test, which 
included statistical analysis of the pair-wise RMSD distributions of His250 in selective versus 
non-selective agonist bound A2AR structures was performed. This yielded a p value less than 
2.2. x 10-16, indicating that the difference between the two types of distributions is statistically 
significant. Furthermore, the RMSD values of His250 for the A2AR structures bound to 
compound 36 and CGS 21680 were compared to a reference residue (Leu249), over the 100 ns 
MD simulation, as illustrated in Figure 31. It is evident that the RMSD values of Leu249 are 
relatively constant for both A2AR structures bound to compound 36 and CGS 21680 over the 
100 ns simulation. This emphasizes that the increase in RMSD values for His250 is characteristic 
of its conformational change upon selective A2AR agonist binding. Hence, the comparison in 
RMSD values for the His250 residue in A2AR structures bound to selective versus non-selective 
A2AR agonists suggests that the conformational change of this residue contributes to shaping 
the orthosteric site pocket to favor the selectivity of A2AR agonists. 
Figure 29. The moving average trend-lines (bin-size of 10 frames) of RMSD values of His250 
for compounds 36, 39, and CGS 21680 (the selective and potent A2AR agonist) and Adenosine 
(the non-selective adenosine receptor agonist), docked to the inactive form of the A2AR protein 
crystal structure (PDB ID: 5IU4) over a 100 ns simulation. The RMSD values of His250 for the 
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docked structures of compounds 36 and CGS 21680 (the two selective A2AR agonists) behave 
similarly by increasing and converging towards similar RMSD values. This indicates that a 
conformational change occurs in this residue upon A2AR agonist binding. In contrast, the 
RMSD values in the case of the docked compounds 39 and Adenosine (the non-selective 
adenosine receptor agonists) are relatively constant. Hence, this suggests that the 
conformational change of this residue contributes to shaping the orthosteric site pocket to favor 
the selectivity of A2AR agonists. 
 
Figure 30. The RMSD distributions for the His250 residue in the last 50 ns of the MD simulation 
performed for compounds 36, 39, CGS 21680, and Adenosine, docked to the A2AR. The 
separation in RMSD value distributions for the selective A2AR agonists (36 and CGS 21680) 
versus the non-selective A2AR agonists (39 and Adenosine) is statistically significant by 
Kolmogorov-Smirnov test, for the pair-wise RMSD distributions (selective versus non-
selective agonist bound A2AR structures) with a p value less than 2.2. x 10
-16. 
 
Figure 31. The moving average trend-lines (bin-size of 10 frames) of RMSD values of His250 
for the A2AR structures bound to compound 36 and CGS 21680 were compared to those of a 
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reference residue (Leu249) over a 100 ns MD simulation. The RMSD values of Leu249 are 
relatively constant for both A2AR structures bound to compound 36 and CGS 21680 
emphasizing that increase in RMSD values for His250 is characteristic of its conformational 
change upon selective A2AR agonist binding. 
 
4.3.4 MD Simulation analysis reveals the shift in Val84 as a requirement for receptor 
activation by A2AR ligands 
The analysis of the active and inactive forms of the available A2AR crystal structures is in 
accordance with reports in the literature, which mention that Val84
 in TM3 has to shift by 
approximately 2Å upon agonist binding to avoid a steric clash between the ligand and the 
receptor.[319–321] Hence, this gave rise to the hypothesis that the motion of this residue might 
discriminate between agonist and antagonist binding. Therefore, a 100 ns MD simulation was 
performed for each of the co-crystallized structures (PDB IDs: 5IU4 and 2YDO), which 
exhibited the largest differences in distance between the α-carbons of Val84 in TM3, and Leu249, 
a relatively fixed residue in TM6 (12.96Å versus 14.53Å respectively, see methods for details). 
The same analysis was carried out for the apo structure of the A2AR (PDB ID: 5IU4), the docked 
triazoloquinazolines 36, 39, and 40 with the highest predicted affinities (and the most potent 
agonists identified by assays performed in the CHO-K1-A2AR cells), compound 41 (which did 
not exhibit any agonist activity), CHEMBL3799351 (a potent antagonist), and CGS 21680 (the 
selective and potent A2AR agonist). All of these compounds were docked into the orthosteric 
site of the inactive form of the A2AR protein crystal structure (PDB ID: 5IU4).  
Figure 32 shows the moving average trend-line (bin-size of 20 frames) for the distances 
between the α-carbons of Val84 in TM3 and Leu249 in TM6, for each trajectory of the apo 
structure and all the docked and co-crystallized structures. Interestingly, in the last 50 ns of the 
simulation, the antagonist-bound A2AR system maintained the distance observed for the 
inactive crystal structure, whereas the agonist-bound systems resembled the properties of the 
active receptor conformation. As for the apo structure, this exhibited an intermediate distance 
between the agonist and antagonist bound structures. The docked structures, CGS 21680, 
compounds 36, 39, and 40 behaved similarly in particular over the last 50 ns (when considering 
the average distance between α-carbons of Val84 and Leu249) by displaying an increase in their 
average distance values (14.04 ±0.51Å, 14.08 ±0.37Å, 14.61 ±0.67Å, and 14.84 ±0.59Å 
respectively) in comparison to the apo structure simulation (12.93 ±0.44Å). The values 
converged towards the average distance value (14.84 ±0.34Å) of the active protein crystal 
structure (PDB ID: 2YDO). In contrast, the potent antagonist CHEMBL3799351, which was 
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docked to the A2AR protein crystal structure (PDB ID: 5UI4), showed a slight decrease in its 
average distance values in comparison to the simulated apo structure. It exhibited similar 
average distance value (11.45 ±0.60Å) to that of the co-crystallized ZM 241385 antagonist 
(PDB ID: 5UI4) (11.44 ±0.51Å) in the last 50 ns. As for compound 41 and the apo-structure, 
their average distance values were alike over the last 50 ns (12.97 ±0.54Å and 12.93 ±0.44Å 
respectively). This could serve as an explanation of why compound 41 did not exhibit any 
agonist activity. 
Violin plots were obtained (Figure 33) for the α-carbon distances between Val84 and Leu249 for 
the remaining 50 ns of the simulation for representative agonist/antagonist systems (agonist 
bound to 2YDO, compound 39, CGS 21680, antagonist (ZM 241385), other potent antagonist 
(CHEMBL3799351)). These plots display the density distributions for the measured distances, 
and highlight the larger inter-residue distance characterizing the agonist binding as compared 
to antagonist binding. A statistical analysis was performed on the last 50 ns distance 
distributions, using a Mann-Whitney test and a Kolmogorov-Smirnov test for the representative 
agonist/antagonist pairs displayed in Figure 33. The differences in medians of the distance 
distributions for each of the agonist/antagonist pairs were significant at a p value less than 0.05, 
and the p value for the Kolmogorov-Smirnov test was less than 2.2 x 10-16.  Hence, the increase 
in the distance between Val84 and Leu249 residues caused upon A2AR agonist binding serves as 
a useful conformational descriptor for receptor activation by the A2AR ligands.  
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Figure 32. The moving average trend-lines (bin-size of 20 frames) are for the Val84-Leu249 Cα 
distances of the apo structure (PDB ID: 5IU4) and the docked and the co-crystallized structures 
(PDB ID: 5IU4 and 2YDO) of the A2AR over a 100 ns simulation.  Compounds 36, 39, 40, and 
41, a potent antagonist (CHEMBL3799351), and the selective and potent A2AR agonist (CGS 
21680) are docked into the inactive form of the A2AR protein crystal structure (PDB ID: 5IU4). 
The variation in computed distances for compounds 36, 39, 40 and CGS 21680 were similar, 
where all increased in their average distances time moving towards the average distance 
observed in the dynamics of the active protein crystal structure (PDB ID: 2YDO). The average 
distances for compound 41, and the apo-structure were similar, which explains why compound 
41 did not exhibit any agonist activity. Hence, the increase in the Val84-Leu249 inter-residue 
distance upon A2AR agonist binding serves as a good conformational descriptor for receptor 
activation by the A2AR ligands. 
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Figure 33.  Violin plots for the α-carbon distances between Val84 and Leu249 for the last 50 ns 
of the MD simulations. It can be seen that larger inter-residue distances characterize agonist 
binding as compared to antagonist binding. Hence, the increase in the Val84-Leu249 inter-
residue distance upon docking of the A2AR agonists to the inactive form of the A2AR protein 
crystal structure serves as a useful conformational descriptor for receptor activation by the 
A2AR ligands. 
4.3.5 Confirmation of triazoloquinazolines as PDE10A inhibitors 
The PDE10A inhibitory activity was experimentally confirmed for the triazoloquinazolines 36-
41 and the trend in potencies was comparable to what has been previously suggested by Kehler 
et al.[382] The rank of potencies for the six triazolquinazolines was 36 > 41 = 39 > 40 > 38 = 
37 (Table 7 and Figure 34). The activity of CGS 21680 was tested and it was shown that it did 
not exhibit any PDE10A inhibitory activity. 
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Figure 34. Dose response curves for PDE10A inhibition by triazoloquinazolines 36-41 and 
CGS 21680. Data are represented as the mean of 6 individual replicates ± SEM (standard error 
of the mean). The rank of potencies obtained for the tested triazoloquinazolines was 36 > 41 = 
39 > 40 > 38 = 37. CGS 21680 did not inhibit PDE10A (plot generated by the Ladds group 
members). 
 
Table 7. pIC50 values for PDE10A inhibition by the triazoloquinazolines 36-41 identified as 













4.3.6 Experimental validation of triazoloquinazolines as A2AR agonists 
Yeast strains, which have been previously characterized, were used in order to validate 
triazoloquinazolines 36-41 as A2AR agonists and assess their selectivity against the human A1R, 
A2AR and A2BR subtypes.[400] Stimulating each strain with the non-selective adenosine 
receptor agonist, NECA, resulted in agonist activity against the three adenosine receptor 
subtypes, with the following rank of potencies A1R = A2AR > A2BR (Figure 35A. and Table 8). 
In contrast, stimulation with the A2AR selective agonist, CGS 21680, solely activated the A2AR 
significantly (Figure 35B. and Table 8). Stimulating the yeast strains with compounds 36-38 
selectively activated the A2AR (Figure 35C. D. E. and Table 8). For compounds 39 and 40, 
despite their ability to activate all three adenosine receptors, they were more potent against the 
A2AR over the other subtypes (Figure 35F. G. and Table 8). Compound 41 failed to elicit a 
response against any of the adenosine receptors in yeast (Figure 35H. and Table 8). As for A3R, 
this receptor cannot be functionally expressed in yeast,[400] thus CHO-K1 cells stably 
expressing the A3R (CHO-K1-A3R) were used. Given that A3R is Gαi/o-coupled, CHO-K1-
A3R cells were co-stimulated with 1 μM Forskolin (to elevate cAMP) in tandem with each 
compound to measure its efficacy in inhibiting cAMP. Inhibition of cAMP was only observed 
upon stimulation with NECA, CGS 21680 and compound 39 (Figure 35 and Table 8). The 
yeast and mammalian screening confirmed agonist activity of the triazoloquinazolines 36-40 
against the adenosine receptor subtypes, exhibiting more potency towards the A2AR, and in 













Table 8. Potency (pEC50) and Emax values for NECA, CGS 21680 and the triazoloquinazolines 
36-41 against A1, A2A and A2B receptors in GPA1/Gαi1/2 or GPA1/Gαs yeast transplants and the 
A3 receptor in CHO-K1-A3R cells. 
 
 
A1R - GPA1/Gαi1/2 A2AR - GPA1/Gαs A2BR - GPA1/Gαs CHO-K1-A3R 
pEC50
a Emax
b pEC50a Emaxb pEC50a Emaxb pEC50a Rangec 
NECA 5.9±0.1 100.4±3.2*** 
6.3±0.2
*** 
91.1±4.8*** 4.2±0.1* 99.8±13.2*** 9.5±0.2*** -44.2±2.7*** 





ND ND 7.6±0.2*** -52.9±2.4*** 
36 NR NR 
5.3±0.2
*** 
69.0±1.9*** NR NR NR NR 
37 NR NR 
5.9±0.2
*** 
54.3±5.1*** NR NR NR NR 
38 NR NR 
5.8±0.2
*** 
60.2±5.5*** NR NR NR NR 
39 5.4±0.3 60.9±9.0*** 
6.1±0.5
*** 
38.8±5.3*** 4.8±0.2* 17.6±2.5*** 9.4±0.1*** -17.0±0.9*** 
40 5.0±0.6 22.7±8.1*** 
8.3±0.9
*** 
10.0±4.0*** 4.6±0.3* 08.7±2.2*** NR NR 
41 NR NR NR NR NR NR NR NR 
 
Data ± SEM of 4-6 individual replicates 
a Negative logarithm of agonist concentration producing half-maximal response 
b Maximal response observed upon agonist stimulation, as a percentage of that observed upon 
stimulation with 100 μM NECA 
c Range of response, as a percentage of that observed upon stimulation with 100 μM Forskolin 
ND – Not determined – full dose-response curve not feasible 
NR – No response 
Statistical difference between each agonist and NECA was calculated using a one-way 







Figure 35. Dose-response curves (produced by the Ladds group members) for NECA, CGS 
21680 and compounds 36-41 in either the A1R and GPA1/Gαi1/2, A2AR and GPA1/ Gαs, or the 
A2BR (with GPA1/Gαs expressed in yeast strains). The efficacy of the compounds (36-41) was 
measured against A3R in CHO-K1-A3R cells. Reporter gene activity in yeast was determined 
using β-galactosidase assays, after 16-hours stimulation with either: NECA (A), CGS 21680 
(B) compound 36 (C), compound 37 (D), compound 38 (E), compound 39 (F), compound 40 
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(F), compound 41 (G), whereas cAMP inhibition was determined when in CHO-K1-A3R cells 
which were co-stimulated with each of the compounds 36-41 and 1 μM Forskolin. In general, 
the triazoloquinazolines 36-41 exhibited agonistic activity against the adenosine receptor sub-
types, with compounds 36-38 being selective A2AR agonists. The data is represented as either 
percentage of the response obtained upon stimulating each receptor (A1R, A2AR, or A2BR) with 
NECA stimulation, or as a percentage response relative to 100 μM Forskolin simulation in the 
A3R ± SEM of 4-6 individual replicates. 
4.3.7 Mammalian validation 
Despite the fact that the yeast system is often an appropriate tool for screening compounds 
against the adenosine receptor subtypes, potencies and efficacies may not strongly correlate 
with those of the mammalian cell types.[434, 437] CHO-K1 cells stably expressing the human 
A2AR (CHO-K1-A2AR) were used to assess the efficacies of compounds 36-41 in elevating 
cAMP. In comparison to CGS 21680, the compounds were partial A2AR agonists with a rank 
order of potency, CGS 21680 > compound 40 = compound 39 > compound 36 = compound 38 
> compound 37 > compound 41 (Figure 36 and Table 9). Compounds 36-40, which are agonists 
were competitively antagonized by the antagonist ZM 241385 (which in fact is an inverse 
agonist, this can be seen from the reduction in basal activity) (Figure 36 and Table 9), 
confirming their agonist activity at the A2AR. As in the case of compound 41, there was not 
any competitive antagonism from the ZM 241385 (Figure 36 and Table 9). The shape of the 
curves obtained in the case of compound 41 could be attributed to the inverse agonism of ZM 
241385. In addition, all compounds 36-41 elevated cAMP when 1 μM ZM 241385 was added 
or in the absence of A2AR.[319] It was hypothesized that elevated cAMP might be due to the 
presence of endogenous PDE10A expressed in CHO-K1 cells, and this has been subsequently 
confirmed by RT-PCR (see Appendix E). By comparing the observed agonist activities of 
compounds 36-41 upon treatment of CHO-K1 and CHO-K1-A2AR cells, a significant increase 
in their efficacies was observed in the CHO-K1-A2AR cells (the over-expressed cell line).  This 
may be explained by their ability to stimulate the A2AR, stably expressed in CHO-K1-A2AR 
cells (Figure 36 and Table 9).  For compound 41, no change in efficacy was obtained suggesting 
that the elevation of cAMP is solely attributed to the action of the compounds upon other targets 
in the background of the CHO-K1 cell, potentially PDE10A (which from RT-PCR experiments 
on the cell system used showed expression of PDE10A). Hence, compounds 36-38 were shown 
to be selective A2AR agonists, whereas compounds 39-40 are non-selective with limited activity 
against other adenosine receptors. Some of the observations suggest off-target activity, so a 
future direction would be to screen the compounds against a panel of receptors commonly 
expressed in this system. This would also further confirm selectivity for the desired targets. 
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Figure 36. CGS 21680 and compounds 36-41 elevated cAMP in A2AR stably expressed in 
CHO-K1 cells, which were antagonized by ZM 241385. A2AR stably expressed in CHO-K1 
cells (CHO-K1-A2AR) were stimulated for 30 minutes with: CGS 21680 (A), compound 36 
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(B), compound 37 (C), compound 38 (D), compound 39 (E), compound 40 (F), or compound 
41 (G), after which the cAMP levels were determined. Subsequently compounds were 
antagonized with either 100 pM, 10 nM or 1 μM ZM 241385, which decreased the cAMP levels 
to the same level of CHO-K1 cells (no A2AR stably expressed). Data represented are relative 
to the response of CGS 21680, ± SEM of 4-9 individual replicates (plots generated by the Ladds 
group members). 
 
Table 9. Potency (pEC50) and range of responses for cAMP elevation upon stimulating CHO-







a Rangeb N pEC50a Rangeb n Δ pEC50c Δ Ranged 
CGS 21680 8.8±0.2**     86.3±7.2* 9 ND ND 4 - - 
36 7.3±0.2*** 61.1±5.2*** 8 6.5±0.3 20.2±2.7 4 0.8±0.5  41.0±7.8 
37 6.3±0.5*** 30.5±8.1*** 6 4.9±0.2 39.5±3.9 4 1.4±0.6   -9.0±10.6 
38 7.3±0.3*** 29.0±6.3*** 6 5.9±0.3 18.3±2.3 4 1.2±0.5  10.6±8.7 
39 7.6±0.2*** 37.7±2.9*** 5 6.6±0.2 18.8±1.7 4 0.9±0.6  19.0±3.6 
40 7.7±0.4***     27.4±4.4* 6 6.3±0.2 19.5±1.7 4 1.3±2.4  7.9±6.1 
41 6.0±0.3***     31.1±5.7** 6 5.8±0.4 33.9±5.9 4 0.1±0.6 -2.9±8.5 
 
Data ± SEM of n individual replicates 
a Negative logarithm of agonist concentration producing half-maximal response 
b Percentage range of response observed upon agonist stimulation, relative to that obtained with 
CGS 21680 stimulation in each cell type. 
c Change in pEC50 between CHO-K1 and CHO-K1-A2AR cells (Δ pEC50
 = pEC50(CHO-K1-
A2AR) - pEC50(CHO-K1)) 
d Change in range between CHO-K1 and CHO-K1-A2AR cells (Δ Range = Range (CHO-K1-
A2AR) - Range(CHO-K1)) 
ND – Not determined, full dose-response curve not feasible 
Statistical difference, between CHO-K1-A2AR cells and CHO-K1 cells, was calculated using 
pair-wise t-tests, for each agonist (*, p < 0.05, **, p < 0.01, ***, p < 0.001) 
 
4.3.8 Dual PDE10A inhibition and A2AR agonism is anti-proliferative in CHO-K1-
A2AR cells 
cAMP elevation has been previously suggested to have anti-proliferative effects.[101, 104, 
438] Indeed, upon stimulating both of the CHO-K1 and CHO-K1-A2AR cells with Forskolin, 
inhibition of cell proliferation was observed in a concentration-dependent manner (Figure 37 
and Table 10). However, there were not any anti-proliferative effects observed upon simulating 
the CHO-K1 and CHO-K1-A2AR cells with the selective A2AR agonist, CGS 21680. This 
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suggests that the activation of the A2AR has no effect upon proliferation (Figure 37 and Table 
10). In contrast, compound 36 inhibited CHO-K1-A2AR cells, and compounds 38-40 inhibited 
the proliferation in CHO-K1 cells, but their pIC50 and Imax increased when A2AR was 
overexpressed in CHO-K1-A2AR cells (Figure 37 and Table 10). Compound 37 displayed anti-
proliferative effects in both cell types, which suggests that it might be toxic, whereas compound 
41 did not exhibit any anti-proliferative effects upon both cell types, which could imply that 
the inhibition of PDE10A has no effect upon proliferation (Figure 37 and Table 10).  
Table 10. Potency (pIC50) and Imax of the responses for the anti-proliferative effects obtained 
upon simulating by Forskolin, CGS 21680 and triazoloquinazolines 36-41 in CHO-K1-A2AR 
and CHO-K1 cells 
 
 CHO-K1-A2AR CHO-K1 CHO-K1-A2AR vs CHO-K1 
pIC50
a Imax
b N pIC50a Imaxb N Δ pIC50c Δ Imaxd 
Forskolin  4.4±0.1*** 59.0±2.2*** 6   4.5±0.1 62.6±3.4 6 -0.1±0.1  -3.6±4.1 
CGS 21680 NR  -2.4±1.4*** 4 NR 4.3±10.0 4 NR  -6.7±10.1 
36  4.4±0.1*** 56.3±5.3*** 6 NR   7.9±1.6 6 - 48.5±5.1 
37 4.7±0.1**** 74.8±2.4*** 6   4.8±0.1 78.5±1.4 6 -0.1±0.1  -3.7±2.8 
38  4.8±0.1*** 70.9±1.8*** 6   4.1±0.1 38.0±1.0 6  0.7±0.1 32.9±2.1 
39 4.4±0.1**** 51.9±0.6*** 6 3.5±0.2 19.5±3.7 6  0.9±0.2 32.4±2.1 
40  4.7±0.1*** 73.2±2.1*** 6   3.7±0.1 20.7±1.4 6  1.1±0.1 52.5±2.6 
41 NR  -0.4±2.7*** 6 NR   4.3±1.9 6 NR  -4.7±3.3 
 
Data ± SEM of n individual replicates 
a Negative logarithm of agonist concentration producing half-maximal inhibition 
b Maximal level of inhibition obtained when cells were stimulated with 10 μM agonist relative 
to that obtained with 1% DMSO treatment  
c Change in pIC50 between CHO-K1 and CHO-K1-A2AR cells (Δ pIC50
 = pIC50(CHO-K1-A2AR) 
- pIC50(CHO-K1)) 
d Change in Imax between CHO-K1 and CHO-K1-A2AR cells (Δ Imax = Imax (CHO-K1-A2AR) - 
Imax (CHO-K1)) 
NR – No response observed 
Statistical difference, between CHO-K1-A2AR cells and CHO-K1 cells, was calculated using 




Figure 37. Stimulation by Forskolin and compounds 36, and 38-40 showed anti-proliferative 
effects in CHO-K1 cells, which was enhanced when the A2AR is stably expressed in CHO-K1-
A2AR cells. As for compound 37, it displayed anti-proliferative effects in both cell types, which 
suggests that it might be toxic. 
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CHO-K1 or CHO-K1-A2AR cells were seeded into 96 well plates and cultured for 24 hours 
before being stimulated with compounds for 72 hours: Forskolin (n = 6) (A), CGS 21680 (n = 
4) (B), compound 36 (n = 6) (C), compound 37 (n = 6) (D), compound 38 (n = 6) (E), compound 
39 (n = 6) (F), compound 40 (n = 6) (G) or compound 41 (n = 6) (H), where CCK-8 was used 
to determine cell number. Data is represented relative to the cell number obtained upon 
treatment with 1% DMSO, ± SEM (plots are produced by the Ladds group members). 
 
4.3.9 Dual PDE10A inhibition and A2AR agonism is anti-proliferative in Lung 
carcinoma cell-lines 
A series of lung carcinoma cell-lines, two lung squamous cell carcinomas (LUSC): LK-2 and 
H520, and two lung adenocarcinoma cells (LUAC): H1563 and H1792 were employed to 
ascertain whether the dual PDE10A inhibition and A2AR agonism is anti-proliferative in these 
cell-lines. First, the target gene expression was quantified for all four adenosine receptors and 
PDE10A in each cell-line.  Then, compounds 36-41 were tested for their ability to elevate 
cAMP, and their anti-proliferative effects in the four cell-lines were investigated. As for 
compound 37, it was not used in these experiments due to its toxicity in CHO-K1 cells but it 
did exhibit anti-proliferative effects in the four lung carcinoma cell-lines comparable to those 
observed in CHO-K1 cells. 
Low expression of PDE10A and the absence of A2AR were observed in the LK-2 cell-line, 
while the A1R, and A2BR are significantly expressed. (Figure 38A. and Table 11). CGS 21680 
and compounds 36 and 38-41 were tested for their ability to elevate cAMP, and were found to 
increase the cAMP levels above basal in a similar manner, (Figure 38A., Table 11). The 
observed activity of CGS 21680 might be attributed to its action via A2BR, whereas the action 
of compounds 36 and 38-41 might be due to inhibition of PDE10A.  Compounds 36 and 38-
41, CGS 21680, and Forskolin were further tested for their anti-proliferative effects in the LK-
2 cell-line. Inhibition of cell growth was only observed for Forskolin and compound 38 (Figure 
38A. and Table 12). This could be attributed to the fact that compound 38 was the most potent 
in elevating cAMP in the LK-2 cell-line.  
In the H520 cell-line, all of four adenosine receptor sub-types were found to be expressed, and 
the PDE10A was also present at low concentrations (Figure 38B.). With the exception of 
compounds 40-41, all tested compounds were more potent in elevating cAMP in comparison 
to their response in the LK-2 cell-line (Figure 38B. and Table 11). Increased anti-proliferative 
effects were observed in tandem with cAMP elevation obtained in this cell-line, in particular 
for compounds 36 and 38-39 (Figure 38B. and Table 12). In the H1792 cell-line an increase in 
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PDE10A expression was detected in comparison to the H520 cell-line, and all of the four 
adenosine receptors were expressed (Figure 38C.). Similar to what was observed in the LK-2 
and H520 cell-lines, compounds 36 and 38-40 elevated cAMP levels, and they exhibited anti-
proliferative effects. In particular, compound 39 was the most potent among the tested 
compounds in both cAMP elevation (Table 11) and anti-proliferation (Table 12) in the H1792 
cell-line, compared to its response in the LK-2 and H520 cell-line. This could be attributed to 
the increased combined expression of PDE10A and adenosine receptor subtypes in this cell-
line (Figure 38C.). 
In the H1563 cell-line, there was the highest combined target expression of A2AR and PDE10A, 
which could explain the highest sensitivity to anti-proliferation observed among the four cell-
lines (Figure 38D. and Table 12). In particular, compound 36, a selective A2AR agonist and a 
PDE10A inhibitor, exhibited a strong correlation between its pEC50 (4.91±0.2, 5.57±0.1,  
5.98±0.1, 6.42±0.1 respectively) and pIC50 (NR, 3.34±0.10, 4.00±0.07, 4.37±0.04 respectively) 
values. They both increased along with the levels of combined target expression (A2AR and 
PDE10A) across cell lines, from LK-2 – H520 – H1792 – H1563. 
As a general trend, an increase was observed for pIC50 values for compounds 36, 38-40, as the 
combined target expression (A2AR and PDE10A) increased across cell lines, from LK-2 – H520 
– H1792 – H1563.  The least sensitive was LK-2, expressing a small level of PDE10A, and the 
most sensitive was H1563, expressing similar levels of A2AR to that of H1792. However, 
PDE10A is over expressed in comparison to the other three cell types (Figure 38). The increase 
in potency (pIC50) (Figure 39A. and Table 12) and Imax was most remarkable for compounds 
36 and 40 (Figure 39B. and Table 12). As for the increase in cAMP elevation (pEC50 values), 
this also correlated with the increase in the combined expression of A2AR and PDE10A, being 
most prominent for compounds 36 and 38 (Figure 39C. and Table 11). For compound 41, it did 
not exhibit any anti-proliferative effects in any of the four cell-lines, but rather an increase in 
proliferation was observed. This could be attributed to the fact that the anti-proliferative effects 
of PDE10A inhibition might be specific to the cancer cell type. For CGS 21680, it was only 
anti-proliferative in the H1563 cell-line, which might be attributed to the high sensitivity of the 
cell-line to anti-proliferation. Hence, it appears that the A2AR activation alone weakly exhibits 
anti-proliferative effects, whereas it is not clear from the experiment whether sole inhibition of 
PDE10A could increase proliferation or have no effects.  In contrast, PDE10A inhibition has, 
for instance, been reported to be anti-proliferative on other cancer cells,[439] and agonsim of 
A2AR was shown to increase fibroblast proliferation.[440] Therefore, it could be inferred that 
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neither A2AR agonists nor PDE inhibitors may solely induce therapeutically relevant cAMP 
mediated cell death in these particular cell-lines.  
It was noted that the maximum achievable IC50 values for the compounds showing anti-
proliferative effects on lung carcinoma cell lines were those with activities of 30-50 μM, 
despite the increase in PDE10A expression in the most sensitive cell types (Figure 39 and Table 
12). This may be due to protocol, which includes chronic stimulation by exposing cells to each 
compound for 72 hours. Indeed, it has been previously reported that GPCRs can desensitize 
and/or internalize upon short or long-term stimulation with agonists[441, 442] which may be 
independent of their potency. This is generally considered to be due to β-arrestin binding 
followed by disposal of the receptor complex in clathrate-coated pits. There is also signaling 
associated with this process. Biased signaling or functional selectivity is not considered in this 
work, although this would be an interesting topic for further exploration[442, 443]. This 
suggests that targeting Gαs-coupled receptors alone as an anti-proliferative strategy may be of 
limited benefit.  
Additionally, when comparing the pIC50 and pEC50 values obtained for proliferation and cAMP 
elevation across the CHO-K1-A2AR, LK-2, H520, H1792, H1563 cell-lines, a strong 
correlation (Figure 39D. r = 0.8238, 95% confidence interval (CI); 0.6232 – 0.9227) is obtained 
for all the anti-proliferative compounds. This finding appears to be more consistent than in 
previous studies, where it was found that the effect of cAMP elevation is cell type specific, 
[99–106] and the magnitude of cAMP elevation did not show a strong correlation with the 
levels of anti-proliferative action.[438] Hence, this study suggests a causative link between 
cAMP elevation and the anti-proliferative effects observed, which is further supported by the 
anti-proliferative effects exhibited by Forskolin (Figure 39 and Table 12). This is similar to 
what was observed in other cell types where increased cAMP levels (induced by Forskolin) 
inhibited fibroblast proliferation.[440, 444]  
Particularly in the case of compound 36, it has been shown that the increased ability to elevate 
cAMP levels through dual A2AR activation and inhibition of PDE10A results in greater anti-
proliferative effects on lung carcinoma cell-lines. This finding suggests that by improving 
efficacy of compounds for cAMP elevation, this would in turn increase the efficacy of their 
anti-proliferative effects in lung carcinoma. Indeed, it has been reported that sustained cAMP 
elevation can impact gene expression.[445] In addition, this is in agreement with what has been 
reported in the literature, namely that A2AR agonists in combination with various PDE 
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inhibitors were anti-proliferative.[98] The novelty of this approach, however, lies in combining 
this strategy into a single ligand, which results in the same anti-proliferative effects with 
potencies which are comparable to those of cisplatin on H520, H1563 and H1792 cell-
lines.[446] Thus, there is the possibility that targeting both of these proteins may have 




Figure 38. Lung squamous cell carcinoma and adenocarcinoma cells show increased 
sensitivity in terms of proliferation to triazoloquinazolines 36-41, depending on the combined 
expression of A2AR and PDE10A. RT-PCR analysis was performed (by DS) on Lung squamous 
cell carcinoma cells; LK-2 (A), and H520 (B), and lung adenocarcinoma cells: H1792 (C) and 
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H1563 (D) in order to determine expression of the A1R, A2AR, A2BR, A3R and PDE10A. Data 
are represented in relation to GAPDH expression ± SEM of 3 individual replicates. 
Subsequently, stimulation of each cell line with CGS 21680 or compounds 36, 38-41 was 
performed for 30 minutes, after which cAMP levels were measured. Data are relative to the 
response of 100 μM Forskolin, ± SEM of 4-8 individual replicates. In addition, stimulation of 
all cells with CGS 21680, or compounds 36, 38-41 for 72 hours was performed, after which 
their cell number was determined with CCK-8. Data is relative to the cell number obtained 
after treatment with 1% DMSO, ± SEM of 4-8 replicates. 
 
Table 11. Potency (pEC50) and Emax values for cAMP accumulation of CGS 21680 and 
triazoloquinazolines 36, 38-41 stimulated by LK-2, H520, H1792 and H1563 lung carcinoma 
cell-lines. 
 
 LK-2 H520 H1792 H1563 
pEC50
a Emax
b pEC50a Emaxb pEC50a Emaxb pEC50a Emaxb 
CGS 21680 5.1±0.1 17.1±0.9 5.5±0.2** 21.3±1.0 5.5±0.1*** 27.3±2.1 5.3±0.1*** 15.5±1.6*** 
36 4.9±0.2 18.4±1.9 5.6±0.1* 26.1±3.0 6.0±0.1*** 32.2±2.8 6.4±0.1*** 29.0±1.1*** 
38 5.5±0.2 18.30±1.5 5.9±0.2** 23.4±1.4 6.5±0.1*** 23.7±1.5 6.5±0.2*** 12.5±0.7*** 
39 5.3±0.2 14.3±2.3 6.4±0.3** 18.5±1.8 7.5±0.1*** 21.8±1.8 6.5±0.1*** 10.0±0.6*** 
40 5.5±0.2 15.2±1.3 5.3±0.1** 16.6±2.7 5.6±0.2*** 27.8±3.1 6.8±0.2*** 15.7±0.8*** 
41 5.0±0.2 14.7±1.7 5.2±0.1** 23.1±2.7 4.3±0.1*** 24.9±2.5 4.7±0.2*** 15.8±1.9*** 
 
Data ± SEM of 4-8 individual replicates 
a Negative logarithm of agonist concentration producing half-maximal response 
b Maximal response observed upon agonist stimulation, as a percentage of that observed upon 
stimulation with 100 μM Forskolin 
The statistical difference between each agonist and CGS 21680 was calculated using a one-
way ANOVA with Dunnett’s post-test (*, p < 0.05, **, p < 0.01, ***, p < 0.001) 
 
Table 12. Anti-proliferative effects of CGS 21680, Forskolin and triazoloquinazolines 36, 38-
41 stimulated BY LK-2, H520, H1792 and H1563 lung carcinoma cell-lines  
 










CGS 21680 NR  -3.6±2.6 NR  0.6±2.0*** NR -4.1±1.6*** 3.7±0.1 18.9±1.8*** 
Forskolin 3.5±0.1  -19.7±2.0 4.1±0.1  31.2±2.1***  3.7±0.1  25.9±1.0*** 3.8±0.1   29.9±1.1*** 
36 NR  -3.6±0.7 3.3±0.1  16.0±3.8***  4.0±0.1  36.0±2.7*** 4.4±0.1   55.3±1.5*** 
38 3.4±0.1   12.6±1.8 4.2±0.1  40.2±2.9***  3.9±0.1  29.4±2.8*** 4.2±0.1   49.3±3.7*** 
39 NR  -5.2±1.9 3.8±0.1  25.0±1.5***  4.5±0.1  56.0±0.9*** 4.0±0.1   29.9±2.9*** 
40 NR  -7.3±1.9 3.2±0.3  17.9±1.0***  3.8±0.1  31.4±2.0*** 4.3±0.1   51.0±0.5*** 
41 NR -15.2±2.1 NR -18.2±3.1*** NR -19.8±5.8*** NR    -7.8±2.1*** 
 
Data ± SEM of 4-8 individual replicates 
a Negative logarithm of agonist concentration producing half-maximal inhibition 
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b Maximal level of inhibition obtained when cells were stimulated with 10 μM agonist relative 
to that obtained with 1% DMSO treatment  
Statistical difference for each agonist compared to its effect upon LK-2 cells was calculated 












Figure 39. (continued) compounds 36, 38-41 in cAMP elevation and proliferation assays for 
LK-2, H520, H1563 and H1792 cell-lines (produced by the Ladds group members). 
A. A summary of the potencies (pIC50 values) for compounds 36, 38-41, CGS 21680 and 
Forskolin for inhibition of proliferation of LK-2, H520, H1792 and H1563 cells. Bars denote 
the mean (± SEM) of data points, whereas individual data are represented by scatter plots.  
B. An overview of the maximal level of inhibition of proliferation (Imax) obtained upon 
treatment of each of the LK-2, H520, H1792 and H1563 cell-lines with compounds 36, 38-41, 
CGS 21680 and Forskolin. Bars denote the mean Imax values ± SEM, whereas a scatter plot 
represents individual data points. A one-way ANOVA with Dunnett’s post-test was used to 
assess the statistical significance of the response obtained in LK-2 cell-line. 
C. Potencies (pEC50 values) obtained for compounds 36, 38-41, CGS 21680 and Forskolin in 
the cAMP accumulation assays upon in LK-2, H520, H1792 and H1563 cell-lines (30 minutes 
exposure). The mean pEC50 values ± SEM are represented by bars, whereas individual data 
points are represented by a scatter plot. A one-way ANOVA with Dunnett’s post-test was used 
to assess the statistical significance of the response obtained in LK-2 cell-line. 
D. Comparison between the pIC50 and pEC50 values obtained for proliferation and cAMP 
elevation of all the anti-proliferative compounds across the CHO-K1-A2AR, LK-2, H520, 
H1792, H1563 cell-lines, shows a strong correlation with r = 0.8238, 95% confidence interval 
(CI); 0.6232 – 0.9227) .
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4.4 Conclusions 
In this work, a novel structure-based approach has been successful in identifying 
triazoloquinazolines as the first dual ligands that activate the A2AR and inhibit PDE10A 
simultaneously. Docking of triazoloquinazolines 36-41, which are known PDE10A inhibitors, 
was performed on the orthosteric site of A2AR (PDB ID: 2YDO), and it is demonstrated 
experimentally that these ligands are indeed A2AR agonists. The agonist activity of the 
compounds was measured by a yeast-screening assay and also in mammalian cells where both 
assays confirmed that compounds 36-40 were A2AR agonists, and revealed that compounds 36-
38 are selective for the A2AR. In addition, the five compounds produced dose-response curves 
obtained from mammalian cells expressing the A2AR with pEC50 values ranging from 6.3 to 
7.7. It is suggested that the observed A2AR sub-type selectivity for 36-38 is attributed to their 
predicted interactions with the His250 residue, which is an interaction present only in the 
selective co-crystallized A2AR agonists, such as CGS 21680 and UK432097. It was further 
demonstrated by MD simulation analysis that this residue undergoes conformational changes 
only when selective A2AR agonists are bound and not when non-selective agonists bind to 
A2AR. This could contribute to shaping the orthosteric site to favor selectivity of A2AR agonists. 
Moreover, MD simulations analysis highlighted the motion of Val84 in TM3 as an essential 
requirement for A2AR activation. Compounds 36 and 38-40 exhibited concentration-dependent 
anti-proliferative effects in lung squamous cell carcinoma cells and lung adenocarcinoma cells 
which correlated with co-expression of A2AR and PDE10A and increased cellular levels of 
cAMP. In particular, compound 36 (as a selective A2AR agonist and a PDE10A inhibitor) 
exhibited correlation between its pEC50 and pIC50 values, which increased in tandem with the 
combined target expression (A2AR and PDE10A) across cell lines, from LK-2 – H520 – H1792 
– H1563. Hence, the MD-assisted approach proposed in this work provides a template for 
generating A2AR agonists as part of a dual-target design objective, which demonstrates 







5 Conclusions & Future Work  
Novel single- and multi-target ligand design approaches have been presented in this work, 
which could be of general use to a wide range of ligand design problems, across (multi-
factorial) disease areas and target families. The design approaches investigated here resulted in 
the discovery of novel compounds with activities at multiple proteins/multiple binding sites 
including allosteric ligands.  First, chemically novel allosteric inhibitors of calpain-1 were 
identified using the PEF(S) domain, which may offer improved selectivity towards the enzyme. 
Second, multi-target ligands with high binding affinity at PDE10A, A1 and A2A receptors (2-
aminopyridine-3-carbonitriles) were found, which may in concert elevate intracellular cAMP 
deemed to be beneficial in neurodegenerative diseases. Third, dual ligands were discovered at 
the A2AR and PDE10A (triazoloquinazolines), which were successful in elevating cAMP at 
these targets, and have been further shown by experiments to exhibit potential clinical value in 
lung carcinoma. 
Future studies could be directed towards finding new dual ligands at the A2AR and PDE10A 
following the structure-based approach described in chapter 4. This could involve docking and 
MD simulations of compounds that are experimentally known PDE10A inhibitors including 
other triazoloquinazolines and additionally compounds with new chemical scaffolds. In 
particular, it would be interesting to investigate the other chemical series that were predicted 
(in chapter 3)[338] as multi-target ligands against the A2AR and PDE10A by the structure- and 
ligand- based techniques. A particular focus in the MD simulation analysis could be on the 
dynamics of Val84 in the A2A receptor upon ligand binding (see chapter 4) in order to shortlist 
candidates of A2AR agonists. This could be followed by experiments to validate these as 
agonists,[400] with further investigation of their selectivity profile against other subtypes of 
both protein families (e.g. A1R, A2BR, A3R, PDE7A, PDE7B, and PDE9A).  
Furthermore, it would be interesting to explore biased cAMP signaling/functional 
selectivity[443] of the novel A2AR agonists. Subsequently, the anti-proliferative effects would 
be tested in lung carcinoma cell-lines. The overall aim of this future study is to search for new 
dual-target ligands with confirmed selectivity against these targets along with signaling bias 
towards cAMP, which could enhance their potency (while reducing desensitization)[441] in 
inhibiting the proliferation of lung carcinoma cell-lines. This could eventually lead to testing 
against lung cancer models in vivo. 
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Additionally, molecular dynamic analysis could be performed on the allosteric calpain-1 
inhibitors that were discovered (chapter 2)[447] once (if) the crystal structure of the full 
calpain-1 complex becomes available. Co-crystallization of these novel ligands would confirm 
the binding and ligand-protein interactions proposed in this work. The dynamics would aim to 
develop an understanding of the causative link between the specific binding of the compounds 
to the PEF(S) domain and their functional effect i.e. their ability to inhibit the activity of the 
calpain-1 enzyme. These suggested mechanistic studies could aid in discovering new and more 
potent allosteric calpain-1 inhibitors, which may offer improved selectivity and a reduced side-
effects profile. 
Hence, finding selective and potent allosteric calpain-1 inhibitors would open the door towards 
discovering potential drug candidates. In addition, identifying new compounds that are more 
potent in inhibiting the proliferation of lung cancer cells could potentially constitute a huge 
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The Chemscore is represented in Equation A1, where the first term C0 is the offset determined 
from the regression analysis, the second term sums up the ligand-atom/receptor-atom pairs, 
which are defined as lipophilic. The third term accounts for the ligand-receptor hydrogen-
bonding interactions. The f, g, and h functions may result in a full score of 1.00 for distances 
or angles that lie within nominal limits, and a partial score within 0.00 and 1.00 for distances 
or angles lying outside these limits but within larger threshold values. For instance, if the H…X 
hydrogen bond distance is within 0.25Å of a nominal value of 1.85Å, then g(∆r) would be 1.00 
but linearly decreases to zero if the distance is between 2.10 and 2.50Å. Likewise, h(∆R) would 
be 1.00 if the Z-H…X angle lies within 30° of 180°, and falls to zero if it is between 120° and 
150°. 
𝛥𝐺𝑏𝑖𝑛𝑑 = 𝐶0 + 𝐶𝑙𝑖𝑝𝑜 ∑ 𝑓(𝑟1𝑟) +  𝐶ℎ𝑏𝑜𝑛𝑑 ∑ 𝑔(∆𝑟)ℎ(∆𝛼) + 𝐶𝑚𝑒𝑡𝑎𝑙 ∑ 𝑓(𝑟1𝑚) +
𝐶𝑟𝑜𝑡𝑏𝐻𝑟𝑜𝑡𝑏  (Equation A1) 
Equation A2 represents GlideScore, where the lipophilic-lipophilic and hydrogen-bonding 
terms are the same as in ChemScore. However, the hydrogen-bonding term is split into various 
weighted parts, which are determined by the charges of the donor and acceptor that could be 
either both neutral (most stable), or at least one or both are charged (least stable). The fifth 
term, which accounts for metal-ligand interaction, is similar to the term in ChemScore but 
differs in three major ways. First, it has been modified to consider only interactions with 
anionic acceptor atoms such as either of the two oxygens of a carboxylate group. In 
metalloproteases, for example, this would allow for preference to be made in the coordination 
to metal centers by the anionic ligand functionality. Secondly, in the case where two or more 
metal ligations are found, Glide would count only the best interaction. Thirdly, the total charge 
on the metal ion is assessed in the apo structure of the protein, and then if it is positive, the 
scoring is modified by incorporating preference for an anionic ligand. 
𝛥𝐺𝑏𝑖𝑛𝑑 = 𝐶𝑙𝑖𝑝𝑜−𝑙𝑖𝑝𝑜 ∑ 𝑓(𝑟1𝑟) +
 𝐶ℎ𝑏𝑜𝑛𝑑−𝑛𝑒𝑢𝑡−𝑛𝑒𝑢𝑡 ∑ 𝑔(∆𝑟)ℎ(∆𝛼)+𝐶ℎ𝑏𝑜𝑛𝑑−𝑛𝑒𝑢𝑡−𝑐ℎ𝑎𝑟𝑔𝑒𝑑 ∑ 𝑔(∆𝑟)ℎ(∆𝛼) +
+𝐶ℎ𝑏𝑜𝑛𝑑−𝑐ℎ𝑎𝑟𝑔𝑒𝑑−𝑐ℎ𝑎𝑟𝑔𝑒𝑑 ∑ 𝑔(∆𝑟)ℎ(∆𝛼) + 𝐶𝑚𝑎𝑥−𝑚𝑒𝑡𝑎𝑙−𝑖𝑜𝑛 ∑ 𝑓(𝑟1𝑚) +
𝐶𝑟𝑜𝑡𝑏𝐻𝑟𝑜𝑡𝑏 + 𝐶𝑝𝑜𝑙𝑎𝑟−𝑝ℎ𝑜𝑏𝑉𝑝𝑜𝑙𝑎𝑟−𝑝ℎ𝑜𝑏 + 𝐶𝑐𝑜𝑢𝑙𝐸𝑐𝑜𝑢𝑙 + 𝐶𝑣𝑑𝑊𝐸𝑣𝑑𝑊 +





Equation B1 illustrates the Taylor series that would account for the position of an atom after a 
short and finite interval of time, denoted by Δt, given the standard position with respect to a 
single component of vector ri, (that is the position along a single dimension, x) at a specific 
time, t.  
𝑥(𝑡 + ∆𝑡) = 𝑥(𝑡) +
𝑑𝑥(𝑡)
𝑑𝑡





+ ⋯ (Equation B1) 
In order to account for higher order terms in the Taylor series, an approximation is made where 
the position x(t), the velocity dx(t)/dt, and the acceleration d2x(t)/dt2 account for a numerical 
solution of the equations of motion. Equation B2 is Newton’s second law for this single 
dimension, which describes the acceleration, where Fx is the component of the net force acting 





















Equation C1 illustrates the functional form of the OPLS force field. It includes harmonic terms 
(the subscript eq denotes the equilibrium bond length r and angle θ) that represent bond stretch 
and angle bending energies. A truncated Fourier series summing up all dihedral angles 
represents the torsional terms, and summing Coulomb and Lennard-Jones terms that cover 
pairwise interactions between interacting sites, denoted by i and j, represent the non-bonded 
energies. The energy is scaled by fij for intramolecular atom pairs separated by 3 bonds or less, 
and for each ij pair, the Lennard-Jones σ and ε parameters are derived from the atom site-
specific parameters coupled according to the geometric combining rule. [278] 












6)] 𝑓𝑖𝑗 + ∑ 𝐾𝑟(𝑟 − 𝑟𝑒𝑞)
2






 (1 + 𝑐𝑜𝑠𝜑) +
𝑉2
2
(1 − 𝑐𝑜𝑠2𝜑) +
𝑉3
2
(1 + 𝑐𝑜𝑠3𝜑) +
𝑉4
2𝑑𝑖ℎ𝑒𝑑𝑟𝑎𝑙𝑠
 (1 − 𝑐𝑜𝑠4𝜑)]   
(Equation C1) 
The OPLS3 fitting protocol incorporates many parameters to ensure the largest extent of 
coverage for the medicinal chemistry space of small molecules, where the experimental data is 
not available in the majority of cases.[278] The protocol was described in detail by Harder et 
al, [278] The general fitting protocol is highlighted as follows: 
(1) The stretching and bend terms are determined as the first step in the protocol as they are 
insensitive to the other terms in the force field, and where they are fit to quantum chemical 
data.  
(2) The van der Waals terms are found from liquid state simulations, along with the core charge 
set employed in these simulations.  
(3) Defining and testing of bond charge corrections (BCC’s) for the CM1A-BCC charge model 
(a model based on combining Cramer-Truhlar CM1A charges with specifically fit BCC’s), is 
done using, for instance, calculations of solvation free energies in water.  
(4) Finally, the fitting of torsional parameters to quantum chemical data is done in the last step. 
This protocol could be used to model compounds, where no experimental data is reported 
provided that the van der Waals parameters are well accounted for by the force field. The 
predictive power of the protocol, however, takes into consideration a set of assumptions which 
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Figure E1. Products obtained (by IW) from RT-PCR using gene specific primers for GAPDH 
and PDE10A on cDNA. These were produced from RNA extracted from CHO-K1 cells, then 
shown in representative (n = 3) agarose gel. The RT-PCR analysis reveals that CHO-K1 cells 
endogenously express PDE10A. 
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